Western University

Scholarship@Western
Electronic Thesis and Dissertation Repository
11-15-2018 5:00 PM

Cost effectiveness of bilateral prophylactic mastectomy with and
without different breast reconstruction techniques versus
screening in women with high risk of breast cancer in the
Canadian province of Ontario
badria Aljohani, The University of Western Ontario
Supervisor: Brackstone,Muriel MD, PhD, FRCSC, The University of Western Ontario
Co-Supervisor: Chris Doherty, The University of Western Ontario
A thesis submitted in partial fulfillment of the requirements for the Master of Clinical Science
degree in Surgery
© badria Aljohani 2018

Follow this and additional works at: https://ir.lib.uwo.ca/etd
Part of the Surgery Commons

Recommended Citation
Aljohani, badria, "Cost effectiveness of bilateral prophylactic mastectomy with and without different
breast reconstruction techniques versus screening in women with high risk of breast cancer in the
Canadian province of Ontario" (2018). Electronic Thesis and Dissertation Repository. 5953.
https://ir.lib.uwo.ca/etd/5953

This Dissertation/Thesis is brought to you for free and open access by Scholarship@Western. It has been accepted
for inclusion in Electronic Thesis and Dissertation Repository by an authorized administrator of
Scholarship@Western. For more information, please contact wlswadmin@uwo.ca.

Abstract
We aimed to investigate the cost-effectiveness of bilateral prophylactic mastectomy
(BPM) with and without different reconstruction for the purpose of determining which
strategies represent value for money. We developed a decision analytic model to project
the lifetime clinical and economic consequences of different strategies. The decision
model was parameterized using 10-year follow up and cost data from Ontario
administrative health databases and Ontario Cancer registry. Compared to the organized
screening-based strategy, surgical strategies ranged from being more effective and costsaving and up to being associated with an incremental cost effectiveness ratio (ICER) of
$63,010 per quality-adjusted life year (QALY) gained, with BPM with immediate onestage acellular dermal matrix (ADM)-assisted implant breast reconstruction having the
greatest incremental QALY of 1.157 and lowest ICER of $9,615. BPM with immediate
one-stage ADM-assisted implant breast reconstruction is the most cost-effective strategy
and appears to offer the highest value for money.
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Chapter 1
Introduction and Objectives
Worldwide, breast cancer is the most prevalent cancer and the second leading cause of
cancer-related deaths among women. The International Agency for Research on Cancer
(IARC) and GLOBOCAN reported in 2012, 1.67 million women were diagnosed with,
and 522,000 women died from, breast cancer [1]. In Canada, 26,300 new cases were
diagnosed in 2017; these cases represented 26% of all newly diagnosed cancers in
women as reported by the Canadian Cancer Society [2]. Breast cancer incidence rates
oscillated from 1988 to 2004, presumably due to population changes in hormoneassociated factors such as age at menarche, gestation, menopause, breastfeeding, oral
contraceptives and hormone replacement therapy use [3]. A familial history, especially in
first-degree relatives, is a major risk factor for breast cancer development [4].

1.1 Breast cancer risk factors
The estimated general population lifetime risk of a breast cancer diagnosis in North
America is 1 in 8. A wide array of factors is associated with an increased breast cancer
risk, but age is the predominant risk factor. Nearly 80% of breast cancers are diagnosed
in women ≥50 years of age, and the odds of a breast cancer diagnosis increases with
increasing age [5], family history of hereditary breast cancer [6], having high-risk benign
breast disease (e.g., atypical ductal hyperplasia, lobular carcinoma in situ [7 ,8] , the
presence of dense breasts in the mammogram image [9], early life exposure to ionizing
radiation [10] and exposure to occupation-associated hazards during carcinogen handling,
and exposure to endocrine disrupting chemicals [11] are additional factors associated
with an increased risk of a breast cancer diagnosis.
Results of genetic studies using profiling technology indicate that the BReast CAncer
gene 1 (BRCA1) and BReast CAncer gene 2 (BRCA2) genes are genetic risk factors
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associated with a breast cancer diagnosis at a younger age [12,13].These genes participate
in some DNA repair pathways [14,15] and are associated with the development of
hereditary breast cancer (approximately 30–70%) [16]. Results of genetic research
studies indicate that the presence of germline mutations involving the BRCA1 or BRCA2
genes increases lifetime breast cancer risk to approximately 80% [17,16]. Over the past
20 years, BRCA1 and BRCA2 have been the primary focus of clinical genetic testing for
hereditary breast cancer risk. These high-penetrance genes are responsible for Hereditary
Breast and Ovarian Cancer Syndrome. Eric and colleagues [18] using US data indicated
that most of patients who had negative test results for BRCA1 and BRCA2 rarely
underwent additional testing. The patients who were tested further tended to be a small
subset of individuals with distinctive personal or family histories, or both, suggestive of
other high-penetrance hereditary cancer syndromes (e.g., associated with the genes
CDH1 (hereditary diffuse gastric cancer syndrome), PTEN (PTEN hamartoma tumor
syndrome), STK11 (Peutz-Jeghers syndrome), and TP53 (Li-Fraumeni syndrome) [18].
The genes ATM, CHEK2, and PALB2 are added to the above list for which there is
sufficient evidence to recommend breast magnetic resonance imaging (MRI) and riskreducing mastectomy [19].

1.2 Breast cancer screening in high-risk women

Since 1995, population and individual breast cancer risks have been assessed using
validated statistical models. Models calibrated for accurate estimation of population risk
are useful for cost-benefit analyses. However, risk assessment methods should also
accurately assess individual risk so that valid prevention and treatment plans can be
designed for individual patients [20].
The decision to refer a patient for testing and genetic counseling can be based on US
Preventative Services Task Force guidelines [ 21]. Breast cancer screening of high-risk
women is useful for early detection of breast cancer. Routine breast cancer screening for
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a high-risk group includes mammographic imaging, breast ultrasound and MRI [22].
Mammography is the initial diagnostic tool used for breast cancer screening [23]. It is the
standard of care for early detection of breast cancer. Mammography has a diagnostic
sensitivity of 77–95% and a diagnostic specificity of 94–97% [24]. If screening
mammogram results indicate the presence of any abnormal clinical characteristics,
women who receive a mammography evaluation in the absence of clinical signs or
symptoms will be referred for further investigation [25]. Ultrasound of the breast at the
target site of interest may also be recommended because the diagnostic accuracy of
mammography decreases as breast tissue density increases [25]. In most breast imaging
practices, ultrasound is predominantly used as an adjunct to mammography. It is
primarily used for problem-solving after the initial mammogram is performed and for
evaluation of palpable findings. Ultrasound is also used as the imaging modality for
initial evaluation of palpable abnormalities in women <30 years of age and in women
who are pregnant or breastfeeding. MRI of the breast is integral in screening the high-risk
patient. Compared with mammography, MRI has increased sensitivity for detecting
cancers, although breast imaging requires intravenous gadolinium which is renally
excreted and therefore contraindicated in pregnancy. Breast MRI screening is a valid
method used for the evaluation of dense breast tissue and in familial breast cancer
screening and for the presence of multiple tumors to delineate disease extent [22].

1.3 The need for this study
Effective use of health-care resources requires knowing which interventions work and
how much they cost, and experience with intervention implementation and delivery. One
of the first CEA guides for clinicians was written by Detsky and Naglie [26]. CEA
compares a new intervention’s costs and outcomes with a current treatment, strategy, or
intervention. The main objectives of CEA are to determine the cost of the new
intervention compared with current practice and whether the new intervention is more
effective. If it is more effective, then the additional benefit is also examined. CEA results
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are presented as additional cost per additional benefit (i.e., additional dollars per unit
benefit gained) [27].
This study provides additional data on the effectiveness of risk reduction and early
detection alternatives in terms of reduction of breast cancer mortality. We evaluated the
effectiveness of subcutaneous and total mastectomy as risk reduction mastectomy(RRM)
techniques. This study identifies relatively inexpensive interventions that may result in
substantial reductions in breast cancer risk and how to redirect resources to achieve these
reductions. It demonstrates the benefits of changing resource allocation from ineffective
to effective interventions and from less to more cost-effective interventions.

1.4 Objectives and research framework

The objective of this study was to perform an economic evaluation of potential
applications of BPM with and without immediate reconstruction in women with a highrisk of breast cancer. The aim was to determine whether these strategies represent value
for money for the Canadian health-care system. The research consisted of the following
steps:
i). Develop decision-analytic models. These models included decision trees with Markov
models as the terminal nodes in the trees. The Markov models were used to simulate
monthly transitions among different and distinct health states.
ii). Fit model parameters using three main sources of information (i.e., the Ontario
Cancer Registry, Ontario health administrative databases, and secondary sources such as
the existing literature) to estimate additional model parameters (e.g., QOL) for various
health states.
iii). Set up the models to perform CEAs of different management strategies in women
who are at high-risk of breast cancer. The results were presented as incremental cost-
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effectiveness ratios, which indicate the average cost per additional unit of health benefit.
The health effects outcomes were measured as QALYs. The life years were weighted by
utility estimates to obtain the QALY values. The cost outcomes were measured as the
mean cost per patient.
iv). Conduct one, two, and three-way deterministic sensitivity analyses of parameters of
interest to characterize uncertainty in the output measures and determine the minimum
conditions in terms of cost and accuracy for which a management strategy would be costeffective.
v). Use Monte Carlo simulations (1000 iterations) to conduct probabilistic sensitivity
analysis to understand the robustness of the results. For each model input, each iteration
consisted of a random draw from an appropriate distribution to produce a distribution of
model outputs.
vi). Conduct value-of-information analysis [28,29] as part of the sensitivity analysis to
determine the expected monetary value of perfect information about different
management strategies in Canadian women at high-risk of breast cancer. Probabilistic
baseline decision models were set up to express different strategy-related parameters (i.e.,
sensitivity and specificity) as probability distributions (i.e., reflecting uncertainty in the
Canadian setting) based on available validation analyses. Simulation techniques (i.e.,
making random draws from the probabilistic model) were used to assess the levels of
model uncertainty. A willingness-to-pay threshold [30] was included in the evaluation to
determine the opportunity costs associated with BPM with and without different
reconstruction techniques. This study provides policy makers who make health carerelated resource allocation decisions with important relative cost information. This
information will help them determine the combination of interventions that will result in
the greatest improvements in health care in Canada.
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Chapter 2
Review of Literature
2.1 Epidemiology of breast cancer

Breast cancer is the most leading cause of mortality in women and the second most
common cause of cancer-specific mortality in women. Results of reviews of 2008 data
from population-based cancer registries indicate that there were approximately 1,384,155
new cases worldwide and almost 459,000 breast cancer-related deaths [31]. The rates of
breast cancer diagnoses and of the mortality associated with the disease are increasing
worldwide [32]. This result indicates that since 2008 there was a nearly 18% increase in
incidence and mortality [1]. During their lifetime, an estimated one out of eight women in
Canada will develop breast cancer; translating into approximately 26,300 women and 320
men in Canada annually who will receive a breast cancer diagnosis [2,31]. Canadian
Cancer Statistics 2017 estimates that from these, 5,000 women and 60 men will die from
their disease [2]. It is estimated that by 2050, the worldwide annual incidence of new
diagnoses of female breast cancer will be 3.2 million cases [33]. There is therefore an
urgent need for measures to prevent and treat breast cancer.

2.1.1 Tumor features

Breast cancer is a genetically and clinically heterogeneous disease [34]. Tumor size has
long been recognized as an important indicator of prognosis. Larger tumors are
associated with poorer rates of survival, compared with tumors that are smaller [35,36];
The absence or presence of metastases to the regional lymph nodes also has prognostic
importance for disease-free and overall survival times. Regional metastasis is partially a
function of time [invasive breast cancers are more likely to become node-positive the
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longer they exist in the early untreated phase], but nodal involvement may also indicate
the presence of a more biologically aggressive breast cancer phenotype [37,38]. The
results of one study indicated that increase negative lymph node count predict favorable
overall survival (OS) and disease-free survival (DFS) in breast cancer with different
lymph node- positive [39]. There is a similar trend for disease recurrence; only 20–30%
of node-negative patients experienced recurrence within 10 years, but recurrence
occurred for approximately 70% of patients with node-positive breast cancers [36]. Rates
of survival decrease as the number of affected lymph nodes increases. Patients with four
or more positive nodes have poorer rates of 5-year survival [37,35] and 10-year survival
[40], compared with patients with three or fewer positive nodes. Revising the staging
system and changes in treatment protocols for systemic disease have resulted in
improvements in the survival of patients with lymph node-positive breast cancer [35].
Cancer staging is used to determine the anatomic extent of a cancer based on its natural
history. This information is used for therapeutic decision-making and for determining
overall prognosis [41]. Tumor-node-metastasis [TNM] staging is determined using the
combined score of the three components tumor size [T], regional lymph node
involvement [N], and presence of distant metastasis [M] [41]. The clinical TNM
classification system is based on evidence acquired from non-invasive diagnostic
methods such as physical examination or imaging, or more invasive methods such as
biopsy [42]. The clinical classification system is prone to unreliability. There is clinicalpathological agreement on tumor size in only 54% of cases [43], and clinical assessment
of lymph nodes is not always accurate [i.e., positive nodes may be impalpable or negative
nodes may be enlarged due to benign changes] [44]. Therefore, use of the pathological
TNM staging system is recommended. This system incorporates pathologic measurement
of tumor size and lymph node status after surgery to remove the primary tumor and
lymph nodes [44]. The presence of metastatic disease is not typically assessed
histologically, and thus the clinical classification of distant metastasis is usually given by
the “M” component [44].
Breast cancers diagnosed at a more advanced stage are associated with a poorer
prognosis. One population-based study of all breast cancer cases in British Columbia,
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which was performed in 2002, found that 10-year breast cancer survival rates were above
99% for stage 0, 95% for stage I, 81% for stage II, 55% for stage III, and 4% for stage IV
cancers [45].
Histologic grade is also strongly associated with breast cancer survival and recurrence,
though has historically not been included in formal staging criteria since its relative
contribution to overall prognosis above size and nodal status was not clear [46]. The
Scarff-Bloom-Richardson grading system Elston-Ellis modification [Nottingham grading
system] is the most commonly-used histologic grading system. Its use is recommended
by the United Kingdom, the European Breast Screening Pathology Groups, the United
States Directors of Anatomic and Surgical Pathology, the World Health Organization,
and the Union for International Cancer Control [44]. Histologic grading accounts for
three morphological features [i.e., tubule formation, mitotic count, and nuclear
pleomorphism]; each is assigned a score from 1 to 3 [47]. A tumor is considered welldifferentiated if the overall score is 3 to 5 [histologic grade I], moderately-differentiated
if the score is 6 to 7 [histologic grade II], and poorly differentiated if the score is 8 to 9
[histologic grade III]. Rakha and colleagues examined the association between histologic
grade and overall survival time. Survival time was significantly decreased for cancers
with a histologic grade of II versus I and III versus I. Rates of disease-free survival were
also poorer for breast cancers with a higher histological grade, though this association
was only statistically significant for grade III versus I [46]. A high mitotic activity index
(reflected in the mitotic count portion of the histologic grade) is also independently
associated with a poorer prognosis [48].
Lymphovascular invasion refers to the presence of tumor emboli within blood vessels or
lymphatic vessels. While not currently included in most staging systems, prognostic
indices, or treatment guidelines, some studies have found that lymphovascular invasion
decrease survival time [49-52]. Similarly to lymph node involvement, lymphovascular
invasion may have the same predictive power for survival [44].

2.1.2 Histological type
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Breast cancer is a heterogeneous disease. It has marked variability in clinical presentation
and behavior. Histologic typing may confer biological and prognostically meaningful
information [53], in addition to that inferred using tumor morphology alone. Invasive
ductal carcinoma of no special type [NST] accounts for 40% to 75% of invasive breast
cancers; it is the most commonly diagnosed carcinoma of the breast [54]. An NST
diagnosis is made based on exclusion of other adenocarcinomas that do not exhibit the
characteristics required to warrant classification as a special type. Special types account
for approximately 25% of all breast cancers, and 18 special types are currently
recognized by the World Health Organization [54]. Some special types, including tubular,
mucinous, invasive cribriform, medullary, infiltrating lobular, and tubulo-lobular breast
cancers, have more favorable prognoses compared with NST [55,56]. These cancers are
typically diagnosed at the grade 1 stage and have 10-year survival rates that generally
exceed 80% [56]. Other special types, such as mixed or solid lobular, mixed ductal and
lobular, and ductal/NST have substantially lower rates of 10-year survival [56]. The 10year population survival rate for patients with inflammatory breast cancer is
approximately 30% [57].

2.1.3 Molecular factors

Breast cancers are further classified by their expression levels of estrogen receptor [ER]
and progesterone receptor [PR] steroid hormone receptors. ER and PR levels are assessed
using immunohistochemistry, while expression of human epidermal growth factor
receptor 2/neu [HER-2] is assessed using both immunohistochemistry and fluorescence in
situ hybridization [58-59]. ER is expressed in 60–80% of invasive breast tumors and over
one-half of ER+ tumors are also PR+ [55,60]. Less than 10% of tumors are ER-/PR+
[60]. The v-erb-b2 avian erythroblastic leukemia viral oncogene homolog 2 [ERBB2]
oncogene, or the human epidermal growth factor receptor 2 [HER-2/neu] oncogene, is
amplified in approximately 20% of invasive breast tumors, leading to HER-2
overexpression [55]. Compared with patients who have ER+/PR+/HER-2- tumors,
patients with ER-/PR-/HER-2+ [Her2 positive] and ER-/PR-/HER-2 [triple negative]
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tumors are significantly more likely to have a late-stage diagnosis and a higher histologic
grade tumor, after adjusting for age [61].
Triple negative tumors also have low rates of overall and disease-free survival [61-63].
ER, PR, and HER-2 receptor expression status are used to indicate which molecular
pathway affects a tumor and to determine the choice of endocrine therapy. ER+/PR+
[early-stage and metastatic] cancers are treated using anti-estrogenic endocrine therapies
such as adjuvant tamoxifen (selective estrogen receptor modulator) or an aromatase
inhibitor [28 ,64]. These treatments have response rates of 60% to 70%. ER-/PR- tumors
have hormone therapy response rates of less than 10% [55]. ER+/PR- tumors have
intermediate response rates of approximately 40%. Tumors with receptor overexpression
or gene amplification of HER2 are treated using anti-HER2 therapies, such as
trastuzumab, which improve chemotherapy response in patients with HER2+ breast
cancers [65]. No specific drug therapy has been identified for treatment of triple negative
tumors, and thus chemotherapy remains the mainstay for treatment of these cancers [65].

2.1.4 Familial breast cancer

Except for age, a family history of the disease is likely the most important risk factor for
breast cancer development [66]. Compared with women who have no relatives affected
by breast cancer, women who have one affected first-degree relative are approximately
two times more likely to develop the disease [67]. The risk increases if more than one
first-degree relative is affected or if the relative has a diagnosis at a younger age
[4,66,67]. Women with an affected mother and one affected sister have approximately
three times the risk compared with women with no family history. Women with three or
more affected first-degree female relatives have nearly four times the risk [4,66]. While
rare, a first-degree family history of breast cancer in a male family member may further
increase the risk [67]. The risk associated with second-degree female relatives having the
disease is lower [relative risk [RR] = 1.5, 95% confidence interval [CI]: 1.4–1.6]
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compared with the risk conferred by having a first-degree family history [66]. A woman
who has a first-degree relative with ovarian cancer has approximately twice the chance of
developing breast cancer, compared with a woman who has no affected relatives [68].
Results of studies performed in the United States indicate that approximately 7% to 11%
of the general population of women have a first-degree family history of a breast cancer
diagnosis [69- 71]. Extrapolated to the female populations of Canada and Ontario 20–79
years of age in 2017; 911,102 to 1,382,731 Canadian women and 353,704 to 555,820
Ontarian women had a first-degree family history [2].
Many studies that have examined differences in the prognostic features of breast cancers
between women with and without a first- or second-degree family history have found no
statistically significant differences [72-77]. However, a few studies have found that
compared to women without a family history, women with a familial risk have smaller
tumors that are more often node negative and ER+ [78-81]. These results may explain
why some studies have found a survival benefit in women with a family history of the
disease [79-81].
Women with a family history with breast cancer have a greater risk of high-risk forms of
benign breast disease [BBD] such as atypical hyperplasia [82]. This increase in risk is
greater in younger women [82-84]. Having a family history of breast cancer and a
diagnosis of a severe type of BBD [i.e., proliferative lesions without atypia or atypical
hyperplasia] increases the risk of developing breast cancer, compared with having no
family history, but having a similar BBD diagnosis [85,86].

2.1.5 Epidemiology of breast cancer in Canada

In Canada, breast cancer is the most frequently diagnosed malignancies in women. There
were approximately 26,500 new diagnoses in 2017, which represented 25.5% of all the
newly diagnosed cancers in women [2]. In Canada, breast cancer incidence has increased
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throughout the early 1990s. This increase is likely due to increases in the use of screening
mammography [2]. Since 2004, breast cancer incidence has stabilized in Canada [2]. The
lifetime probability of having a breast cancer diagnosis for Canadian women of all ages is
12.4% [2]. In 2017, there were 10,100 new breast cancer diagnoses and 1,900 breast
cancer deaths in Ontario [2]. The breast cancer prevalence was just below 1.0% in 2010,
with approximately 63,000 women in Ontario having a breast cancer diagnosis sometime
during the 10 years leading to the beginning of 2010 [2].
Breast cancer ranks second [following lung cancer] in female cancer mortality in Canada
[2]. Age-standardized mortality rates for deaths from female breast cancer have been
declining since the mid-1980s. There was a projected relative reduction of 55%, from
41.7 per 100,000 women in 1988 to 23.3 deaths per 100,000 women in 2017 [2]. This
change likely resulted from increased participation in breast cancer screening
[mammography], combined with the use of targeted adjuvant therapies following breast
cancer surgery [2] . Similar declines in rates of breast cancer mortality have also been
noted in the United States, United Kingdom, and Australia [87].

2.2 High-risk breast cancer

The general average population risk of a breast cancer diagnosis is 1 in 8 to 1 in 12 [88],
and age, family history, endocrine exposure, breast density, radiation to chest wall and a
history of one or more benign proliferative breast disorders can considerably increase the
risk. Mutations in moderately or highly penetrant cancer susceptibility genes that result in
an inherited predisposition are responsible for approximately 5% of breast cancer cases
[89]. Discovery of specific germline genetic susceptibility factors [e.g., mutations in the
BRCA family of tumor suppressor genes] is important for accurate risk assessment
results. The lifetime risk of developing breast cancer in women who carry these genes is
40%–87%, and the cancer typically occurs at a younger age [90-92]. The definition of
‘high risk’ is inconsistent in the medical literature. This variability presents an important
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challenge to successful evidence-based management of high-risk women. A ≥25%
lifetime risk has traditionally been used as the definition of ‘high risk’ in the Canadian
context [93], although some studies define high-risk as a ≥20% lifetime risk [94].
Prevention research, cancer screening, and/or clinical practice have tended to stratify risk
into an inherited type [i.e., genetic or ‘familial’ risk] of risk category and a personal risk
factor-based risk category [95].

2.2.1 Breast cancer risk assessment models

Since 1995, breast cancer risk assessments have increasingly become included in routine
medical care. Individuals at elevated risk of breast cancer are identified and offered a
different approach for prevention and screening. Statistical models to assess individual
risk and to accurately estimate population risk have been designed and validated [96151].
There are two main approaches in breast cancer risk models that can be used to assess
risk. Current risk prediction models quantify a woman’s risk based on risk factor
combinations and is estimated over a time interval [i.e., a 5-year interval, a 10-year
interval, or lifetime risk] [96-133]. Models that provide a probability that a woman has a
mutation in a gene known to cause a hereditary cancer predisposition syndrome are also
used for risk estimation [134-151].
These model types can be further subdivided into the two broad categories of empirical
and genetic models [20,152]. Empirical breast cancer risk models combine personal or
family history factors, or both, to estimate the probability of detecting a BRCA1 or
BRCA2 mutation. They do not include genetic factors such as mode of inheritance,
mutation prevalence, or penetrance [i.e., the chance of developing cancer in someone
carrying a gene mutation]. The Gail model is the most well-known and often-used breast
cancer risk assessment model [103]. Other empirical models include the Shattuck-Eidens
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model [the Myriad I model] [151] and the Couch model [Penn Model]. The Couch model
[updated as the Penn II model] now includes more family and personal variables relating
to cancer history [153]. The details about the development and validation of the Penn II
model remain unpublished. The Myriad II model [the Frank model] is one of the
empirical models derived from the Myriad Genetic testing program [139,140]. The
Myriad II is based on genetic testing of >10,000 individuals [139]. Two similar models
were developed to simplify the use of these models [i.e., the Manchester model [143] and
the family history assessment tool [154]. Another group of empirical models includes the
LAMBDA model [144] and the National Cancer Institute model [196]. These models
were developed for use in Jewish women of Eastern European descent [Ashkenazi Jews].
The models developed from data collected in Spain [146] and Finland [148] are also used
for risk assessment. Results of an analysis using a Spanish dataset indicated that these
scoring system models and the Myriad II model have similar discriminatory power.
Compared with models that are not aimed at specific populations, models intended for
use for specific populations do not have better discriminatory accuracy [155].
Genetic risk prediction models, as discussed by Amir and colleagues [20], include
assumptions about susceptibility gene numbers, cancer risks caused by gene mutations,
and mutation frequencies in the general population. The primary advantage of these
models is that they can be used to estimate mutation carrier probabilities and cancer risks
without requiring information about the family structure and disease pattern [20]. Genetic
models provide a probability that a woman has a mutation in a gene known to cause a
hereditary cancer predisposition syndrome. Hereditary breast and ovarian cancer
syndrome [i.e., the BRCA1 and BRCA2 genes] and Cowden syndrome [PTEN gene]
models include assumptions about the numbers of cancer susceptibility genes, the
population-wide allele frequencies, and the risks associated with the alleles. Specific
within-family relationships are included in the pedigree analysis methods that are used in
the models. The underlying assumptions of the models affect the accuracy of the risk
prediction. Approximate risk estimates are produced by the current models used because
additional genes that affect breast cancer susceptibility remain to be identified [152]. The
BRCAPRO model is the most used and validated of the group [136,156 ,157]. The
International Breast Cancer Intervention Study [IBIS] model [Tyrer–Cuzick model]
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[100], the Yale University model [158], and the Breast and Ovarian Analysis of Disease
Incidence and Carrier Estimation Algorithm [BOADICEA] [135] are other validated and
commonly used models.
BRCA1 and BRCA2 risk estimation models [136,156-162] have been validated and
compared. The empirical and genetic models have high discriminatory power between
mutation carriers and non-carriers, but the between-model and between-population
sensitivity and specificity varies [163]. In one study, the five models most frequently
used for populations in the United Kingdom [i.e., BOADICEA, BRCAPRO, IBIS,
Myriad II, and Manchester] were used to compare data from six genetics clinics in the
United Kingdom [134]. The BOADICEA was the only model that accurately predicted
the overall observed number of mutations that were detected in the patient populations. It
also had the best between-group [i.e., mutation carriers versus non-carriers]
discriminatory power. The difference was statistically significant between the
BOADICEA and all the other models, except the BRCAPRO [area under the curve
[AUC]: BOADICEA = 0.77, BRCAPRO = 0.76, IBIS = 0.74, Manchester = 0.75, and
Myriad II = 0.72]. The numbers of BRCA1 and BRCA2 mutations in populations with a
low estimated risk of having BRCA1 or BRCA2 mutation carriers were underestimated
by all models, including the BOADICEA model. The BRCAPRO, Penn II, Myriad II,
Couch, family history assessment tool, BOADICEA, Manchester, and IBIS models were
compared using a single-institution study, which was performed in Toronto, Canada. The
results indicated that all except the Manchester, IBIS, and Couch models had similar and
good discriminatory accuracy [AUCs all approximately 0.75]. The AUC values for
discriminatory accuracy for the Manchester and IBIS models were 0.68 and 0.47,
respectively. Compared with the other models, the Penn II model had higher diagnostic
sensitivity at the 10% testing threshold for assessment of the probability of carrying a
mutation [164].
The limitations of risk assessment models that reduce their accuracy and validity include
small family size, adoption, and lack of family history information [165]. The genetic risk
assessment models generally underestimate cancer risk because they include data about
first- or second-degree relatives, but not about more distant relatives. Prostate and
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pancreatic cancer are examples of two types of cancer that are not included in the family
history assessments of some models. These cancers are also affected by BRCA1 or
BRCA2 mutations [165].
Amir and colleagues used a prospective analysis to compare the Gail, BRCAPRO, and
IBIS cancer risk models. Fifty-two cancers were recorded in a population of 1,933
women who attended a family history clinic [166]. They calibrated the BRCAPRO model
to use the Claus [89] and Ford [91] mutation prevalence estimates. The investigators used
data collected during a mean follow-up of 5.27 years to derive the model inputs and
obtained estimates of breast cancer risk. The results [i.e., ratios] for the expected to
observed numbers of breast cancers were 0.48 [95% CI: 0.37–0.64] for the Gail model,
0.56 [95% CI: 0.43–0.75] for the BRCAPRO [Claus] model, 0.49 [95% CI: 0.37–0.65]
for the BRCAPRO [Ford] model, and 0.81 [95% CI: 0.62–1.08] for the IBIS model.
Receiver operating characteristic curves were used to evaluate the accuracy of the models
for individual assessment [AUC = 0.735, Gail; AUC = 0.716, BRCAPRO [Claus]; 0.737,
BRCAPRO [Ford]; 0.762, IBIS]. The IBIS model was the most consistently accurate for
breast cancer risk prediction [166]. The results of subgroup analyses indicated that the
Gail, BRCAPRO [Claus], and BRCAPRO [Ford] models underestimated breast cancer
risk, especially during individual assessment of women with one first-degree relative with
breast cancer. In this subgroup of women, risk prediction was accurate when the IBIS
model was used. All models were accurate for risk prediction for women who had two
first-degree relatives or one first-degree relative and two other relatives with the disease
[166]. Taken together, these results suggest that having one affected first-degree relative
affects risk more than predicted.
The only models that accurately predict breast cancer risk in women with a family history
of ovarian cancer are the BRCAPRO [Ford] and IBIS models [167]. Analyses using these
models include a woman's family history of ovarian cancer. Therefore, a family history of
ovarian cancer has a substantial effect on risk. The values for risk in women who were
nulliparous or whose first live birth occurred at >30 years of age were underestimated by
the Gail, BRCAPRO [Claus], and BRCAPRO [Ford] models; the results were statistically
significant [166,167]. The Gail, Claus, Claus extended, Jonker, IBIS, and BOADICEA
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models were included in a more recently published retrospective analysis. The Gail,
Claus, and Jonker models underestimated breast cancer risk. Taken together, these results
suggest that the IBIS and BOADICEA models are the most accurate models available for
assessment of breast cancer risk , these are the models used in Ontario by CCO [165167].

2.2.2 Genetic counseling

A complex interaction of genetic, genomic, and environmental factors results in the
initiation and progression of breast cancer [168]. Since 1995, specific genes have been
recognized as associated with hereditable breast and gynecologic cancers, and the need
for cancer genetic counseling has consequently grown [169]. Individuals who have
cancer predisposition gene mutations and family and personal histories that affect overall
risk are identified by genetic counselors. Counseling is an important part of the risk
assessment process and accurate information and emotional support can be provided to
individuals who have inherited deleterious mutations present in parents or siblings a well
as to those who may have a generalized increased risk for cancer development with and
without having inherited any specific mutations [169]. Counselors use different risk
assessment approaches to evaluate individual risk for carrying a deleterious cancer
susceptibility gene. Counselors provide nondirective counseling concerning the decision
to undergo genetic testing or to initiate screening, diagnostic, or preventative measures.
They also perform psychosocial assessments because patients often endure psychological
upset and emotional stress when the results of the counseling and testing are revealed.
Before counseling and risk assessment proceeds, counselors should obtain information
from patients regarding expectations about the counseling experience, perceptions about
the effects of the cancer[s], the economic effects of counseling and testing and the
possible clinical outcomes, as well as their relationships with relatives and their ability to
get information from those relatives. In the case where an increased risk for cancer is
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determined, the counselor should also determine if the patient has the desire to implement
lifestyle changes and preventative measures.
US Preventative Services Task Force [21] guidelines for when to refer a patient for
genetic counseling and testing include having two first-degree relatives with breast
cancer, at least one diagnosed at ≤50 years of age; three or more first- or second-degree
relatives with a breast cancer diagnosis; any pattern of breast and ovarian cancer among
first- and second-degree relatives; a diagnosis of bilateral breast cancer in a first-degree
relative; a diagnosis of ovarian cancer at any age in two or more first- or second-degree
relatives; both a breast and ovarian cancer diagnosis, regardless of age, in a first- or
second-degree relative; a breast cancer diagnosis in any male relative; a woman of
Ashkenazi Jewish heritage who has a first-degree relative [or any two second-degree
relatives] who had a diagnosis of breast or ovarian cancer [21].

2.2.3 Familial breast cancer risk

The first of many reports of a familial pattern of breast cancer was published in 1866
[170]. One family member had early-onset carcinoma of the breast, and a pedigree
analysis revealed that four generations of family members also had the disease. Breast
cancers arising from a hereditary cancer susceptibility syndrome [i.e., caused by
mutations in high-penetrance susceptibility genes] are seen in only approximately 5% of
all breast cancer cases. Approximately 16% of presumed hereditary breast cancers are
due to germline mutations in the BRCA1 or BRCA2 early-onset genes [172,173]. The
BRCA1 and BRCA2 genes were identified in 1994, and since then a few other highpenetrance breast cancer susceptibility genes have been described [174].
A meta-analysis performed by Antoniou et al. revealed that BRCA1 mutation carriers
have a 65% [95% CI: 44%–78%] lifetime breast cancer risk and a 39% [95% CI: 18%–
54%] lifetime ovarian cancer risk. BRCA2 mutation carriers have a 45% [95% CI: 31%–
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56%] lifetime breast cancer risk and an 11% [95% CI: 2%–19%] lifetime ovarian cancer
risk [90]. Associations between BRCA2 mutations and an increased risk of pancreatic,
gastric, bone, prostate, laryngeal cancers, and melanoma are significantly elevated
[139,175-178]. Numerous studies have investigated mutation penetrance, and some
lifetime risk estimates for carriers of either BRCA mutation exceed 80% [138,179,180].
Penetrance estimates differ by method of case ascertainment; family studies tend to
produce higher estimates than studies based on cases unselected for family history [181].
The penetrance of BRCA1/2 mutations is high, but these mutations are rare. In the
general population, the estimated carrier rate is 1 in 345 to 1 in 1000 [173,182,183]. The
values for BRCA1/2 mutation prevalence are higher among specific geographic and
ethnic sub-populations [184,185]. Clusters of BRCA mutations have also been identified
in the Netherlands [186], Iceland [187,188], Sweden [189], and the Bahamas [190].
Mutation carrier status is also linked to breast cancer outcomes. Numerous studies have
investigated prognosis in BRCA-associated breast cancers. The results of some early
studies suggested that patients with BRCA-associated breast cancer have a better
prognosis, compared with patients with a sporadically-occurring cancer type [191-194].
Later studies using more rigorous methodologies [i.e., larger sample sizes, inclusion of
important prognostic factors, adjustment for treatment type] found that BRCA-associated
cancers have a poorer prognosis [195-199]. A review of this evidence suggests that the
overall prognosis for patients with BRCA-associated breast cancer is similar to the
prognosis for patients with sporadic breast cancer [200]. However, contralateral breast
cancer risk is higher in patients with BRCA-associated breast cancers [201,197]. Survival
may depend on whether adjuvant chemotherapy is administered [195,196].

2.2.3.1 BRCA1and BRCA2 gene and multi-gene panels
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In 1990, linkage analysis revealed that the BRCA1 gene [chromosome 17q21] was
associated with breast cancer in a large group of families with members affected by earlyonset disease [202]. The gene was cloned in 1994, and researchers found that in families
with more than one case of breast cancer, the BRCA1 coding sequence contained
truncating mutations [203]. The BRCA2 gene [chromosome 13q12.3] was found in 1995.
Linking analysis and positional cloning were used to examine breast cancer pedigrees in
successive generations of families [204,205]. The BRCA2 mutation was also found in
families with high frequencies of male members with breast cancer [202-205].
In addition to increased breast and ovarian cancer risks, the risks of fallopian tube,
gastric, colon, melanoma, prostate, and pancreatic cancer are increased in individuals
with BRCA1 and BRCA2 mutations [206-212].
BRCA1 and BRCA2 are separate and distinct tumor suppressor genes that cause
approximately 5% of all cases of breast cancer [213] and 85% of all hereditary breast and
epithelial serous ovarian cancer cases [214]. In the absence of epithelial serous ovarian
cancer in the family pedigree, BRCA1 and BRCA2 are responsible for a smaller
percentage of familial breast cancer cases [215,216]. The general population frequencies
of mutations in these two genes is approximately 1/300 to 1/800 [183]. However, results
of a study by Risch and colleagues in Canada suggested that these frequencies may be
considerably higher, at 1/140 to 1/300 [92]. Some populations and communities have
higher frequencies of specific BRCA1/2 mutations compared with the general population
[183,92].
Family linkage studies have identified additional high-penetrance genetic mutations on
the phosphatase and tensin homolog [PTEN] and tumor protein 53 [TP53] tumor
suppressor genes [217]. Female carriers of the TP53 mutation have a breast cancer risk of
approximately 30% by 30 years of age [218], and 50% by 50 years of age [219].
Mutations on ataxia telangiectasia mutated [ATM] kinase, checkpoint kinase 2 [CHEK2],
RAD51 paralog C [RAD51C], BRCA1 interacting protein C-terminal helicase 1 [BRIP1],
and partner and localizer of BRCA2 [PALB2] are associated with a moderate increase
[20% to 40%] in the lifetime risk [217,218]. Commonly-occurring low-penetrance alleles
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associated with slightly increased or decreased risk have been identified by genome-wide
association studies [GWAS] [217,218]. Only 5% to 10% of breast cancer cases likely
result directly result from genetic mutations; BRCA1 and BRCA2 mutations account for
the largest proportions [2% to 5% of all breast cancers on a population level] [219].
Approximately 5%–10% of the patients who undergo testing for BRCA1/2 mutations
have a variant of uncertain clinical significance [VUS] [220]. More than 1,500 VUSs
have been identified and are frequently identified in individuals in minority ethnic
populations, Most VUSs have only been reported in one to two individuals, so analysis of
the clinical effects of VUSs is challenging [221]. Once a VUS is identified, further
analyses such as segregation analysis or analysis of study variants in multiple unrelated
individuals are used to characterize the VUS as clinically relevant [favor deleterious] or
irrelevant [favor polymorphism] [220,221]. However, small family sizes and few
individuals with any particular VUS impede the mathematical estimation needed to better
characterize the clinical effects of a specific VUS [221]. A VUS finding is difficult to
manage clinically because it can lead to considerable emotional distress concerning the
unknown clinical implications of the genetic test result. Counselors must use their skills
to provide a clear and measured overview of the meaning and implications of the test and
provide emotional support for a patient who may be distraught because a definitive
assessment of risk cannot be given [221,222].

2.2.3.2 Tumor characteristics in familial breast cancer

2.2.3.2.1 Tumor characteristics of BRCA1-related breast cancer

The histopathological characteristics of BRCA1-associated breast cancers differ from the
characteristics of sporadic breast cancers. Invasive ductal adenocarcinoma is the most
common [74%] BRCA1-associated tumor, while 2% of sporadic breast cancers versus
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13% of BRCA1-associated tumors are medullary-like carcinomas [223]. The frequencies
of other histological types are similar between BRCA1 and sporadic tumors. Compared
with the sporadic tumors, BRCA1 tumors tend to have higher mitotic counts, be more
poorly differentiated [grade 3] and have higher numbers of necrotic areas in a given
tissue sample [224]. The BRCA1 tumors have characteristics of more aggressive
phenotypes; they have less tubule formation but have more pleomorphism [192,223-226].
They have high rates of lymphovascular invasion, tend to be well-demarcated, and have
high degrees of lymphoplasmacytic infiltration [227].
Statistically significant differences in grade [higher] and in percentage of medullary type
tumors [more cases] are present in the younger population [<50 years of age] compared
with the older population [≥50 years of age] of BRCA1 mutation carriers who develop
breast cancer [228]. Initially, it was reported that compared with non-carriers, the
BRCA1 mutation carriers have lower rates of ductal carcinoma in situ [DCIS] [41% for
non-carriers and 2% for carriers] and lobular carcinoma in situ [LCIS] [56% for noncarriers and 6% for carriers]. However, these estimates were developed from cases of
invasive breast cancer that contained non-invasive disease within it [229]. Results of
analyses of tissue from prophylactic mastectomy (PM) of BRCA1 mutation carriers
indicated that non-invasive disease occur more frequently in carriers [e.g., DCIS [230232], LCIS [230], atypical ductal hyperplasia [ADH] [230-232] and atypical lobular
hyperplasia [ALH] [230-232] , usual ductal hyperplasia , columnar cell lesions [232],
and fibroadenoma [233,234]. Breast cancers of BRCA1 mutation carriers are likely to
have ER [ER] overexpression and low progesterone receptor [PR] expression
[228,235,236].
human epidermal growth receptor 2 [HER-2/neu] , epidermal growth factor receptor
[EGFR], Cyclin D1 [CCND1] ,are major oncogene in breast cancer ,Compared with
control cancers, human HER-2/neu expression is usually low in BRCA1-related breast
cancers, and there are few reports of amplification of HER-2/neu [226,235]. Because
HER-2/neu is near BRCA1 on chromosome 17, HER-2/neu may be lost during loss of
heterozygosity at the BRCA1 locus [237-239]. Compared with HER-2/neu, EGFR
overexpression is strongly associated with BRCA1-associated breast cancers [240,340].
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Cyclin D1 [CCND1] is often not expressed in the BRCA1-related breast cancers [242].
tumor protein TP53 gene mutations which plays an important role in cell cycle control
and apoptosis, are detected in 30%–77% and approximately 20% of BRCA1 tumors and
sporadic controls, respectively; TP53 often accumulates in BRCA1 tumors. The BRCA1
and BRCA2 genes might affect the distribution of TP53 mutations [235,243].
BAX and BCL2 are apoptosis-associated proteins that have lower expression in BRCA1
breast tumors compared with sporadic malignant breast tumors [246,247,239], but
BRCA1 tumors have high levels of caspase 3 activity [247]. The hypoxia response is
mostly controlled by the key regulator hypoxia inducible factor-1α [HIF-1α], which is
correlated with a poor prognosis and is overexpressed during sporadic breast
carcinogenesis [248-250]. HIF-1α is overexpressed in most BRCA1-related breast tumors
[251]. The BRCA1-associated breast tumors likely have an increased cancer stem cell
population compared with sporadic cancers, stem cell marker ALDH1 expression is
higher in the BRCA1 tumors [252]. M.R. Heerma van Voss compared breast tumors with
normal breast tissue among healthy control breast specimen and found that there are no
differences in HIF-1α expression in normal breast tissue of BRCA1 mutation carriers
[252]. Taken together, the results of studies of this immunophenotype indicate that the
BRCA1-associated tumors have the breast progenitor cells’ immunophenotype, so the
BRCA1s might be derived from these cells [227,253]. The immunophenotypes of the preinvasive lesions in the BRCA1 carcinogenetic spectrum remain to be determined [227].
The immunophenotype of accompanying invasive cancers is similar to the BRCA1
carrier DCIS immunophenotype [253].
Higher rates of brain and lung metastases and lower rates of bone metastases have been
found in patients affected by BRCA1 tumors [199]. The results of studies comparing
BRCA1 breast cancer with age-matched sporadic breast cancer patients indicate that
survival rates are lower for BRCA1 patients in some populations but are similar in other
populations [194,197].
Breast cancer subtypes can be differentiated using gene expression profile analysis
[254,255]. These analyses have revealed that BRCA1-related breast cancers are typically
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the basal subtype; they express basal markers [e.g., CK 5/6, CK14, EGFR, P-cadherin,
caveolin 1, vimentin, and laminin] [240,244]. These results indicate that in BRCA1
germline mutation carriers, carcinogenesis frequently occurs along the “basal”
progression route. BRCA1 germline mutation-associated breast tumors have less
promotor hypermethylation of tumor suppressor genes than do sporadic tumors, but the
rate is still higher when compared with the rate in normal tissue [256].
Compared with the tumors used as sporadic controls, the BRCA1 tumors have a different
pattern of chromosomal copy-number gains and losses [e.g., gains of 3q, 7p, 8q, 10p,
12p, 16p, and 17q and losses of 2q, 3p, 4p, 4q, 5q, 12q, 16p, and 18q]. This pattern has
only a partial overlap with the copy-number changes in the sporadic and BRCA2
germline mutation breast tumors [257-258].

2.2.3.2.2 Tumor characteristics of BRCA2-related breast cancer

Like BRCA1-associated tumors, invasive ductal carcinoma is the most common
histological type found in BRCA2 tumors [76%]. Compared with sporadic breast cancers,
invasive [pleiomorphic] lobular, tubular, and cribriform carcinomas have been reported at
higher incidence rates for BRCA2-associated breast cancers [192,223,225,962].
Compared with controls, they have more nuclear pleomorphism, less tubule formation,
and higher mitotic rates, which results in a carcinoma that is poorly- or moderatelydifferentiated [grades 2 and 3] [223,239]. Also similar to the BRCA1s, the BRCA2 breast
tumors have a greater proportion of continuous pushing margins [i.e., compared with the
sporadic breast cancers] [ 223,259]. In BRCA2 mutation carriers, the pre-invasive DCIS
and LCIS tumors occur at the same frequencies [52% and 3%, respectively] compared to
sporadic patients’ tumors [56% and 6%, respectively] [229,260,261]. Compared with
BRCA1 mutation carriers, tissue from PMs of BRCA2 carriers can range from no
difference to more frequently occurring premalignant lesions [e.g., DCIS, LCIS, ALH,
ADH, and columnar cell]. The same lymph cytoplasmic infiltration found in invasive
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BRCA2- and BRCA1-related cancers has also been found in DCIS lesions, and T-cell
lobulitis is also present in normal breast tissue [230,234].
Sporadic and BRCA2 breast cancers have similar immunophenotypes, so most BRCA2
tumors have an immunophenotype different from the BRCA1-associated breast tumors.
ERα and PR are expressed at higher rates in BRCA2 cancers [228,240]. As patient age
increases, the probability of having an ER-positive BRCA2 breast cancer decreases
[242]. Compared with sporadic breast cancer, there is no or low expression of HER-2/neu
in BRCA2 cancers; HER-2/neu amplification is only rarely found [239-241]. Levels of
fibroblast growth factor 1 [FGF1] and fibroblast growth factor receptor 2 [FGFR2]
expression are higher in the BRCA2 compared with the BRCA1 breast cancers.
Physicians might use this difference to differentiate the BRCA2 breast cancers from
others. Typically, only “luminal” cytokeratins [e.g., CK8 and CK18, and not CK5/6 and
CK14] are expressed in the BRCA2 breast cancers [247]. No caveolin1 expression has
been described [ [239]. Compared with the BRCA1s, p53 incidence is the same or lower
for the BRCA2 breast cancers [247]. Compared with BRCA1 and non-BRCA carriers,
BAX, cyclin D1, and BCL2 expression can be greater in the BRCA2-related breast
cancers [239,247]. BRCA2-related cancers also can have high EGFR expression [based
on anecdotal evidence]. No results suggest that BRCA2-related carriers are positive for
HIF-1α, P-cadherin, vimentin, or ALDH1 expression [253].
Invasive BRCA2-related cancer immunophenotypes have been well-studied, but
immunophenotypes of the pre-invasive BRCA2 carcinogenetic spectrum lesions have
not. The DCIS immunophenotypes in BRCA2 carriers and in accompanying invasive
cancers are similar [253].
Unlike the BRCA1 breast cancers that likely originate from progenitor cells, most of the
BRCA2 related breast cancers are luminal type cancers and overexpress PR, ER, CK8,
and CK18 Therefore, it is likely that these cancers originate from breast luminal cells
rather than progenitor cells [239-241].
The ER positivity is likely associated with the bone and soft tissue metastases that affect
women with BRCA2-related breast cancer [199]. Similar to the studies that attempted to

26
predict outcomes in BRCA1 patients, the results of studies that examined outcome for
BRCA2 patients have been conflicting [194-197].
Discriminating genes [i.e., transcription, signal transduction, cell adhesion and
proliferation, and extracellular matrix remodeling] were examined using gene expression
analysis to study unique characteristics of BRCA2-associated tumors [261-263]. The
relatively high levels of expression of FGF1 and FGFR2 were confirmed using
immunohistochemistry. Most of the BRCA2-related breast cancers examined were found
to be of luminal origin [254,255]. Chromosomal copy-number gain and loss patterns are
present in BRCA2 breast cancers that are not present in sporadic controls [i.e., gains of
8q, 17q22-q24, and 20q13, and loss of 8p, 6q, 11q, and 13q] [257,258].

2.2.3.2.3 Tumor characteristics of non-BRCA1- and non-BRCA2-related
breast cancers

The cancers of patients with a strong family history of breast cancer but without BRCA1
or BRCA2 germline mutation have various phenotypic characteristics and result from
mutations in low- to moderate-penetrance genes or undiscovered genes. Compared with
the sporadic breast cancers, these tumors are typically an lower grade and the
immunophenotype is approximately similar to that for sporadic breast disease [264,265].
The results of a study that classified non-BRCA-related breast cancers into two
homogenous subsets indicated that ribosomal genes were more frequent in one group
compared with the other, based on a 60-gene set [266].

2.2.3.3 Penetrance [low, moderate, and high]
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Six uncommon but highly penetrant breast cancer genes [e.g., BRCA1, BRCA2, PTEN
[267], [268], TP53 [269] , [270], [271], CDH1 [272], and STK11 [273], [274], and four
rare but moderately penetrant breast cancer genes [CHEK2] [ [278], BRIP1 [BACH1]
[279], ATM [280], and PALB2 [281] have been identified and confirmed. Most of the
<30% of the cases with a personal and/or family history of hereditary breast cancer for
whom a causative gene mutation has been identified, have a mutation in one of the six
highly penetrant genes. These patients are typically managed following specific
published guidelines [282]. Some of the cases result from mutations in the moderately
penetrant genes. Genetic testing methods have also been used to identify low-penetrance
alleles. The low-penetrance alleles should not be routinely screened because they have a
polygenic effect in only a small number of cases. Until the gene identification accuracy
and the effectiveness of clinical case management improve, a high index of suspicion for
a speciﬁc etiology should be present before mutation testing is performed [283].

2.2.3.4 Ashkenazi Jewish population risk

Since the 19th century, race has been thought to predispose its members to increased
susceptibility to specific diseases [281, 282]. Researchers study different ethnic and racial
groups to find between-group differences in disease susceptibility [283]. For example,
Jewish people of Ashkenazi descent are predisposed to the development of autosomal
recessive disorders [e.g., Tay-Sachs disease] [284,285]. The prevalence of these disorders
is greater among those of Ashkenazi descent compared with other groups. Many distinct
mutations occur only in this genetically unique group of people [284,286], which
represents >90% of the approximately 6 million people of Ashkenazi descent in the
United States and Canada.
Compared with non-Ashkenazi Caucasians who are not of Jewish descent, those who are
of Ashkenazi descent have a greater risk of breast cancer [287,288] associated with nongenetic and genetic risk factors. The results of a large sample size case–control study
[289] indicated that the RR for breast cancer associated with Jewish ethnicity is 1.10
[95% CI: 0.84–1.44]. These women who also have a first-degree relative with breast
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cancer or whose breast cancer was diagnosed at <50 years of age have higher RR values
for being BRCA mutation carriers [RR: 1.95, 95% CI:0.88–4.63; RR: 1.55, 95% CI:
0.92–2.63, respectively]. BRCA1 and BRCA2 mutations have been found to be present at
higher frequencies among Jewish patients. Compared with the general population, the
frequencies of these mutations are approximately five times greater among those of
Ashkenazi descent and may be affecting 2.0%–2.5% of Ashkenazi Jewish men and
women overall [290-294]. About 2.5% of Ashkenazi Jewish descent carry one of three
ancient (founder) mutations in BRCA1 or BRCA2 (185delAG or 5382insC in BRCA1 and
6174delT in BRCA2). Founder mutations of BRCA1 or BRCA2 in Ashkenazi Jewish are
responsible for the majority of hereditary breast and ovarian cancer and some Ashkenazi
families with histories of an inherited cancer have been shown to segregate other (nonfounder) mutations of BRCA1 or BRCA2. the information regarding the incidence of
these non-founder mutations is limited and it makes Counselling these families difficult
[149, 233, 290-292].

2.2.3.5 Male breast cancer

By 2018, The American Cancer Society estimates that in the United States,
approximately 2,550 men will receive a diagnosis of breast cancer. These cases of male
breast cancer represent 0.5%–1% of all cases of breast cancer, and it is anticipated that
among these,480 will die as a result of their disease [295]. The results of a meta-analysis
indicated that men who have a first-degree relative with breast cancer, BBD, or who have
Jewish ancestry, are at significantly increased risk of developing breast cancer [296].
Evans and colleagues found that having a gene mutation in the BRCA2 gene is associated
with an 8% lifetime risk of breast cancer development in men. All male breast cancer
[MBC] patients should undergo a thorough genetics evaluation [297]. An increased risk
for developing MBC is seen among BRCA1 and BRCA2 gene mutation carriers, and
guidelines recommend that individuals who have a personal or family history of MBC
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should be tested for mutations in these gene [298]. Four to 40% of MBC patients have a
BRCA2 gene mutation. Mutation in the BRCA2 gene is the most common mutation
found in MBC cohorts, depending on the population examined and whether there is a
family history of a breast and ovarian cancer diagnosis [139,150,187,299-303]. Males
who are BRCA1 and BRCA2 pathogenic mutation carriers have cumulative lifetime
breast cancer risks of 1%–2% and 5%–10%, respectively, and the lifetime risks for
pancreatic and prostate cancers are also increased in these individuals [304,305].
Only a limited number of studies have examined the associations between MBC risk and
other genes. An association between a specific CHEK2 mutation [1100delC] and
increased MBC risk was found in two studies [275,306], but the results of other studies
were not concordant with this finding [307-314]. The effects of other CHEK2 pathogenic
variants are unknown. Other studies have found that MBC patients can have PTEN,
androgen receptor [AR], NF1, and PALB2 germline pathogenic mutations, but the
clinical significance of these mutations and the risk estimates associated with them
remain to be determined [315-318]. The utility of multi-gene panel testing beyond
BRCA1/2 is limited in MBC patients, and the validity of any such results has not been
determined. The results of a study that included multi-gene panel testing of a group of
MBC cases indicated that 31.8% [n = 7/22] had positive test results; 4 (18.2%) had
BRCA1/2 mutations, and 3 (13.6%) had other mutations [i.e., PALB2, CHEK2, and
ATM] [302].
Anderson and colleagues found in a. study published in 2010, based on an analysis of
SEER database between 1973–2005, that 92% of the 5,494 MBC cases and 78% of the
838,805 female breast cancer cases were ER-positive [319]. Similar to women, most
MBCs are invasive ductal carcinomas [320,321]. Compared with women, papillary
carcinomas are more, and lobular carcinomas are less, common in men [322].
Patterns of HER2 status and tumor grade for MBCs are unclear because retrospective
study databases contain missing or conflicting data. Anderson and colleagues in their
analysis of SEER database between 1973–2000, found that 39% of the 1,180 tumors from
men for whom grade was known, were grade 3. This result is consistent with the
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proportion of grade 3 tumors seen in postmenopausal women with breast cancer but is
less than that found in premenopausal women [323]. A separate smaller study of 41 MBC
cases found in contrast that 73% of patients had grade 3 tumors and 45% had HER2positive tumors [324]. Other studies have found HER2 overexpression rates of 2%–42%
[325-328]. Because of the increased risk of BRCA mutations, genetic counseling should
be offered to patients with MBC, especially if an individual has a family history of breast
or ovarian cancer [315]. The BRCAPRO has been validated for use in patients with MBC
[329]. However, compared with the male proband, BRCA testing may have greater
clinical relevance for the female family members. Family members of MBC patients have
an increased risk of breast cancer [330], especially if other members of the family have
had a diagnosis of prostate or other BRCA-related cancers [331,332].

2.3 Breast cancer screening

Breast cancer screening is used for the purposes of detecting the disease at an early stage.
Early detection facilitates treatment and the potential improvement in the prognosis may
not exist if the disease is detected at a later stage.

2.3.1 Breast cancer screening in Canada

In Canada, mammography is freely available to screen-eligible women through organized
screening programs operated at the province level. It is also available opportunistically
[i.e., with referral by a physician] through mammography facilities that operate outside of
the provincial screening programs [333]. Canada’s first organized breast cancer screening
program began in British Columbia in 1988, followed by programs in Ontario,
Saskatchewan, Alberta, and the Yukon Territory in 1990 [333]. There now exist
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organized breast cancer screening programs in all Canadian provinces and territories
except Nunavut, where only opportunistic screening is available [333]. Organized
programs provide all women 50–74 years of age, without a prior diagnosis of breast
cancer, with a biennial, bilateral, 2-view [cranio-caudal and medio-lateral oblique]
screening mammogram that is paid for through a provincially managed universal health
insurance plan [333]. Some programs continue to offer clinical breast examinations
[CBE] performed by a trained nurse or technologist. However, most provinces have
removed CBE from screening programs because of an absence of scientific evidence for
mortality benefit [333]. Canada’s organized breast screening programs also facilitate the
navigation of women with abnormal or inconclusive screening results through the
diagnostic phase, and typically issue recall notices to participants who have normal or
non-malignant screening results so that they are advised as to when their next screening
mammogram is due [70]. In some cases, screening programs in some provinces and
territories also screen women outside of this age group or at more frequent intervals when
the patient has a history of breast cancer in a first degree relative, at the request of the
health-care provider or client [333].
In 1990, the Ontario Breast Screening Program [OBSP] was established by the Ontario
Ministry of Health under the auspices of Cancer Care Ontario. The OBSP offers
mammographic screening through self- or physician-referral to average risk women 50–
74 years of age [2,334,236].
As of July 1st 2011, the OBSP expanded to include annual combined breast MRI [or
breast ultrasound where MRI is contraindicated] and mammographic screening for
women at a high breast cancer risk. Ontario was the first region worldwide to offer
screening to high-risk women within the context of an organized screening program
[2,335]. This expansion was supported by clinical practice guidelines that suggest that
high-risk women benefit from annual combined mammography and breast MRI screening
[335]. Twenty-eight of the OBSP screening sites now offer eligible women high-risk
screening services and each of the regions across Ontario has at least one OBSP
screening center for high-risk women [2,334].
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Screen-eligible women include those aged 30 to 69 years with no acute breast symptoms.
These women are considered to be at a high risk of developing breast cancer because they
have either a known deleterious BRCA1/2 mutation or another gene mutation that
predisposes to a significantly elevated risk of breast cancer; [ii] are a gene mutation
carrier’s untested first-degree relative; [iii] have a family history that suggests the
presence of hereditary breast cancer syndrome and have a personal lifetime breast cancer
risk ≥25%; [iv] have a history of therapeutic chest irradiation [where radiation was
received at <30 years of age and at ≥8 years in the past] [93]. In 2011, approximately
34,000 women in Ontario [<1%] became eligible for screening based on these criteria and
it is assumed that 17 cancers per year will be detected for every 1,000 high-risk screens
performed by this high-risk program [2,334]. The year 1 OBSP high-risk screening
program results suggested that an annual MRI in combination with mammography may
be an effective strategy for early detection in high-risk women, especially those who are
BRCA mutation carriers. Thirty-five cancers were detected at the initial screening. None
were detected using only mammography, while 23 [65.7%] were detected using only
MRI, and 12 [34.3%] were detected by both MRI and mammography. Twenty-five
[71.0%] breast cancers were detected in women known to have BRCA mutations [97].
Combined use of MRI and mammography resulted in the greatest positive predictive
value [12.4%].

2.3.2 Breast cancer screening potential harm

Mammography screening of women aged 40–49 years and 50–74 years contributes to
statistically significant reductions in breast cancer specific mortality [336]. However, the
potential harms associated with screening for breast cancer must also be addressed. The
balance between the benefits and potential harms of breast cancer screening is a topic of
much controversy and debate. The issue of over diagnosis is central to this debate. Overdiagnosis of breast cancer refers to finding cancers that would never have been clinically
apparent during a woman’s lifetime without the intervention of screening. Because there
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is no method to distinguish between cancers that would never be symptomatic and
cancers that would lead to death if left untreated, both types are treated similarly. Thus,
treatment of an over-diagnosed cancer subjects a woman to the harms of cancer treatment
without a therapeutic benefit [337]. While it is difficult to quantify the magnitude of
over-diagnosis, estimates range from 0% to >50% because of major differences between
populations, cancer types, and estimation methods [337,338]. The most robust method to
estimate over-diagnosis is to compare cumulative breast cancer incidence in the screened
and unscreened groups of a randomized controlled trial [RCT] in which there are
adequate years of follow-up after screening ends and in which the control group was
never screened [339]. The results of two reviews [Pace & Keating [337] and Marmot et
al. [338]] suggest that this question of over-diagnosis could be addressed based on the
evidence gleaned from the long-term follow-ups of three RCTs [i.e., the Malmo I trial
[340] and the Canadian National Breast Screening Study trials [341,342]], where the
investigators never invited the control groups to be screened, The results of a metaanalysis of these trials looking at the over-diagnosis estimates indicated that 10.7% of
breast cancers were over-diagnosed in women invited for screening mammography [343].
A false-positive breast cancer screening result refers to a positive or abnormal result on a
screening test that is subsequently found not to be cancer during recall for further
assessment. Women <50 years of age are more likely to have a false-positive result [344].
Harms from a false-positive result include undergoing unnecessary diagnostic procedures
[e.g., additional mammograms or other imaging tests, fine-needle aspiration, or open
biopsy] and psychological distress [345]. A recent systematic review found that having a
false-positive mammogram result is associated with psychological distress that persists
for up to three years, that distress increases with the level of invasiveness of the
diagnostic procedure, and that women are significantly less likely to return for the next
round of screening [345].
Moderate- and high-dose chest irradiation is a risk factor for greater breast cancer
incidence and breast cancer-specific mortality. The greatest risk is associated with chest
wall radiation exposure before 20 years of age [346,347]. The radiation dose from a
standard two-view mammogram is very low. The risks of radiation-induced breast cancer
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are likely outweighed by the reduction in mortality achievable with annual or biennial
screening mammography for women ≥40 years of age [348], but regular exposure to lowdose chest irradiation starting at a young age might increase the lifetime risk.
Mammography screening begins as young as 25-30 years of age in women with a firstdegree family history of breast or ovarian cancer, or both, who are known or suspected to
be BRCA mutation carriers. It has been hypothesized that carriers of BRCA mutations
have increased radio-sensitivity due to an impaired response to double strand DNA
breaks, which can be caused by ionizing radiation [349]. Millikan et al. found a
significant positive association between breast cancer and the lifetime number of
mammograms in genetically predisposed women [350]. Results reported by Pijpe et al.
suggest that mammogram use before 30 years of age increases the risk of breast cancer in
women who are carriers of BRCA1 or BRCA2 mutations [351]. The results of other
studies indicated there is no increased risk for these women [352-354]. Much of the
evidence regarding breast cancer risk associated with diagnostic and screening
mammography comes from studies that include screen-film mammography. The average
radiation dose from digital mammography is approximately 20% lower than that from
screen-film mammography [4.7 mGy for a standard two-view screen-film mammogram
versus 3.7 mGy for a digital mammogram] [355]. Given that the use of digital
mammography is increasing, the risks of breast cancers felt to be mammography-induced
in the future may be lower than those reported by previous studies.

2.3.3 Participation in breast cancer screening

The 2008 Canadian Community Health Survey [CCHS] found that 72.5% of Canadian
women 50–69 years of age self-reported undergoing a mammogram in the previous 2
years [356]. While this result represented a significant increase from the 40.5% of women
who reported having a mammogram in 1990, all this increase occurred during 1990–
2001. Self-reported rates from 2001–2008 remained stable at approximately 72% [356].
In Ontario, self-reported mammogram participation during the previous 2 years was
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73.2% in 2008, down slightly from 73.6% in 2000–2001 [356]. These self-reported
participation rates do not distinguish between screening and diagnostic examinations, but
91% of the 2008 CCHS respondents reported that their mammogram was for screening
purposes [356].
Epidemiologic research relies heavily on self-reported mammography data to determine
rates of screening participation. Study results indicate that the use of self-reported
mammography data is a valid approach [355-359]. Evidence from meta-analyses
indicates that self-reported data performs well in terms of accuracy when evaluating
whether a woman has had a mammogram, and the sensitivity rates exceed 90% [357359]. However, self-reported data is much less accurate at determining the exact time of
mammography use [357-367]. Studies have consistently found that the time since the last
mammogram is often underestimated by women [357-367]. This phenomenon,
‘telescoping’, occurs when an individual recalls an event as more recent than it was
[368]. In the case of mammography, the effect of telescoping results in an overestimation of mammogram use and inflates rates of screening adherence. Some studies
have found that age, ethnicity, income, education, marital status, indication for a
mammogram, recency of a mammogram, and a family history of breast cancer are all
associated with the accuracy of self-reported mammogram data. Other studies have found
no evidence that factors such as age, income, ethnicity, perceived risk, or number of years
since the last visit to a health professional are significantly associated with recall [361375]. The quality of self-reported mammogram use data has been examined in depth, but
studies have focused on women who have a population-level breast cancer risk. The two
studies that validated the use of self-reported mammogram data in women with a familial
risk only included those with very strong familial breast cancer histories [376,377].
Compared with women in the general population with familial risk, these women were
likely to have different breast cancer screening behaviors and recall of these behaviors.
Results of analyses of Ontario Health Insurance Plan (OHIP) and OBSP data indicate that
participation in mammography screening in Ontario is lower than suggested by the results
of analyses of self-reported data from the CCHS. In 2010–2011, 60.8% of eligible
women in Ontario were screened using mammography. This rate was similar to the
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2008–2009 result, when 61.1% of eligible women in the province were screened using
mammography [335]. However, these rates were slightly lower than the 2007–2008
result, when an estimated 66.3% of eligible average-risk women were screened, and
lower again than the 64.0% in 2005–2006 and 61.5% seen in both 2003–2004 and 2001–
2002 [335]. The current screening mammography participation rate in Ontario is
currently below the national target of 70% [335]. Most screening mammograms
performed in Ontario occur within the context of the OBSP where, in 2010–2011, 71.1%
of screening mammograms were performed at an OBSP site [335]. This result represents
an increase from 2008–2009, when 65.7% of women were screened within the OBSP
[335], therefore it is possible that OBSP data under-estimates the screening rates that
would be calculated if all screening mammograms could be data captured.

2.3.4 High-risk breast cancer screening

A 19-study meta-analysis found a positive association between a family history of breast
cancer and mammogram use. Compared with women without a family history of breast
cancer, women with a familial risk were more likely to undergo mammography screening
[Pearson’s r = 0.27, p < 0.001] [378]. However, many of these studies examined whether
screening mammography was ever used instead of its use as part of a guideline-adherent
screening interval. The results of several subsequent studies in women with a familial
breast cancer risk [e.g., BRCA1/2 mutation carriers, attendance at genetic counseling],
have suggested that these women have relatively high rates of mammography adherence
[67–90%] and CBE guideline adherence [379-382]. One Australian and two NorthAmerican population-based studies of women with family histories of breast cancer in
multiple of their family members, found high adherence [74%] and lower levels of
adherence, respectively, when compared to mammography guideline recommendations
[383-385]. One study found that that during the previous 11 months, only 40% of women
in North America had a mammogram [384]. The results of another study indicated that
36.1% of average risk women and 55.5% of moderate to high risk women had a
mammogram within the last 12 months [394]. One hypothesis to explain this finding is
that the inverted u-shaped curve can be used to represent breast cancer risk. When
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compared with women at moderate levels of breast cancer risk, women at the extreme
ends of risk due to family history may be complying with screening recommendations at
lower rates [386]. This pattern might be mediated by fear of a cancer diagnosis [387,388].

2.4 Breast cancer risk reduction techniques

2.4.1 Risk reduction mastectomy
The use of risk reduction mastectomy for high-risk women is controversial. It presents a
difficult decision for the women at risk and a clinical dilemma for health-care providers.
PM has also been used for women with extremely painful breasts, with a strong family
history of breast cancer, women who have had breast biopsies, and women with
“cancerphobia” [389].
The interest in PM as a viable option for risk reduction has increased as the availability of
BRCA1/2 mutation testing has increased, but the indications for use of PM remain
unclear [390,391]. results of studies have suggested that risk can be significantly reduced
using surgery, but complete prophylaxis might not be achieved [32]. The results of two
studies performed in Denmark [392,393] suggested that breast cancer risk can be reduced
by up to 50% when a large volume of breast tissue is removed. The survival benefits
achieved with the use of surgery for risk reduction in BRCA1/2 mutation carriers have
been assessed using decision analysis [394,395]. Survival data from the SEER database
and cumulative breast cancer incidence rates [293,396] were used to construct survival
models for a simulated cohort of 30-year-old women who were BRCA1/2 mutation
carriers. Eighty-five percent [394] and 90% [395] reductions in risk from PM use were
included in the model assumptions. Three estimates of breast cancer risk used in these
models, which ranged from 40%–85%. The results indicated that PM conferred a life
expectancy increase at every risk level [i.e., 2.9–5.3 years [394] and 2.8–3.4 years [[395]
of increased survival time]. Life expectancy gains decreased as the age of the woman at
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the time of surgery increased; women ≥60 years age had minimal gains [394]. Taken
together, the results of these modeling studies suggest that PM does confer a survival
advantage.
The value of PM for risk reduction has also been measured more directly using
retrospective studies of incidence and survival data from women who underwent PM
[32,396]. Pennisi and colleagues [396] used a database started in the mid-1970s, where
165 plastic surgeons who were members of the American Board of Plastic Surgery
contributed patient information to the database. They examined a group of 1,500 women
who were followed for an average of 9 years after subcutaneous mastectomy. In this
cohort, six women developed breast cancer. Estimates of the expected numbers of breast
cancers and the degree of risk reduction as a result of mastectomy were not included. The
study’s limitations included a 30% loss to follow-up, possible biased selection of patients
who had favorable outcomes, no defined breast cancer risk, and no central pathology
review.
Hartmann and colleagues [32] examined data from a group of 639 women with a family
history of breast cancer who had PM during 1960–1993 and were contacted after being
identified. Each woman was classified as high [n = 214] or moderate [n = 425] risk based
on family history. Women with family histories that suggested the presence of an
autosomal-dominant predisposition to breast cancer were classified as being at high-risk.
Women with family histories that did not include any high-risk criteria were classified as
being at moderate-risk. Between 2 and 25 years after risk reducing mastectomy [RRM], 4
moderate-risk women and 3 high-risk women developed breast cancer [32].
Hartmann and colleagues used two methods to estimate the expected number of breast
cancers cases that would have occurred if no PM surgeries had been performed. In the
group of women at moderate-risk with a median follow-up time of 14 years, the Gail
model [103] predicted that 37.4 breast cancers would occur. There were four cases of
breast cancer that actually occurred during that period, resulting in a risk reduction
benefit of PM was 89.5%. A sister control group was included in the analysis because the
Gail model can under-estimate the risk in women with strong family histories of breast
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cancer. The expected number of breast cancer cases in women at high-risk were
calculated for this control group, and 30–53 expected cases were estimated by the model,
depending on the statistical approach used. There were actually three cases of breast
cancer that developed in this cohort, with the risk reduction of 90%–94.3%. The numbers
of deaths from breast cancer were reduced in both groups [103].
None of the 18 women in the PM surgery cohort with known deleterious BRCA1/2
mutations or of the 8 women who had mutations of uncertain clinical significance
developed breast cancer [398]. The results of using the Easton [395] and Struewing [293]
penetrance models to estimate the level of risk reduction indicated that the risk reduction
was statistically significant. Breast cancer occurred in 3 of the 214 high-risk women,
where 2 of these women had a known mutation status, but neither had a BRCA1 or
BRCA2 mutation. PM effectiveness among BRCA1/2 carriers was calculated two ways:
first, including the assumption that the patient with unknown mutation status was a
carrier and, second, including the assumption that she was not a carrier. The results
indicated that with either assumption, the risk reduction was approximately 90%.
A study of a Dutch population [275] estimated PM-associated risk reduction in 76
carriers of BRCA1/2 mutations. Without PM, six cases of breast cancer would have been
expected during the median follow-up time of 2.8 months.
Taken together, these study results indicate that prophylactic removal of a substantial
amount of breast tissue results in a decreased risk of breast cancer in women at high-risk
for the disease; PM might also reduce the risk for women with BRCA1/2 mutations. The
limited amount of information about the patients' actual level of risk [32] and the brief
follow-up interval used [275] limit the results of these studies. A non-randomized
prospective trial of women at defined levels of risk likely could be performed to obtain
high-quality data if physicians had clinical equipoise regarding the perceived benefit of
PM, however, the use of PM for risk reduction is supported by these results.
The perceptions by women regarding PM when the women have not undergone genetic
testing but have an increased breast cancer risk related to family history or breast
pathology, or both, have been investigated [399,400,382,401]. A study of French women
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[400] visiting, or waiting for an initial appointment at, cancer genetic clinics revealed that
20.3% [n = 473] of women agreed that PM was an acceptable option for women who
have BRCA1/2 mutations. However, only 4.7% agreed that PM was reasonable option
for women <35 years of age. Meiser and colleagues [382] surveyed a population of 333
women visiting, or waiting for an initial appointment at, cancer genetic clinics. Nineteen
percent responded that they would consider PM if they had a BRCA1/2 mutation, while
54% were unsure. A woman’s age, personal risk estimate value, and degree of anxiety
about breast cancer correlated with the response about PM. Women with a high personal
risk estimate, who were younger, and who had higher levels of anxiety about breast
cancer were more likely to respond that they would consider PM.
Two studies used a vignette approach to examine perceptions regarding PM among
women in the United States [399, 401]. A clinical scenario that involved a woman with
an increased risk of breast cancer was presented to the study participants. They were
instructed to view themselves in the same position and select from options for follow-up.
The study completed by Stefanek and colleagues [401] included a population of
unaffected women who had [n = 129] or did not have [n = 104] a family history of breast
cancer. The results of this study were consistent with the previously described studies.
The only alternative follow-up option to PM offered to these women was surveillance
[i.e., annual mammograms starting at a young age, three times per year CBE, and
monthly breast self-examination]. PM was selected by approximately 25% of the women.
There were no differences in PM selection by the women who did [29.5%], and did not
have[22.1%] a family history of breast cancer. Anxiety about breast cancer and the
personal risk estimate were statistically significant predictors of PM choice. Eighty-two
percent of the women in the study population agreed that surgery should be discussed as
an option for women at increased risk.
Geller and colleagues [399] used a vignette format during a survey of 426 unaffected
women, where each woman had a family history of breast cancer. Five percent responded
that they would be likely or very likely to agree to undergo PM if they had a positive test
result for BRCA1/2 mutation. Compared with the previous studies, the PM acceptability
rate estimate in this study was much lower. Between-study differences in vignette
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content, the instructional sets, or the population cultural attitudes and beliefs of the
populations might account for this difference [402], as well as social media and cultural
acceptance of PM in terms of body image perceptions among women changing over time
with increased uptake among well-known celebrities.
Perception of PM among BRCA1/2 mutation carriers has also been examined
[34,403,453]. In one study of 13 BRCA1/2 carriers in Austria without any personal
history of breast cancer, the investigators found that at 5 months after disclosure of test
results, 8% [1/13] of these carriers certainly would or would be likely to consent to PM
[403]. Lerman and colleagues [404] found that during the 12 months after testing, 3%
[1/29] of unaffected BRCA1/2 mutation carriers underwent RRM.
At least one study has reported findings that are inconsistent with these findings. A study
performed at the Rotterdam Family Cancer Clinic [275] found that 55% [76/139] of
women with BRCA1/2 mutation chose PM. However, these women were not offered the
option of chemoprevention, and may have been referred to this center specifically
because they were seeking PM as a risk-reducing intervention.
The ability to make definitive conclusions about the perceptions of at-risk women about
PM is affected by between-study differences in study design and unexamined risk factors.
Some investigators inquired about preferences for follow-up, while others used a vignette
format. Small sample sizes were used in the few studies that examined carriers of
BRCA1/2 mutations. Compared with other studies, the study published by MeijersHeijboer and colleagues [275] found that a much larger proportion of women selected
surgery. Differences in culture, health-care services delivery systems, the medical
specialties involved in the discussions about follow-up options, or in the type of followup information provided may have contributed to differences in study findings [402].
Overall, the risk and benefit information about PM that was provided to the study
participants was not adequately described in these publications. The type of information
provided could absolutely substantially influence the perception of benefit for PM among
high-risk women. However, the studies did support the recommendation that the PM
option should be discussed with women at an increased breast cancer risk.
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2.4.1.1. Prophylactic mastectomy

Enhanced screening, chemoprevention, and risk-reducing surgery are the options
presented to women at elevated risk of breast cancer due to gene mutations or a strong
family history of breast cancer. Total or subcutaneous BPM is used for women who
select risk-reducing surgery because BPM is the most effective surgical method for
cancer risk reduction. Use of BPM also reduces the risk by approximately 90% in
BRCA1/2 mutation carriers [405].
Mailed surveys were used to examine the effects of BPM on characteristics associated
with long-term quality of life (QOL) [406]. The surveys were sent to 195 women who
underwent BPM between 1979–1999. They were also sent to 117 randomly-selected
women at increased breast cancer risk who did not have BPM. The survey included
validated measures of body image, QOL, breast cancer apprehension, sexuality, health
perception, depression, and demographic characteristics. Logistic regression analysis was
used to examine associations between QOL and other domains. The response rate for
completed surveys was 58%, which included 106 women who had BPM and 62 women
who did not have BPMs. Eighty-four percent of the women who underwent BPM were
satisfied with their decision to have the procedure. Sixty-one percent of these women
reported high contentment with QOL, compared to an identical 61% of those who did not
have BPM [P = 1.0]. Among all participants, diminished contentment with QOL was
associated with dissatisfaction with sex life [adjusted odds ratio [OR]: 2.5, 95% CI: 1.0–
6.2], possible depression [CES-D > 16, OR: 4.9, CI: 2.0–11.8], and a poor or fair general
health perception [OR: 8.3, 95% CI: 2.4–29.0]. Most women responded that they were
satisfied with BPM and had psychosocial outcomes no different from women with a
similarly elevated breast cancer risk who did not undergo BPM [406].
Risk factors that predict QOL were examined in women in Ontario, Canada who
underwent BPM between 1991–2000 [407]. The survey questions were used to assess
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metrics that measure current psychosocial functioning [e.g., Quality of Life Index [QLI].
The results indicated that the mean QLI score value was 23.34 [range 9.53–30.00]. There
were statistically significant negative correlations between mean QLI score and
psychological distress, cancer-related distress, and worries about body image, while there
was a statistically significant positive correlation between QLI score and level of social
support. Psychological distress and the vulnerability component on the body image
subscale were statistically significant predictors of QOL [407].
Compared with BPM, little is known about the psychosocial outcomes for women who
choose contralateral prophylactic mastectomy (CPM). CPM is a risk-reducing
mastectomy performed in patient who are at elevated risk of developing a contralateral
breast cancer (such as patients with lobular carcinoma in situ of the affected breast, or
who have significant anxiety with the thought of having annual screening of the
contralateral breast and don’t want to accept the low risk of a new contralateral breast
cancer in the future). Results of quantitative, closed-ended format surveys indicate that a
large proportion of women who undergo PM are satisfied with their decision to choose
the procedure [408]. The components of this response were assessed using questions with
a qualitative, open-ended format. The open-ended questions were included in a mailed
survey of the psychosocial outcomes of PM. Qualitative methods were used to code and
analyze the responses. The demographics of the entire surveyed population were
compared to the demographics of the women who answered the open-ended questions
using simple descriptive statistics to analyze the responses. The responses to the closedand open-ended satisfaction questions were compared, and between-group comparisons
of the responses of women with BPM versus contralateral prophylactic mastectomy CPM
were performed. Of the 71% of women with BPM who responded to the survey, 48%
answered all the open-ended psychosocial outcome-related questions. The responses were
coded as positive, negative, or disparate. In the subgroup of women with both open- and
closed-ended responses, over 70% of women providing negative and disparate comments
to the open-ended question simultaneously indicated satisfaction on a closed-ended
question. Negative and disparate open-ended responses were twice as common among
women with BPM [52%] than women with CPM [26%] [408].
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BPM reduces the risk of breast cancer development by approximately 90%. More women
at high-risk are choosing BPM as part of a strategy to reduce risk. This may be related to
increased visibility of this option among well-known celebrities such as Angelina Jolie
and is possibly also related to improved access to immediate breast reconstruction over
time. Reconstructive breast surgery is frequently part of the immediate treatment plan.
Breast reconstruction has important emotional and physiological effects on QOL, body
image, and sexuality. Before surgery, the type of mastectomy planned, the timing of the
reconstructive surgery, the availability or appropriateness of all reconstruction options,
and potential preservation of the NAC must be discussed with the patient [409].
Since the early 1990s, Karolinska University Hospital [Sweden] medical teams have
performed BPM as a risk reduction method for women with a familial risk for breast or
ovarian cancer, or both. Short-term follow-up evaluations [1–3 years] were used to
investigate the perceptions of the women who underwent these procedures [410]. The 10year long-term physical and psychological consequences of BPM was also examined in
this cohort. Thirteen of these women responded to semi-structured interviews about their
long-term experience with the consequences of BPM and immediate breast reconstruction
(IBR). The results indicated that the respondents thought that they had a negligible risk of
breast cancer and were satisfied with the decision to choose BPM. For most women,
BPM did not affect lifestyle or family life [n=8/13], and the cosmetic results were mostly
positive [n=10]. Eight women responded that BPM had positive [n=3] or negative [n=5]
effects on their relationship with their spouse [ 410].
Aesthetic and long-term oncologic outcomes, complications, and patient satisfaction of
were examined using a retrospective study of a 25-year period during which patients
underwent the procedure [511]. Forty of 52 patients had CPM; 12 had BPM [i.e., 64
breasts removed]; 1.56% [1/64] of the mastectomy specimens contained breast cancer
cells. Subcutaneous PM was performed in 65.62% [42/64] and simple total PM was
performed in 34.37% [22/64] of the breasts. Alloplastics were used for reconstruction of
90.62% [58/64] of the breasts; autologous tissue was used for 9.37% [6/64] of the breasts.
Five breasts [7.81%] received a latissimus dorsi flap with an alloplastic implant; 1
[1.56%] breast had a TRAM flap. Post-surgery, capsular contracture occurred in 6.25%
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[4/64] breasts, 3.12% [2/64] breasts developed a hematoma, and infection occurred in 1
[1.56%] breast. Seventy-five percent [39/52] of the patients reported being highly
satisfied, 19.23% [10/52] reported being partially satisfied, and 5.76% [3/52] reported
being unsatisfied with the outcome [411]. The objectives of one systematic review were
to identify studies of health-related QOL [HRQOL] in patients after BPM [with or
without reconstruction], assess the effects of BPM in these patients, and identify
predictors of post-BPM HRQOL characteristics. Following Preferred Reporting Items for
Systematic Reviews and Meta-Analyses guidelines, the investigators performed a
systematic literature review that included a search of the Embase, PubMed, Web of
Science, PsycINFO, Cochrane, and Scopus databases [512]. A total of 1,082 studies were
found by the initial search, and 22 studies met the inclusion criteria. The review results
indicated after BPM, women were satisfied with the outcomes, had high psychosocial
well-being, and a positive body image. BPM had the greatest negative effects on
somatosensory function and sexual well-being. Pre-operative cancer distress,
psychological distress, and vulnerability were statistically significant negative predictors
of post-BPM QOL and body image. The researchers concluded that more high-quality
data on outcomes of different post-BPM HRQOL domains are needed, and that validated
and breast-specific patient-reported outcome instruments should be used to measure
HRQOL. Use of this approach should allow surgeons to provided evidence-based
information to patients and improve the outcomes of shared decision-making [412].
A prospectively maintained database was used to examine the factors that can affect
decision making in a study of a group of BRCA mutation carriers who chose BPM,
compared with carriers who chose surveillance [513]. The surveillance cohort [n = 313]
consisted of high-risk clinic patients examined between 2014–2016, while the surgery
cohort [n = 142] consisted of women who had BPM between 2010–2016. The results for
a between-group [i.e., BPM versus surveillance group] comparison of clinical and
familial factors indicated that the women who chose BPM were more likely to have a
BRCA1 mutation than a BRCA2 mutation, compared with the surveillance group [57%
versus 45%, p = 0.02]. They were also less likely to have a personal history of ovarian
cancer [10% versus 20%, p = 0.01]. It is reasonable to expect that this reflects the
prognosis for patients with ovarian cancer and the significant 5 year mortality which
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would deter patients from engaging in prophylactic surgery if it were not going to impact
on their survival. The women who underwent BPM were more likely to be married [78%
versus 62%, p = 0.01], and to have more children [median 2 versus 1, p < 0.001]. The
women who chose BPM had more first-degree relatives [63 versus 48%, p = 0.01] or a
sister [23 versus 14%, p = 0.02] with a history of breast cancer, and they were more likely
to have a family member with ovarian cancer <40 years of age [9% versus 4%, p = 0.03].
The between-group differences in the numbers of previous breast biopsies or in rates of
personal history of atypia/lobular carcinoma in situ were not statistically significant. The
researchers concluded that the decision to have a BPM is multifactorial; gene mutation,
family history, and relationships have the strongest effects during the decision-making
process [ 413].

2.4.1.2 Breast cancer risk after prophylactic mastectomy

Use of surgery to reduce risk of breast cancer is an effective option for women at highrisk for breast cancer [414]. Bilateral mastectomy can reduce the risk of breast cancer by
approximately 90% [ 32]. The remaining risk is presumably related to the residual
mammary gland epithelial tissue that remains after surgery. The two techniques, SSM
with or without nipple-sparing and total mastectomy have the potential to leave different
amounts of mammary gland tissue. During nipple-sparing SSM, a small amount of the
sub-areolar breast epithelium remains after the subcutaneous mastectomy is completed
[415].Study results indicate that overall, 0.2%–1% of patients who undergo BPM develop
invasive breast cancer [416]. However, higher rates have been reported where breast
cancer occurred after BPM in 1% [six cases] and 19% [three cases] of high-risk women
[416-417].
Hartmann and colleagues [420] examined a cohort of 1,125 women who underwent BPM
and completed a questionnaire that asked about family history of breast cancer. A family
history was reported by 580 respondents where 203 had a family history that suggested
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that they had a single-gene inherited risk. During the mean 17-year follow-up, 7 women
developed breast cancer; 5 of the cases were in women who reported having a family
history. Compared with Gail model risk analysis and age-adjusted SEER incidence rate
results, the breast cancer risk reduction was 91% [420].
Therefore, PM markedly decreases the risk, but does not eliminate the possibility of new
breast cancer in the residual breast tissue, axilla, or chest wall on the PM side [421].
During long-term follow-up of 1,065 women who underwent BPM and 1,643 women
who had CPM for contralateral breast cancer, 25 women developed locoregional,
invasive breast ipsilateral to the PM. Little has been published on the development of
breast cancer after PM because it is a relatively rare clinical entity. Mutter and colleagues
[421] published a study in a population of patients felt to represent the largest population
to be followed for development of breast cancer after PM. The authors include details
about the most common presentations, treatment, pathology, and outcomes. Their results
indicate that use of PM [subcutaneous and total] results in a high-level of risk reduction.
Consistent with these results and the results from other cohort studies [422], the breast
cancer risk reduction is estimated to be 94%–95% when bilateral risk reduction
mastectomy (RRM) is used [421,422]. Although studies have indicated that overall risk
reduction rates of >90% can be achieved using PM, many studies were not done in gene
mutation carriers exclusively.
The studies by Pennisi and Capozzi [419] and Woods [418], as well as others, reported
that a few out of >1,000 patients in their studies of prophylactic mastectomy developed
breast cancer after years of follow-up [incidence, 0.6%]. Yet, nipple sparing mastectomy
(NSM) raises some major concerns. One concern had been that when it is used for
prophylaxis, it could theoretically pose a persistent risk of developing breast cancer.
There was also controversy in terms of the oncological perspective regarding the safety
of such procedures [423 ,424] but this has been resolved with recent guideline
publications [335]. BPM decreases breast cancer risk by >90% [32]. Vulnerability to
cancer-specific worry is often found with women who have consistently estimated that
they have a breast cancer risk greater than it is [425]. This situation might push women
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who are not at very high risk to take unusual measures against breast cancer, including
having a BPM.
Rebbeck and colleagues [405] examined a population of 483 women with BRCA1/2
mutations. Two [1.9%] of the 105 women who had BPM and 184 [48.7%] of the 378
matched controls [no surgery] had a diagnosis of breast cancer during the mean follow-up
of 6.4 years. The authors concluded that use of BPM results in an approximately 90%
reduction in breast cancer risk in women with BRCA1/2 mutations. A prospective study
of 139 women with BRCA1/2 mutations found that breast cancer developed in 8 of 63
women who chose surveillance; none of the 76 carriers who chose prophylactic surgery
developed breast cancer [405].
There are few studies that describe the mammographic and sonographic appearance of
breast cancer when it occurs in BRCA-positive patients' reconstructed breasts. The
morphologic features of post-PM tumors in BRCA1 and BRCA2 mutation carriers
include the presence of continuous pushing margins [223]. Because there is reduced
potential for stromal infiltration, the tumor’s appearance on the mammographic and
sonographic images might mimic the appearance of a benign lesion [426].
Risk-reducing surgery options for women who are BRCA1/2 gene mutation carriers also
include prophylactic bilateral salpingo-oophorectomy in addition to BPM. The survival
benefits arising from different treatment options have been studied using the Markov
model. Grann and colleagues [395] compared bilateral oophorectomy, bilateral
mastectomy, or having both procedures with surveillance alone. They found that
compared with surveillance alone, survival of a 30-year-old BRCA1/2-positive woman
was increased by 0.9 years [95% probability interval, 0.4–1.2 years] with bilateral
oophorectomy, 3.4 years [2.7–3.7 years] with bilateral mastectomy, and 4.3 years [3.6–
4.6 years] with both procedures. The results of this study suggest that significant survival
benefits result from the use of prophylactic surgery. The results of other studies indicated
that compared with the use of breast and ovarian screening, the average life expectancy
gain for 30-year-old carriers in the high-risk category is 11.7 years for combined PM and
oophorectomy, 9.5 years for breast-screening and prophylactic oophorectomy, and 4.9
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years for PM with ovarian screening. The gains for carriers at medium risk are 6.6 years
for combined PM and oophorectomy, 5.3 years for breast-screening and prophylactic
oophorectomy, and 4.4 years for PM with ovarian screening. These results indicated that
use of combined PM and oophorectomy confers the greatest survival benefit [427].
Prophylactic oophorectomy also appears better at prolonging survival than BPM. The
findings by Schrag and colleagues [394] were similar. The results of the study published
by Grann and colleagues [395] also suggested that life expectancy gains declined with the
age at the time of prophylactic surgery and were found to be minimal for women ≥60
years of age. Oophorectomy could be delayed by up to 10 years with little loss of the life
expectancy gain.

2.4.1.3 Skin-sparing prophylactic mastectomy

Prophylactic skin-sparing mastectomy [SSM] or nipple-sparing mastectomy [NSM] is
considered standard of care for risk reducing surgery, with NSM increasingly being
performed. Researchers investigated whether NAC preservation during NSM increases
patient satisfaction in women who had prophylactic bilateral SSM or NSM and
immediate implant breast reconstruction between 2002–2012 [428]. NAC sensitivity after
NSM was measured. Patient satisfaction and body image were compared between SSM
and NSM. The Breast-Q reconstruction questionnaire was used to assess patient
satisfaction. Hopwood's body image scale was used to assess body image. Satisfaction
with the reconstructed NAC was assessed using a questionnaire designed for the study. In
the NSM group, NAC sensitivity was assessed using Semmes Weinstein monofilaments
[5-point scale] and was compared with NAC sensitivity in a control group [where no
surgery was performed]. There were 25 women [50 SSMs] in the SSM group and 20
women [39 NSMs] in the NSM group. The median follow-up time was 65 months in the
SSM group, compared with 27 months in the NSM group. The SSM group had higher
Breast-Q scores, compared with the NSM group ["satisfaction with breasts", 66.2 for
SSM group versus 56.6 for NSM group, P = 0.06; "satisfaction with outcome", 76.1 for
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SSM group versus 61.5 for NSM group, P = 0.09]. The mean body image scale score was
7.1/30 in the SSM group and 9.3/30 in the NSM group [P = 0.35]. There were no
statistically significant differences in Breast-Q scores or body image scale scores after
adjusting for follow-up. Levels of satisfaction with the reconstructed NAC were similar
after SSM and NSM. NAC sensitivity was lower in the NSM group [mean score, 1.9;
95% CI: 1.5–2.3], compared with the control group [mean score, 4.7; 95% CI: 4.6–4.9].
The SSM group had greater Breast-Q scores for satisfaction with breasts and with overall
outcome [ 428], although these patients would have likely had 2 stage reconstruction
rather than one-stage reconstruction, which is more challenging in NSM patients
compared with SSM and might be responsible for the difference in satisfaction scores.

2.4.2 Chemoprevention

In the United States, tamoxifen is the only medication approved by the US Food and
Drug Administration [FDA] for breast cancer risk reduction in high-risk women, which
was initially approved in 1998. National Surgical Adjuvant Breast and Bowel Project
Breast Cancer Prevention Trial [BCPT] [429] results contributed to the approval decision.
The trial used a randomized, controlled [placebo] study design, where the study
population consisted of >13,000 women at high breast cancer risk. The results indicated
that use of tamoxifen reduced invasive breast cancer risk by 49% overall and by 44% for
women <50 years of age, while there was a 50% reduction in the risk of non-invasive
breast cancer. The incidence of ER positive tumor was reduced by 69%, but there were
no between-group differences in ER negative tumor incidence. Compared with the
placebo group, the group of patients who took the tamoxifen experienced a greater
number of serious adverse events [e.g., endometrial cancer, vascular events such as
pulmonary embolism, stroke, deep venous thrombosis, and cataracts] [430]. The overall
RR value for endometrial cancer was 2.53 [95% CI: 1.35–4.97] overall, and 1.21 [95%
CI: 0.41–3.60] for women <50 years of age. The RR value for cataracts was 1.14 [95%
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CI: 1.01–1.29] overall and the RR value for pulmonary embolism was 3.01 [95% CI:
1.15–9.27] [429, 431] overall.

2.4.2.1 Breast cancer risk after chemoprevention

Tamoxifen efficacy for reducing the risk of breast cancer risk in women with BRCA1 or
BRCA2 mutation remains unclear. This high-risk subgroup might respond to tamoxifen
therapy [431], but tamoxifen may not be as effective in this group because 70%–80% of
the tumors that develop are ER negative [432]. One case–control study found that the use
of adjuvant tamoxifen resulted in a statistically significant reduction in the odds of
contralateral breast cancer in women who were mutation carriers [484], although these
would have been women whose index cancer was ER positive and therefore the
contralateral risk reduction benefit might not be generalizable to the BRCA mutation
cohort overall. Women with ER positive disease would have been more likely to be
prescribed tamoxifen. The risk reduction estimates included very wide CIs, and there was
an increase in the odds of contralateral disease after tamoxifen was taken for >4 years,
likely reflecting the overall increased contralateral risk of breast cancer in patients not
undergoing CPM.
The conflicting negative results from two European trials have also indicated that
questions about tamoxifen use remain to be answered [434, 435]. Optimal dose and
treatment duration, and whether tamoxifen use benefits overall health or survival remain
to be determined [432, 436]. Ninety-six percent of the BCPT participants were
Caucasian, so the findings may not be generalizable to populations of non-Caucasian
women. The BCPT participants were not permitted to take hormone-replacement therapy,
androgen, or oral contraceptives, so the efficacy of tamoxifen when it is given with
hormonal agents was not examined. These agents as well as any medications [such as
anxiolytics metabolized by the hepatic CYP2D6 pathway] might interfere with tamoxifen
efficacy.
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2.5 Breast reconstruction techniques

Patients are not required to have reconstructive surgery with their BPM as this choice is
very individual and therefore a portion of patients chose to forego reconstruction after
mastectomy, either felt to be related to individual choice or in patients where their overall
prognosis is so poor that breast reconstruction is unjustified [437]. The factors that
contribute to a patient’s decision to undergo breast reconstruction were examined by
Reaby and colleagues [438] and Ng and colleagues [439]. Lack of information about the
procedure, feeling reconstruction is unnecessary for physical or emotional well-being,
and fear that reconstruction can mask cancer recurrence are reasons given by patients for
refusal [438]. The approximately 33% [440] who chose reconstruction in this study did so
that they could avoid problematic external prostheses, to improve thei ability to wear a
variety of clothing types, to regain their femininity, and to feel “whole” as breast cancer
survivors [438]. Compared with patients who did not undergo reconstruction, patients
who had the procedure reported better post-surgical social functioning and emotional
well-being [440]. Dissatisfaction with the outcome were found to occur when patients
had unclear and inaccurate expectations about breast appearance and physical sensations
[e.g., the “unnatural feel”, firmness, and lack of movement] after reconstruction [441].
When reconstruction is chosen, the goal is to restore the breast’s appearance and to
improve psychological well-being. Reconstruction of the breast mound and the NAC are
both addressed during the decision-making process [442]. Implant [alloplastic] and
autologous reconstruction are the two main techniques used for breast reconstruction.
Implant reconstruction involves the use of an implant filled with saline, silicone gel, or a
combination of these. Autologous reconstruction uses a tissue flap [e.g., from the belly,
back, or thigh] and might also include use of an implant. Prosthetic breast reconstruction
is thought to be a lower-cost procedure, since it is associated with shorter procedure
times, hospital stays, and recovery times [443]. The implant-based approach does not
require use of a tissue donor site [444]. The factors considered during discussions
between the patient and surgeon when deciding between implant or autologous
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reconstruction include the patient’s general medical health, breast size and ptosis, areola
size, donor site suitability, the patient’s expectations, preferences, smoking status,
lifestyle factors, and resource availability. The surgeon’s preferences and experience are
also considered.

2.5.1 Prophylactic mastectomy with implant-based reconstruction

Use of implants is the most commonly-used breast reconstruction approach.
Approximately 75% of breast reconstructions performed in the United States are implantbased. In most cases, the existing breast reconstruction options are felt to result in a
satisfactory outcome [445]. The reconstruction can be performed at the same time as the
mastectomy [Immediate Breast Reconstruction, or IBR]. It can also be a two-stage
reconstruction consisting of a tissue expander placement, serial inflation in clinic
followed by subsequent permanent implant placement in a second surgery [446].
Restoration of mammary volume and shape results in physical and psychological benefits
[447]. Therefore, immediate reconstruction is the preferred approach, with a high degree
of patient satisfaction felt to be associated with use of immediate reconstruction
[448,449]. Disadvantages of the use of prosthetic [implant] IBR include the potential
need for additional surgery for reconstruction revision [450,451] and prosthesis failure
over a patient’s lifetime [452]. The best candidates for ipsilateral mastectomy and IBR
have small, minimally ptotic breasts [453] because larger or ptotic breasts, or both,
require the use of contralateral balancing procedures during surgery or as a second
procedure, to achieve symmetry, which can be very challenging at the time of IBR [454].
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2.5.1.1 One-stage ADM-assisted implant breast reconstruction

ADM-assisted IBR enables the reconstruction of breasts with varying degrees of ptosis
[455]. For the most part, implants used in breast reconstruction are placed beneath two
layers of tissue: pectoral muscle and breast skin. In patients wishing one stage implantbased reconstruction during their mastectomy surgery, the pectoral muscle is too tight
and short to permit full muscle coverage of the implant, therefore ADM can be used as a
pectoral expander to cover the inferolateral pole of the implant and prevent the need for
elevation of the surrounding serratus muscle, thus reducing postoperative pain [456458]. ADM can also be used as an internal sling to completely cover the implant during
subcutaneous breast reconstruction, anchoring the implant to the chest wall without
elevating pectoralis, yet providing an additional layer of tissue support, an emerging
potential method of implant-based reconstruction being explored by some plastic
reconstructive surgeons [459- 461].
The use of ADM is felt to provide the reconstructed breast with a natural shape, a welldefined inframammary fold, and enhanced inferior pole projection that is a better match
to the contralateral native breast [462]. Characteristics of the breast soft tissue and skin
elasticity of the trunk and overall body habitus are typically evaluated before surgery
[463] to optimize the changes of a natural appearing reconstruction.
A well-vascularized mastectomy skin flap with a reasonably thick subcutaneous layer is
essential for a successful outcome [463, 464]. The intra-operative judgment of the
surgeon is the single most important factor that affects the success of direct-to-implant
IBR [465-467]. Only patients with good-quality mastectomy flaps [thick and wellvascularized] should be candidates for IBR to minimize the chance of mastectomy flap
necrosis [462]. Intra-operative objective assessment tools such as real-time perfusion
mapping [e.g., SPY®, Novadaq Technologies Inc., Bonita Springs, FL, USA] can assist
surgeons during this key decision-making stage [468].
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2.5.1.2 Two-stage ADM-assisted TE-Implant-based breast reconstruction

Like single-stage implant IBR, two-stage tissue expander/implant-based reconstruction
aims to create a naturally appearing breast mound. The two stages of surgery are
separated by a period to allow for gradual expansion, without compromising the
mastectomy flap blood supply. The skin flaps are inspected after mastectomy, and tissue
expanders are placed in a sub-pectoral pocket, which is filled to the tolerated volume
[10%–50% of the total volume]. The expansion procedure begins during days 10–14 after
surgery, where 60–120 ml fluid is added at each visit. The objectives include achieving
adequate ptosis and formation of a well-defined inframammary fold. The projected final
breast size and other objectives are usually achieved at the fifth or sixth visit. When
expansion is completed, final exchange can take place.
The total period for expansion and overall impact on patients can be reduced by
maximizing expansion volumes and minimizing the number of expansions. It is also
beneficial to fill the expander with as much fluid as possible during surgery. A poorquality skin flap, previous radiotherapy, and an excessively tight skin or muscular
envelope are contraindications for the use of accelerated expansion. Experienced
physicians develop clinical judgment that is invaluable for decision-making during this
process.

2.5.1.3 One stage dermal sling (non-ADM)-assisted implant-based breast
reconstruction

Breast reconstruction can be performed using simple implant-based or more complex
myocutaneous flap procedures. One often-used option for implant or tissue expander
breast reconstruction is superior placement of the pectoral muscle and inferolateral
placement of the biological material [457,469, 470]. During bilateral reconstruction, well-
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contoured, symmetrical breasts can be created in some patients with a redundant breast
skin envelope using the lower portion of the skin as a dermal sling [lower pole skin is deepithelialized to create a vascularized local dermal flap] in an inferior position to
completely cover the implant or tissue expander and create a tension-free sub-muscular
pocket [471-473]. A de-epithelialized vascularized flap covers the lower portion of the
implant or tissue expander, which allows for local wound care during a superficial skin
infection or skin necrosis. There are many variations in terminology and technique, but
most surgeons use an anchor-shaped reduction incision or a transverse non-nipple sparing
incision across the breast along with the lower dermal de-epithelialized flap sling for
coverage of the lower pole.

2.5.1.4 Two stages traditional TE-Implant based breast reconstruction

Traditional TE/implant-based reconstruction is one of breast reconstruction technique
that can be performed without using ADM or Inferior dermal sling, as a two-stages
procedure either immediately at the time of the mastectomy or delayed. During the first
stage and after mastectomy, a complete sub muscular pocket is created for the TE by
elevating the pectoralis major muscle and the anterior insertion of the anterior serratus
muscle. In The second stage once the desired breast expansion is achieved, TE-implant
exchange is performed.

2.5.2 Prophylactic mastectomy with autologous-based reconstruction

Ptosis, texture, and flexible response to body weight fluctuation are superior late cosmetic
results associated with autologous tissue breast reconstruction, compared with implantbased reconstruction. Lower abdomen deep inferior epigastric perforator [DIEP] and
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transverse rectus abdominus myocutaneous [TRAM] flaps are the more commonly used
of the options available for autologous tissue reconstruction [474].

2.5.2.1 One-stage autologous breast reconstruction

Adequate volume, a reliable blood supply, and excellent aesthetic results are achieved
when lower abdominal skin flaps are used [475]. The transabdominal muscle flap
(TRAM ) [476] can be used as a local pedicle or a free tissue transfer flap [477]. DruckerZertuche and colleagues [478] compared 85 patients who underwent TRAM, implantbased, or latissimus dorsi reconstruction. They found that the patients who had TRAM
flap reconstruction had more natural breast consistency and mobility [478]. TRAM flap
patients also report higher levels of satisfaction with the aesthetic result [479]. TRAM
flap reconstruction is associated with donor site complications [e.g., weakness of the
abdominal wall] and bulging at the lower inner part of the breast. Therefore, its use has
mostly been replaced by the use of the abdominal wall-origin muscle-sparing free flap
[e.g., Deep inferior epigastric perforator flap (DIEP)].
Compared with the TRAM flap, the DIEP flap [480 ,481] has donor site advantages and
allows transfer of larger volumes of tissue. Rates of post-surgical complications [e.g.,
asymmetry, muscular weakness, bulging, and hernia] are reduced because the total
abdominal musculature and aponeurotic layers are preserved [482]. Compared with the
TRAM flap, during the DIEP flap and superficial inferior epigastric artery flap
procedures, the same amounts of tissue are transferred from the abdomen, but the rectus
muscle and fascia are unaffected [442]. Like the native breast, the new breast is mostly
fat and skin, and patients have a more realistic abdominal contour. The DIEP flap
procedure requires a high degree of technical skill. Because SSM allows limited surgical
access, identification and dissection of recipient-site vessels can be challenging and
incisions are usually extended to allow for access to vessels for anastomosis [internal
mammary or lateral thoracic].
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The results of a review of 30 DIEP flap surgeries [average follow-up, 29 months] found
that during the follow-up period, small areas of necrosis developed on the breast skin of 2
patients. Two patients had partial flap loss that consisted of <15% of the total flap area.
One patient experienced total flap loss and one had local breast cancer recurrence. Highlevels of satisfaction with the outcome were reported by the patients [483]. Another study
compared DIEP flap SSM and IBR with breast conservation. Use of the DIEP flap was
associated with a statistically significant better cosmetic outcome and comparable QOL
outcomes among the study population of 42 patients [484]. Fujino and colleagues [485]
suggested the use of a free flap of soft tissue from the gluteal region. Allen and Tucker
[486] used a free superior-gluteal artery perforator flap. Free transfer of skin and fat
without loss of the gluteus maximus and minimal donor site complications are advantages
of this technique. Limited sensory nerve function can sometimes be achieved when
nerves included in the flap are connected to local branches at the recipient site [481]. This
method can be used when the abdomen is not a suitable donor site. A study of 142
women who underwent the gluteal artery perforator flap procedure found that use of the
superior-gluteal artery perforator flap method had statistically significant advantages over
use of the inferior-gluteal artery perforator flap. Ninety-eight percent flap survival, low
morbidity rates, high patient satisfaction levels, and good cosmetic results were outcomes
associated with the use of the superior-gluteal artery perforator flap method [487].
The myocutaneous transverse upper gracilis free flap has also been used for autologous
breast reconstruction [488-490]. Jimenez [491] used free omental flaps harvested using
laparoscopy for IBR after SSM. During SSM, a myocutaneous flap might allow
replacement of a small area of excised skin and replace the approximate total volume of
breast tissue removed, with or without a prosthetic implant [491]. Despite these
advantages, a survey of female plastic surgeons [n = 453] in the United States and
Canada found that 66% would prefer implant-based compared with autologous breast
reconstruction if they themselves had breast cancer [492].
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2.6 Acellular dermal matrix (ADM)

Human and animal tissues [e.g., pericardium, back dermis, small intestinal submucosa]
can all be processed to obtain a biomaterial acellular reconstruction material. ADM is a
dermal matrix and therefore human cadavers, porcine, and bovine sources can all be
harvested, processed and de-cellularized to be used for ADM. During the processing
procedure, which varies between manufacturer of each ADM type, cells are removed by
digestive processes, and the extracellular matrix is retained. This cell-free composition
distinguishes ADM from the classical xenografts and allografts, where use of animal
tissue will typically contain cells from that animal. Harvested ADM is commercially
harvested and has been FDA-approved for many clinical uses in humans for over 10
years [Figure 1] [493].
Figure 1. Acellular dermal matrix (ADM),This photo provided courtesy of Allergan.

60
The potential for inflammation or rejection is eliminated during the processing to obtain
ADM. The tissue is separated using mechanical methods, then is de-cellularized and
disinfected. Some products are dehydrated or lyophilized and sterilized. The ADM
architecture [and interaction with host tissue] can be affected by each step in this process
[494].
Integration, resorption, and encapsulation are the three main immunological responses to
an implanted ADM [495,496]. Successful integration occurs when there is no
immunological recognition and the matrix is rapidly revascularized and incorporated into
the recipient site. An inflammatory reaction at the ADM/host interface suggests that the
material is being resorbed, with resulting breakdown and elimination [Figure 2] [495]. A
foreign body reaction results in encapsulation of the ADM with scar tissue. Sandor and
colleagues [496] found that encapsulation is more common when a cross-linked matrix
ADM product is used.
Figure 2. Acellular dermal matrix revascularized and incorporated into the recipient site,
This photo provided courtesy of Allergan.
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Duncan and colleagues [497] were the first to publish a report for the use of ADM in
breast surgery. They used AlloDerm® in a series of 34 patients undergoing revision
surgery to their implant reconstructed breasts to correct post-implant rippling. ADM
provides surgeons with an alternative method to obtain enough vascularized soft tissue
volume to cover the implant and prevent some complications. Breuing and Warren [498]
were the first to report results of the use of ADM for reconstructive breast surgery.
Within 10 years after the first report, the use of ADM was included in more than 60% of
all alloplastic reconstruction surgeries performed in the United States [Lifecell].
Additional allogenic and xenogenic ADMs are now available, but AlloDerm® has the
longest history of use and is the most-studied product [497]. Other ADMs include Derma
Matrix [Synthes, USA], Flex HD [Ethicon, USA], SurgiMend [TEI Biosciences, USA],
and AlloMax [Bard Davol, USA]. TIGR Matrix [Novus Scientific, USA, absorbable
synthetic] mesh and TiMesh [Biomet, USA, titanized] are synthetic non-ADM mesh
products. Processing differences result in between-product differences in handling,
incorporation, shelf life, and cost. The effects of these variables on outcomes remain to
be determined.

2.6.1 The novel application of ADM in immediate breast reconstruction

The use of ADM for implant-based breast reconstruction has potential clinical advantages
including post-operative pain reduction, elimination of the need for elevation of the
serratus anterior muscle for lateral coverage of the prosthesis, improved lower pole
projection, better aesthetic shape, and improved soft tissue characteristics [46,470,499].
Other reported clinical benefits of ADM include making it easier for the surgeon to
determine inframammary fold and expander/implant placement, more protection between
the prosthetic implant and poorly-vascularized mastectomy skin, a larger initial submuscular pocket that can result in more efficient use of the native mastectomy flaps,
more rapid expansion, and more time to finish the reconstruction [500,501]. Improved
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management of threatened implants and a lower incidence of capsular contracture are
other benefits revealed by ADM studies [500-503]. Berna and colleagues [504]
described a significant benefit of one-stage IBR, reporting “Rapid return to work and
prompt administration of adjuvant therapy when needed are further advantages.
Moreover, the ADM/mesh-assisted wrapping technique is a muscle sparing-technique
that can achieve good cosmetic outcome while preserving the pectoralis major muscle
elevation and occurrence rate of other minor complications.” The longer a patient is away
from work, the more impact it may have on personal finances, potentially higher
insurance bills, and potential stress on the employer. Using ADM for a one-stage IBR can
reduce or eliminate these negative outcomes.

2.6.2 Analysis of NSQIP Database in patients undergoing ADM-assisted
breast reconstruction: complication rate with ADM

All surgical procedures have associated risks that, although carefully managed and
controlled, can result in complications. The reported outcomes for ADM compared with
traditional non-ADM techniques vary extensively [505, 506]. A review published by Kim
and colleagues [507] found ADM-assisted reconstruction-associated complication rates
ranged from 8.6%–19.5%. The pooled published average of 15.4% for ADM-associated
complications is greater than the non-ADM pooled average of 14.0% and this difference
is statistically significant although a difference of 1% is not expected to be very clinically
meaningful. Only one well-designed RCT that examined complication rates was
published [508]. This study found equivalent outcomes between ADM and non-ADM
breast reconstruction, however the conclusions of this study may have been limited by the
use of an older, no longer available ADM size and therefore cost [509]. The ongoing
randomized controlled Multi Center Canadian Acellular Dermal Matrix Trial may
provide more information about complication rates [510].
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Few study results have indicated that the use of acellular dermis–based reconstruction is
unsafe, and most studies have found acceptable complication rates and improved
aesthetic outcomes [511,512]. There are generally no statistically significant differences
between the complication rates associated with ADM-assisted reconstruction [3.2%–
48.7%] compared with traditional expander reconstruction [eg. wound infection,
hematoma or seroma] [512,513].
A study published by Chun and colleagues [514] evaluated 269 ADM-assisted breast
reconstruction surgeries and found that the infection rate was 8.9%, the necrosis rate was
23.4%, the seroma formation rate was 14.1%, and the hematoma formation rate was
2.2%. Compared with complete sub-muscular breast reconstruction, the ADM procedure
was associated with greater post-operative seroma formation rates and infection rates. In
a study of 153 breast reconstructions, Antony and colleagues [512] found a 23.6% overall
complication rate; the seroma formation rate was 7.2%; 2.0% of the patients developed a
hematoma; 3.9% developed cellulitis; 4.6% developed flap necrosis and 3.3% developed
an infection. Rawlani and colleagues [515] found that after 121 breast reconstruction
surgeries, the overall complication rate was 16.5%, while the infection, seroma, and flap
necrosis rates were 7.4%, 1.7%, and 6.6%, respectively.
Few studies have compared and stratified differences in outcomes with respect to
acellular dermis type, radiation exposure, body mass index, or intraoperative expander
volume. Becker and colleagues [516] found an overall complication rate of 4%. Losken
and colleagues [513] found one case of native skin necrosis in a study of 31 breasts.
Between-process differences in changes in the protein and collagen structure that can
occur during processing and sterilization might cause differences in revascularization and
recellularization.
Higher complication rates have been associated with the use of bovine ADMs. During a
median 3-year follow-up of 41 patients [52 breasts] who received ADM breast
construction, the complication rates were 7% for human, 14% for porcine, and 31% for
bovine ADMs [517].
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Study results suggested that ADMs have better resistance to radiation effects compared
with standard tissue expander reconstruction [518,519]. Rawlani and colleagues [515]
compared the complication rates for adjunct breast irradiation without the use of
irradiation [control group]. They found overall complication rates of 30.7% in the
treatment group and 13.7% in the control group. They also compared the use of prehydrated ADM and freeze-dried ADM and found that the complication rates and
outcomes were similar between the groups [515].
Winocour and colleagues [520] found that the 30-day surgical site infection rate is higher
when ADM is used for immediate tissue expander breast reconstruction. The national rate
is 4.5% for ADMs and 3.2% for non-ADMs. The rates at their institution were 2.1% after
use of ADM and 1.6% after use of non-ADM products [520].
The result of these studies indicated that the use of ADM resulted in higher complication
rates, compared with the use of non-ADM products. However, the results of an analysis
of a National Surgical Quality Improvement Program data set found that the differences
in overall complication rates were not statistically significant [5.3% ADM versus 4.9%
non-ADM, p=0.396] [521]. The results of another analysis of the same program’s data set
indicated that the rates of wound-associated complications [e.g., infection and seroma
formation] after use of ADM for prosthesis-based breast reconstruction were significantly
lower than those published in single-institution reports [522].

2.6.3 Tolerance of ADM to chemo-radiation

The use of ADM has been thoroughly discussed and found to result in favorable effects
with normal to below normal complication rates in comparison with what was
anticipated. However, the treatment outcome needs to be examined further when ADM is
subjected to chemotherapy, radiation therapy or both. The following cited studies
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examined use of ADM in breast surgery patients who underwent chemo-radiation
therapy.
The uncertain association between pre-operative radiation exposure and poor outcomes is
likely the result of the negative effects of irradiation on tissue microvasculature, which
provokes fibrosis [519,523-526]. Infiltration of fibroblasts into the matrix interferes with
incorporation into the surrounding tissue. The probability of successful matrix integration
can be negatively affected by serious complications including infection, explantation,
seroma, and a poor aesthetic outcome when the ADM stimulates a foreign body response
[526-528].
Evidence suggests that exposure to pre-operative radiation is a contraindication for ADM
use [529]. However, when ADM is in place before post-operative radiotherapy begins, it
can increase the rate of prosthetic pocket expansion and protect against post-operative
radiation-induced skin flap necrosis. The pectoralis tightness that can result from postoperative radiation-induced fibrosis may also be lessened when the pectoralis major’s
inferior border is released during reconstruction. A study of two-stage prosthetic breast
reconstruction [n = 428 breasts] found that explantation rates after post-operative
irradiation were reduced in the ADM group compared with previously reported rates
[528].
Seth et al. [530] compared an ADM and non-ADM cohort and found that when ADM
was not used during reconstruction, there was a 2.63-fold increase in the rate of
complications associated with post-mastectomy radiation therapy. No benefits have been
found when ADM is used for reconstruction of breasts exposed to pre-operative
radiotherapy [465, 523, 531,532].
Many women who undergo breast reconstruction have previous radiation exposure or
require post-operative radiotherapy. The literature on whether women who have
reconstruction that includes ADM use do better when they also have radiation exposure is
contradictory. Some study findings indicate that capsular contracture, infection, revision,
and reconstructive failure rates are higher in these women when prothesis-based
reconstruction is used [533-535]. Results of analyses of retrospective series that include
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pre- or post-operative radiation exposure have been published [465, 536,537]. Colwell
and colleagues [465] found that that there were no statistically significant differences in
complication rates between radiation groups. Kobraei and colleagues [537] published an
analysis of a study population that consisted of a small number of patients found that
exposure to post-operative radiation was the only statistically significant variable
associated with implant loss in the patients for whom ADM was used as part of their
reconstruction.
Results of experimental animal models consistently indicate that ADMs are incorporated
and vascularized in fields exposed to radiation or to post-implant radiation [531,538].
Komorowska-Timek and Gurtner [539] used an animal model to examine radiation
effects on implants wrapped in ADM. These implants had decreased inflammation and
pseudo-epithelium formation, and matrix incorporation was successful despite radiation
exposure [539].
Negative effects can result from delay of chemotherapy to allow more complete
incorporation of ADM after IBR [475]. However, use of IBR generally requires no delay
or only a modest delay in the start of adjuvant chemotherapy [540,541]. In some studies,
but not all, neoadjuvant and adjuvant chemotherapies have been found to not be
associated with increased rates of complications. [542,543].

2.6.4 Economic disadvantages of ADM

Use of ADM adds several thousand dollars to the costs of breast reconstruction.
However, this cost may be balanced by reductions in the numbers of follow-up treatments
required when ADM is not used. Results of numerous studies also indicate that these
upfront costs are countered by the reduced costs associated with lower complication
rates, higher patient satisfaction, and the better QOL experienced by the patient [544550].
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In addition to improvements in outcomes, use of algorithms for decision-making about
ADM use may reduce health-care costs because ADM will be used more selectively and,
consequently, less frequently. The total cost may be less than use of non-ADM two-stage
methods, even when a patient chooses to have additional aesthetic procedures after a
direct-to-implant ADM-assisted breast reconstruction [544]. A cost-minimization
analysis of the United States health-care setting found that the direct-to-implant
reconstruction cost using ADM was US $5,423.02, compared with US $10,934 for use of
the traditional non-ADM two-stage procedure [544]. This finding suggests that surgical
technique [e.g., direct-to-implant] should be included in decision-making algorithms for
ADM use.
Some patients are not candidates for single-stage breast reconstruction. It is difficult to
determine whether, compared with the use of similar non-ADM two-stage techniques,
ADM use in two-stage techniques is good economic decision. de Blacam and colleagues’
[545] analysis found that the cost of ADM use in two-stage reconstructions was US
$11,255 compared with US $10,934 for a similar non-ADM option. The results of
Krishnan and colleagues’ [546] analysis was similar, demonstrating that the increase in
cost was US $362 when ADM used. This price difference is negligible. However, Bank
and colleagues [547] found a US $3,047 greater cost when ADM was used during twostage reconstruction, which was almost ten times greater compared with Blacam’s or
Krishnan’s estimates. Use of ADM alternatives [e.g., dermal allografts] may also result in
the same benefits, but at a lower cost [546-549].
The cost-effectiveness of ADM used for two-stage reconstruction can be affected by
many variables. The number of post-operative expansion visits can be reduced when it is
used for tissue expander surgery because the intra-operative fill volumes are larger
compared with similar non-ADM procedures [544,547]. Bank and colleagues [547]
suggested that since breast reconstruction costs increase as the numbers of visits for
expansion increase, use of ADM for breasts greater than 500 mL volume is costeffective. From this perspective, including breast size in algorithms may be beneficial,
but delayed reconstruction might be necessary for large breasts. The variance in
complication rates remains the main reason for the uncertainty about the cost of ADM

68
use [50,545]. The actual costs are affected by the severities of the associated
complication rates, where high severity will increase the overall cost. An algorithm that
results in rational selection of ADM use will reduce complication rates and improve the
cost-effectiveness of ADM.
Cost of materials is likely the most important factor affecting analyses of ADM costutility [546,547]. As such, an algorithm that can help surgeons be more selective
choosing patients would substantially improve the practice of cost-effective surgery. A 6
cm × 16 cm ADM sheet is approximately US $3,100. Jordan and colleagues [550]
suggested that use of their algorithm could result in a US $150,000 materials costs
savings during 1 year of 100 prosthetic breast reconstructions, assuming that the use of
the algorithm resulted in a decline in ADM use from 84% to 36% [550].

2.7 Cost-effectiveness analysis (CEA)

Total health-care expenditures in Canada were $182.1 billion in Canadian dollars (CAD)
in 2009, CAD $192.9 billion in 2010, and CAD $200.5 billion in 2011 to CAD $242
billion in 2017. These values represented 11.9%, 11.9%,11.6% and 11.5% of Canada’s
gross domestic product in 2009, 2010, 2011 and 2017, respectively [551].
One objective of a health care economic evaluation is to determine the value for money
associated with a new intervention. The types of economic evaluations used for CEA
include cost-benefit analysis, cost-minimization analysis, and cost-utility analysis [552].
CEA estimates effects on one outcome, which is typically measured using clinical units
[e.g., gain in number of symptom-free days or number of life years]. Cost-utility analysis
measures patient outcomes in QALYs. A QALY is a unit of measurement of the number
of remaining life years multiplied by a QOL factor [weighting factor, 0 [death] to 1
[perfect health]]. Use of QALY as a unified outcome variable facilitates comparison of
the cost-effectiveness of different interventions across disease sites and treatments [ 553].

69
Cost-effectiveness thresholds vary between countries. Threshold values of US $20,000,
US $50,000 or US $100,000 per QALY or life year gained are typically used in
individual analyses [554].

2.7.1 Cost-effectiveness of breast cancer treatment

Cost is an important part of the decision-making process for breast cancer treatment. Cost
to the government health-care system, the financial burden on the insurance providers,
accountability to a private center’s stakeholders and investors, and the direct and indirect
financial and non-financial costs to the patients are included in the cost spectrum. The
overall costs incurred with a breast cancer patient encompass a broad spectrum of factors
such as age of the patient when the disease is first diagnosed, stage of breast cancer,
socioeconomic background of the patient, and procedures and device selection. These
factors have positive or negative and direct or indirect effects on the cost-effectiveness of
breast cancer treatment.
Breast cancer accounts for the greatest numbers of new cancer cases in the United States,
with considerable societal resources used to care for these patients [555]. In 2016, greater
than 60% of the approximately 250,000 women with a new breast cancer diagnosis [555]
were predicted to present with localized, early-stage disease [556]. Evidence-based local
management options identified by National Comprehensive Cancer Network Guidelines
include mastectomy, mastectomy plus reconstruction, lumpectomy plus whole-breast
irradiation, and lumpectomy plus brachytherapy or lumpectomy followed by endocrine
therapy alone without radiation [557].
Smith and colleagues [558] found that early-stage breast cancer treatments have different
relative values. A treatment with fewer complications may be significantly less expensive
than a treatment associated with more complications. However, the treatment decisions
made by the patient may be based on factors unrelated to medical value [558]. Smith and
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colleagues identified 105,211 women who had early breast cancer that was diagnosed
between 2000 and 2011. They examined the data for treatment-related complications
within 24 months of the diagnosis and compared complications by type of treatment. A
payer's perspective was used for calculation of the mean total and complication-related
costs. The results indicated that the most commonly-used treatment was lumpectomy plus
whole-breast irradiation and that mastectomy plus reconstruction had almost two times
the complication risk of the most commonly-used treatment [54.3% for mastectomy plus
reconstruction versus 29.6% for lumpectomy plus whole-breast irradiation among
younger women with private insurance; 66.1% for mastectomy plus reconstruction versus
37.6% for lumpectomy plus whole-breast irradiation among older women with
Medicare]. Mastectomy plus reconstruction was associated with a higher adjusted total
cost [for younger women, a mean value of US $22,481 more; for older women with
Medicare, a mean value of US $1,748 more] and higher complication-related cost [for
younger women, a mean value US $9,017 greater; for older women, a mean value US
$2,092 greater]. Compared with whole-breast irradiation treatment, brachytherapy had
slightly greater total costs and complications. Only the women with Medicare insurance
had lower lumpectomy-associated costs and complications.
Some of the increase in the use of bilateral mastectomy and reconstruction to treat early
breast cancer can be attributed to the recommendation that it is medically necessary, such
as in patients with extensive in situ disease or a diagnosis of cancer in high risk or gene
mutation carriers. However, nonmedical factors [e.g., patients preferring removal of the
entire breast to obtain a more “complete” cancer treatment, those fearing local recurrence
when lumpectomy plus whole-breast irradiation is used, or those anxious about the
requirement for follow-up visits for mammography screening of the remaining breast]
also affect the decision and account for some of the increase.
An important conflict related to “value” in health care is illustrated by the finding that
mastectomy plus reconstruction has a significantly higher cost, compared with
lumpectomy plus whole-breast irradiation. A higher-cost treatment may be requested by
the patient for non-medical reasons even when an equally effective but less expensive
treatment is available. Conversations between the patient and her physicians should
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include information about the potential for significant complications when mastectomy
with reconstruction is used.

2.7.2 Cost-effectiveness of breast cancer screening

It is easy to understand that undergoing mammography can help detect cancer early
during the onset of the disease. However, mammography is associated with long-term
health effects and costs for scheduled screenings. Mammogram schedules typically vary
from annual, biannual, and triennial screening. Various international institutes
recommend different frequencies based on their independent conclusions. American
recommendations vary from one to two-year intervals while the United Kingdom
recommends triennial screening. To improve cost-effectiveness, the recommended age at
first screening in the United States is now 50 years of age instead of 40 years of age. In
Canada, the recommended screening interval is biennial mammography for average-risk
patients, annual mammography for elevated risk patients [first degree relatives, especially
those diagnosed at an age younger than 50 years], and annual mammography with annual
MRI for high risk patients with greater than 25% lifetime risk of developing breast
cancer.
The increasing breast cancer incidence and the accompanying reduced QOL and high
medical care costs burden health systems and society. The implementation of national
mammography screening programs in many countries [e.g., North America, Europe,
Australia, and Japan] has been based on RCT results that indicate that a decline in the
breast cancer death rate is associated with mammography screening [559]. However,
results of systematic reviews of RCTs of breast cancer screening programs suggested that
mammography screening is a less effective intervention than initially believed [560].
CEA can provide the results needed to balance budgets, allocate limited national breast
cancer control program resources, and determine the most cost-effective diagnostic and
therapeutic care protocols [561].
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The parameters used to quantify the cost-effectiveness of a breast cancer intervention
include cost to detect a breast cancer, cost to prevent a breast cancer death, and cost per
QALY [562]. Cost per year of life expectancy gained is the most relevant parameter for
quantification of screening modality cost-effectiveness.
Annual and biennial screening of women 40–49 years of age had a cost per life year
gained of US $26,200 and US $14,000, respectively [563,564]. Barratt and colleagues
[565] found that beginning screening at 40 years of age instead of 50 years of age would
have a per QALY gained cost of US $24,000 to US $65,000. Madan [564] found that the
per QALY gained cost for triennial screening of women 47–49 years of age is
approximately US $45,000.
Compared with no screening, active screening strategies have a narrow range of
incremental cost ratios [i.e., within US $40,000 to US $60,000 of each other]. The
incremental ratios increase marginally as screening age eligibility increases from 69 years
of age to 74 years of age because the additional screening costs are offset by improved
outcomes. Incremental ratios likewise increase when screening age eligibility is reduced
from 50 years of age to 40 years of age because the screening costs increase, but there is
also a corresponding increase in QALYs gained [566]. The undiscounted overall costs to
screen 1,000 average risk women from the general population once each year range from
US $11.3 million [50–69 years of age] to US $16.0 million [40–74 years of age] [566].
Screening 1,000 average risk women once every 2 years costs US $8.4 million to US
$11.2 million [50–69 years of age and 50–74 years of age, respectively]. Screening 1,000
average risk women once every 3 years costs US $7.6 million to US $8.3 million [50–69
years of age and 50–74 years of age, respectively]. Over a lifetime, the overall cost of no
screening for 1,000 women is US $4.9 million [US $4,875 per woman].
An analysis of population-based mammography screening strategies for the Canadian
health system used screening diagnostic and treatment cost and utility values. The results
indicated that the most cost-effective strategy is biennial screening of women 50–69
years of age and 40–69.27 years of age [ 467]. That model used different per treatment
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costs, did not include triennial screening, and did not include costs associated with lost
productivity or negative effects on society [566].
Brown and colleagues’ [568] systematic review found that the range in cost-effectiveness
for breast cancer screening was US $3,400 to US $83,830 per life year saved. Other
estimates of cost per life year saved range from US $1,634 for a one-time screening at 50
years of age in India [569] to US $45,700 for once per year screening during 50–69 years
of age in the United States [570]. A multi-country study of the results of screening every
2 years found that that most cost-effective option was biennial screening from 50–70
years of age [Britain, US $2,685 per life years saved] [571]. The range in cost per QALY
gained was US $9,801 [Slovenia, triennial screening 50–65 years of age] to $46,500
[United States, annual screening 50–69 years of age [570]. A 2006 Netherlands study
[572] found that the costs per disability-adjusted life year prevented were US $75 for
Africa, US $915 for North America, and US $75 for Asia. This study found a
considerably lower cost per disability-adjusted life year saved, compared with the other
studies [572]. The accuracy and generalizability of the estimated costs and disabilityadjusted life years prevented remain to be determined.
A US study of breast cancer screening for women greater than 70 years of age found that
compared with no screening, the cost per life year saved was US $35,000 for once per
year screening from 80–85 years of age [563]. Barratt and colleagues’ [565] systematic
review found that the cost of per QALY gained after changing screening from 50–69
years of age to 50–79 years of age ranged from US $8,119 to US $27,751.
Taken together, the study results indicate that biennial screening from 50–70 years of age
is the most cost-effective option for women who are not at high-risk for breast cancer.
The 2016 American Cancer Society guidelines for screening high-risk women for breast
cancer recommend that annual MRI and mammography should start at 30 years of age
[573]. Because most study results are based on screening younger women at high-risk for
breast cancer, there are no data on the effectiveness of screening high-risk patients using
MRI and mammography after 69 years of age [574].

74
The results of RCTs and meta-analyses indicate that mammography screening reduces
cancer-associated mortality in the general population. However, there was no evidence
that screening reduces mortality in women at high-risk for breast cancer [575].
Prospective studies that began in the 1990s compared MRI with mammography for
screening high-risk patients. The results indicated that MRI has significantly greater
diagnostic sensitivity, compared with mammography [575-583].
Values for diagnostic sensitivity range from 71%–100% for MRI alone versus 13%–59%
for mammography alone. A meta-analysis of 11 studies found that the values for
diagnostic sensitivity are 77% for MRI alone, 39% for mammography alone, and 94% for
mammography combined with MRI [584]. The higher diagnostic sensitivity of MRI
alone is limited by lower diagnostic specificity and increased false-positive rates, which
increases the recall rate [for additional imaging] and the biopsy rate [574,575].
Plevritis and colleagues [585] examined the cost-effectiveness of mammography with
MRI compared with mammography alone in a population of women at very high-risk for
breast cancer [35–54 years of age]. Their results indicated that the costs per QALY were
US $55,420 and US $130,695 for BRCA1 and BRCA2 patients, respectively. The
estimated costs were US $41,183 [BRCA1 mutation] and $98,454 [BRCA2 mutation] for
women with denser breast tissue. Cott and colleagues [586] also examined the costeffectiveness of MRI combined with mammography for women with BRCA1 and
BRCA2 mutations. The results indicated that alternating MRI and digital mammography
at 6-month intervals beginning at 30 years of age [i.e., current guideline] is more costeffective for patients with the BRCA1 mutation than for patients with the BRCA2
mutation [586]. The incremental cost of adding MRI to mammography was US $40,911
per cancer detected [579]. Taneja and colleagues [587] designed a model to evaluate the
cost-effectiveness of screening high-risk women using MRI and mammography
compared with mammography alone. The incremental cost per QALY for MRI and
mammography versus mammography was US $25,270, compared with non-BRCA
women [i.e., up to US $315,210]. The results indicated that use of MRI is a cost-effective
approach for high-risk patients.
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2.7.3 Cost-effectiveness of breast cancer risk reduction techniques

Use of genetic screening for BRCA diagnosis has been possible since the 1990s. The
numbers of women who elect to pursue PM based on the results of genetic screening
have increased, but only more recently. There are few data on the fiscal effects that the
breast cancer treatment options chosen will have on lifetime costs of treatment [588].
Since 2004 and the advent of one-stage IBR, this option has become more popular and
mastectomies have also become more popular, particularly the use of BPM [ 589].
Anderson and colleagues [590] completed a cost-utility analysis comparing different
surveillance and preventive strategies in BRCA gene carriers. They estimated that the
most cost-effective approach was PM with bilateral salpingo-oophorectomy [BSO]. This
approach increased in cost-effectiveness the younger the patient and cost as little as US
$100 per QALY gained. However, endometrial cancer, pulmonary emboli, and cataracts
were the only complications included in the model. The costs of reconstructive options
were not included. The standard threshold used to decide whether a treatment is costeffective is US $50,000/QALY [i.e., anything below this threshold is considered a
worthwhile investment]. Therefore, US $100/QALY is an extremely low cost. Another
study found that PM and BSO imparts a survival advantage and results in QALY gains in
the highest risk patients [591]. The cost for PM was up to an additional US
$1,277/QALY, which is well within the range of cost-effectiveness. A follow-up study
[395] found that that BPM and BSO were both less expensive throughout a patient’s
lifetime compared with starting with tamoxifen treatment or regular surveillance. In some
cases, use of BPM and BSO resulted in more than US $40,000 in savings throughout a
patient’s lifetime. Although the study did estimate a contribution to overall patient
survival, its estimates suggested there was a slight drop in QOL. A Norwegian study
found that there were cost savings when prophylactic BSO and BPM were chosen,
especially after including the productivity gains and indirect costs associated with longterm gains, and an increase in life expectancy based on its model of BPM at 30 years of
age and BSO at 35 years of age [592].
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The results of an analysis of unadjusted and patient preference-weighted data indicated
that BPM is more cost-effective than annual mammography when the lifetime breast
cancer risk is 50%; the mean values were US $21,042.50 for BPM, compared with US
$20,980.44 for screening alone [593]. When the MRI cost was based on Medicare
reimbursement rates, for any level of lifetime risk screening using mammography with
MRI was always less cost-effective than BPM. The MRI cost would have to be less than
US $177.74 to be more cost-effective than BPM, at a lifetime risk of 20% [the American
Cancer Society threshold for annual MRI screening]. At a lifetime risk of 43% and a
willingness-to-pay threshold of US $50,000 per life year, BPM with breast reconstruction
was a cost-effective alternative. It was also cost-effective at a 26% lifetime risk and a
willingness-to-pay threshold of US $100,000 per life year. The results of adding
preference ratings to the Markov model indicated that BPM with reconstruction was costeffective when the lifetime risks were 57% and 51% for willingness-to-pay thresholds of
US $50,000 and US $100,000 per QALY, respectively. At these thresholds, use of
mammography combined with MRI was never cost-effective compared with
mammography screening or BPM. Taken together, the results of the study indicated that
projected lifetime breast cancer risk must be ≥50% for BPM to result in cost benefits for
the number of lives saved [593].

2.7.4 Cost effectiveness of Chemoprevention

The National Surgical Adjuvant Breast and Bowel Project P-1 trial found that tamoxifen
prophylaxis reduced invasive breast cancer risk by nearly 50% [ 429]. After the results
were published, the US FDA approved tamoxifen as a chemopreventive agent for women
at higher than average risk. However, the elevated risks associated with tamoxifen use
include endometrial cancer and thromboembolic events. Although a large proportion of
women are eligible for tamoxifen treatment [ 594], few agree to it because of the risks of
these severe side-effects [595,596]. CEA has been used to identify populations of women
who would benefit from tamoxifen treatment. To balance the benefits with the potential
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harms, these analyses usually target women at an increased 5-year Gail model risk [597].
The study results indicate that although breast cancer incidence is reduced by tamoxifen
treatment, extensive use is not cost-effective because of tamoxifen’s cost, side-effects,
and sensitivity to QALY assumptions [598-599]. The studies used RR values for sideeffects that were taken from the National Surgical Adjuvant Breast and Bowel Project
clinical trial results. The researchers also assumed that the reduction in breast cancer risk
was limited to the period during active treatment [usually 5 years]. The results of
prospective trials with longer follow-up times indicate that the analyses should be
repeated using different assumptions [602,603].

2.7.5 Cost-effectiveness of ADM-assisted breast reconstruction

A cost-minimization analysis was used to compare ADM-assisted direct-to-implant one
stage reconstruction with the traditional two-stage approach [no ADM] [49]. A decision
analysis model and data from a previous systematic review were used to examine
probability values for eight outcomes [no complications, seroma, capsular contracture,
hematoma, infection, mastectomy flap necrosis, and implant exposure with salvage or
loss]. The results of the modeling indicated that the costs of ADM-assisted direct-toimplant reconstruction and the traditional two-stage approach were CAD $10,734 and
CAD $11,251, respectively [49].
Cost savings are associated with direct-to-implant reconstruction because, when
compared with the two-stage approach, direct-to-implant reconstruction eliminates the
second stage of surgery and has lower revision rates. Estimates of revision rates are
obtained from short-term follow-up observational studies. More accurate cost estimates
would likely result from long-term follow-up studies of the Canadian health care singlepayer system.
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De Blacam and colleagues [545] used a cost-minimization analysis of a US health-care
model to compare tissue expander/implant reconstruction with and without ADM and
direct-to-implant reconstruction with ADM. The probability values for five outcome
states [no complications, seroma, cellulitis, skin necrosis, and implant removal] were
estimated from results of a systematic review. They found that the expected tissue
expander/implant reconstruction cost was US $10,934 [604]. tissue expander/implant
with ADM was US $11,255 [605], and direct-to-implant reconstruction was US
$5,423.02. The ADM cost [US $321, Medicare fee] and hospital and surgical fee
differences were three factors that affected the results of the US analysis compared with
Jansen and Macadam’s [49,606] analysis of the Canadian system. Differences in costs
between health-care systems are apparent from these two studies. In the US study, De
Blacam and colleagues [545] used estimates of US $3000 and US $2000 differences in
surgical fees between the procedures. In the Canadian study, equivalent hospital fees
were estimated for each technique. A CAD $500 difference in surgical fees between the
two procedures was estimated by Jansen and Macadam [49,606].
The cost-benefit analysis to examine ADM use for revisional surgery to achieve cosmetic
benefits is more complex. A cost savings to the patient might result from the use of ADM
at an initial revisionary surgery if fewer additional revision surgeries are required [607,
608]. Of a series of patients who underwent ADM-assisted aesthetic revisionary
procedures, 2.6% [2/78] required subsequent surgery during a mean follow-up time of
approximately 12 months [607]. Spear and colleagues [608] found that during a 9-month
follow-up, 5.8% [3/52] of patients who had ADM used at the initial or first revisional
surgery required additional revisional surgery. These rates were lower than the 40.5%
secondary revision rate found by the Allergan Core Study during the 7-year follow-up
after breast augmentation surgery and an initial revision [608].
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2.8 Outcome after prophylactic mastectomy and immediate reconstruction

BPM is an effective risk reduction option in high-risk women. Mastectomy is a traumatic
event and patients most likely agonize over post-procedure appearance, and social and
sexual interactions. Breast reconstruction is proposed to improve aesthetic outcomes and
HRQOL characteristics.

2.8.1 Quality of life
Studies have found that as many as 72% of patients report favorable psychosocial wellbeing results after BPM. Compared with baseline values, levels of psychological
morbidity and anxiety declined by 6 and 18 months, respectively [p<0.05] [609].
Brandberg and colleagues [610] found that compared with baseline values, there were
statistically significant declines in anxiety levels by 6 months and 1 year [p<0.05].
Statistically significant declines in levels of distress about cancer have been found at the
6- and 21-month follow-ups [p<0.05] [611]. The results of Stefanek and colleagues’
[612] study indicated that 86% [n=12] of the patients who underwent BPM thought that
they would be affected by moderate or greater levels of breast cancer-related worry, but
none had clinically significant levels of depression. Geiger and colleagues [613] found
that 56% [n=59] of the patients who had a BPM procedure were concerned about breast
cancer after the procedure, but the results for the depression scores indicated that 65%
[n=69] were not affected by depression. In one population of women [n=26] who
underwent BPM and reconstruction, 11.5% had symptoms that suggested anxiety and
3.8% had symptoms that suggested depression, based on Hospital Anxiety and
Depression Scale scores. None of the women who only had BPM [n=2] had scores that
indicated they were affected by anxiety or depression [614], recognizing that any study
with two patients cannot be used to draw any meaningful conclusions.
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Hatcher and colleagues [609] found no statistically significant changes at 6 or 18 months
that indicated improvements in body image after BPM [609]. The results of Brandberg
and colleagues’ [610] study were similar in that here were no statistically significant
changes in body image at 6 or 12 months. They found that at 1 year, more than 50% of
the women were dissatisfied with their appearance and body and felt self-conscious and
less physically attractive. Gopie and colleagues [611] found that there were statistically
significant declines in body image by 6 months post-BPM. The results of studies that
examine the effects of BPM on sexual well-being vary. Some have found no negative
effects, and some have found statistically significant negative effects on sexual wellbeing. Hatcher and colleagues [609] found no sexual discomfort and high sexual pleasure
at 6 and 18 months after BPM, and there were no statistically significant changes
compared to baseline values. Gopie and colleagues [611] found that at the 6- and 12month follow-ups after BPM, there were no statistically significant changes in the high
sexual and partner relationship satisfaction that was present at baseline. Brandberg and
colleagues [610] reported that compared with baseline, there were statistically significant
changes in pleasure by 1-year post-BPM. There were no statistically significant
differences in sexual habit or discomfort. At 6- and 12-months post-BPM, more than 50%
of women [15%–31%] had positive reactions to intimate situations or questions about
feelings of femininity. Study results suggest that after BPM, patients have persistent
feelings of discomfort and loss of sensation in their reconstructed breasts [615-617],
which may have negative effects on sexual well-being. More than 69% [69%–94%]
reported sensitivity to touch and temperature after BPM with reconstruction [615-618].
Brandberg and colleagues [619] reported that at 6 months and 1 year after BPM, 73% of
the women had negative breast sensibility [619].
Evaluations of QOL have found higher or similar satisfaction levels in women in nonreconstruction BPM cohorts, compared with women in cohorts that had BPM with
reconstruction [612,614,620]. In these studies, the sample sizes of women who had only
BPM were generally small [i.e., 11–38 patients], so the results may not be accurate.
Compared with women who choose BPM alone, women who choose BPM with postmastectomy reconstruction may have expectations that are more difficult to meet.
Stefanek and colleagues [612] and Gahm and colleagues [616] found that 86% [n=12]
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and 92% [n=22], respectively, of women would recommend BPM to other women at a
high breast cancer risk. Another study found that 67% [n=381] of a group of women who
had BPM responded that they would definitely or probably choose to have the procedure
again [620]. Spear and colleagues [621] reported that 100% [n=11] of the women in their
study population said they would undergo reconstruction again.

2.8.2 Patient satisfaction

Few studies have examined the psychosocial sequelae of RRM. Six months to 30 months
after the procedure, Stefanek and colleagues [612] asked 14 women if they were satisfied
with their decision to have RRM. The participants were asked about levels of satisfaction
with the decision to have RRM, degree of support from family and friends, physical and
emotional recovery, and the side-effects of the procedure. In general, the women reported
having high levels of satisfaction, except for those who had breast reconstructive surgery.
Four of these 11 women were dissatisfied with the procedure because they experienced
post-operative complications such as hematoma and implant rupture. Borgen and
colleagues [622] found that during a median 14-year follow-up 6% [21/370] of women in
a voluntary national PM registry reported that they had regrets about their decision to
have RRM. However, the survey results may have been affected by bias because all of
the women volunteered to sign up for the PM registry. Except for satisfaction with the
decision to have RRM, and other aspects related to the surgery, there are few studies of
other psychosocial sequelae of RRM [609,620]. Frost and colleagues [620] also
examined data from the large population of women in Hartmann and colleagues’ [32]
RRM follow-up study. Ninety percent [523/639] completed a questionnaire that asked
about emotional status and satisfaction with the decision to have RRM [median followup, 14.5 years]. Seventy-four percent reported having decreased emotional concern about
developing breast cancer. Seventy percent were satisfied or very satisfied with their
decision to undergo RRM. Sixty-seven percent responded that they definitely or probably
would make the same choice again. Four factors explained 36% of the variance in
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satisfaction [satisfaction with appearance, stress levels, implant problems, and the
physician's advice to have the operation]. The patients with higher levels of satisfaction
with their appearance, lower stress levels, and fewer post-surgery implant problems
reported higher satisfaction levels. Some study results suggest that dissatisfaction or
regret after BPM is associated with the physician’s initiating the discussion about having
the procedure [620,622].
Most women report no changes in or positive change in stress, emotional stability, selfesteem, feelings of femininity, and sexual relationships with breast reconstruction.
Hatcher and colleagues’ [609] prospective UK study examined 79 high-risk women who
chose RRM and 64 high-risk women who refused RRM. The results indicated that at 6
and 18 months after surgery, the women who underwent RRM had significantly reduced
anxiety and psychological morbidity, while the women who refused RRM experienced no
changes in anxiety and psychological morbidity. Any changes in sexual functioning were
not statistically significantly different in either group. Brandberg and colleagues. [619]
examined patient satisfaction with outcomes after BPM and found that for more than
70% of the women they studied, there was high correspondence between preoperative
expectations of BPM and their perceptions of outcomes at the 6-month and 1-year
follow-ups. Overall, 70% of the patients were satisfied with their BPM-associated
outcomes. Sahin and colleagues [623] found that 100% [n=21] of the patients they
examined were satisfied with their reconstruction-associated outcomes.

2.8.3 Purpose and Hypothesis
The purpose of this study was to evaluate cost of various reconstruction methods to
account for reconstruction related complication costs not captured in any other studies
and provide a real cost effectiveness estimate for each option among high risk women
using current Canadian costing data. The hypothesis of this study is that, based on
suggestive evidence that single stage procedures are less costly in previous limited US
studies, that one stage implant based reconstruction will be the most cost effective breast
reconstruction option for high risk women.
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Chapter 3
Material and method
3.1 Model Overview
We developed a decision-analytic model [Figure 3] to estimate the lifetime clinical and
economic consequences of different strategies for managing women at high-risk for
breast cancer with no history of breast malignancy. The model begins with a decision to
use one of the breast cancer risk management strategies available in the current Canadian
clinical practice for high-risk women including: (1) Prophylactic bilateral mastectomy
with immediate one-stage ADM-assisted implant breast reconstruction; (2) Prophylactic
bilateral mastectomy with immediate two-stage ADM-assisted TE-implant breast
reconstruction; (3) Prophylactic bilateral mastectomy with immediate two-stage
traditional TE-implant breast reconstruction; (4) Prophylactic bilateral mastectomy with
immediate autologous breast reconstruction (with or without TE or breast implant); (5)
Prophylactic bilateral mastectomy with immediate one-stage non-ADM (no-flap) breast
reconstruction; (6) Prophylactic bilateral mastectomy with delayed breast reconstruction;
(7) Prophylactic bilateral mastectomy without breast reconstruction; (8) Intense screening
and surveillance [Figure 3a].
Each strategy was followed by a Markov model, which is used to project the lifetime
health and economic consequences of a hypothetical cohort of high-risk women
undergoing each strategy [Figure 3a]. Markov model structure “A” follows strategies that
include bilateral prophylactic mastectomy with any type of immediate breast
reconstruction [i.e., strategies 1, 2, 3, 4, and 5]. Markov model structure “B” follows the
bilateral prophylactic mastectomy with delayed breast reconstruction strategy [strategy
6]. Markov model structure “C” follows the bilateral prophylactic mastectomy without
reconstruction strategy [strategy 7]. Markov model structure “D” follows the intensive
screening and surveillance strategy [strategy 8]. These Markov models differed from each
other in that additional health states were created to account for possible short and longterm complications or delayed breast reconstruction (if applicable) associated with
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different breast cancer risk management strategies. We assumed short-term complications
as having skin necrosis, infection and hematoma, or autologous necrosis (if applicable)
during the first six months following the surgical interventions [450-453]. We assumed
long-term complications as having capsular contracture (if applicable), implant removal
(if applicable), or revision surgery due to other complications any time during life-time
following surgical interventions [450-453]. We assumed complications would require
interventions in outpatient clinics and operating rooms or hospitalization and include
those that occur at both the donor and recipient sites in the case of autologous breast
reconstruction. The Markov models used were distinctively parameterized according to
the type of breast cancer risk management strategy.
Markov model structure “A” simulated monthly transitions among the following nine
distinct health states: (1) Initial surgical intervention and no postoperative complication;
(2) Skin necrosis; (3) Infection and hematoma; (4) Capsular contracture; (5) Autologous
necrosis when applicable; (6) Implant removal; (7) Revision surgery due to other
complications; (8) Breast cancer; (9) Death (Figure 1b). Markov model structure “B”
simulated monthly transitions among the following 12 distinct health states: (1) Initial
surgical intervention and no postoperative complication; (2) Delayed two-stage ADMassisted TE-implant breast reconstruction; (3) Delayed autologous breast reconstruction
(with or without TE or breast implant; (4) Delayed one-stage non-ADM breast
reconstruction; (5) Skin necrosis; (6) Infection and hematoma; (7) Capsular contracture;
(8) Autologous necrosis; (9) Implant removal; (10) Revision surgery due to other
complications; (11) Breast cancer; (12) Death [Figure 1c]. Markov model structure “C”
simulated monthly transitions among the following five distinct health states: (1) Initial
surgical intervention and no postoperative complication; (2) Skin necrosis; (3) Infection
and hematoma; (4) Breast cancer; (5) Death [Figure 1d]. Markov model structure “D”
simulated monthly transitions among the following three distinct health states: (1) Initial
extensive screening and surveillance; (2) Breast cancer; (3) Death [Figure 3f].
High-risk women entering any Markov model start the model upon receiving the
intervention (i.e., surgical intervention or extensive screening) and remained in the first
health state unless they develop a short or long-term complication (if applicable), have a
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delayed reconstruction (if applicable), develop breast cancer, or die. Because
development of a complication maybe associated with subsequent complications
[630,631], women who developed any complication (if applicable) remain in that
complication’s health state unless they develop another complication, breast cancer or
die. Women who develop breast cancer remains in that health state unless they die
[Figure 3 b, c, d, e and f].
The analysis was conducted from the Canadian health care payer’s perspective. We
applied a discount rate of 1.5% per annum to costs, life years (LY) and quality adjusted
life years (QALYs) following recommendations by the Canadian Agency for Drugs and
Technologies in Health [632]. We used a lifetime horizon and half cycle correction
[633]. We used TreeAge Software (Tree- Age Software, Inc.) to produce and evaluate the
decision analytic model.
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Figure 3 Decision analytic model for women at high risk for breast cancer.
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c Schematic representation of Markov model structure “B”
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d Schematic representation of Markov model structure “C”
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f Schematic representation of Markov model structure “D”
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3.1.1 Data Sources

We used two main sources to parameterize the model: Ontario administrative datasets relevant to
cancer health services research held by the Institute for Clinical Evaluative Sciences (ICES) and
data from published sources.

3.1.1.1 Health Administrative Data
The primary source of data was Ontario administrative databases, the population-based
administrative databases for Canada’s largest province (population 12.5 million). The Ontario
Cancer Data Linkage (cd-link) project is a data release mechanism in which Ontario
administrative databases relevant to cancer research, are linked, de-identified, and, with the
protections of a comprehensive Data Use Agreement (DUA), provided directly to investigators at
academic institutions in Ontario. We used the CD-Link project to access the following
administrative databases: Registered Persons Database (RPDB), CIHI Discharge Abstract
Database and Same Day Surgery (DAD/SDS), Ontario Health Insurance Plan (OHIP), CIHI
National Ambulatory Care Reporting System (NACRS), Ontario Cancer Registry (OCR), New
Drug Funding Program (NDFP). Data collection and analysis involving these administrative
databases were approved by Western University Research Ethics Board.
Brief description of the Ontario administrative databases used in this study
The RPDB database contains demographic information on all individuals eligible for health
insurance coverage in Ontario, including an individual’s date of birth, sex, address, date of death
(where applicable), and captures changes in eligibility for health insurance coverage. DAD/SDS
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contains administrative, clinical and demographic information on hospital discharges and day
surgery in all Ontario facilities. The NACRS dataset contains data describing all visits to the
emergency room, day procedures, and high cost ambulatory clinics (namely dialysis and
oncology) in Ontario. The OHIP database contains all claims made by physicians (and other
health care providers) for insured services provided to residents of the province. The OCR is a
provincial database that contains the records for all cases of cancer in Ontario. The OCR collects
information on cancer staging, patient demographics, diagnostic confirmation methods, clinical
characteristics of primary and secondary tumors, and death. The NDFP database contains patient
and treatment data on utilization of systemic intravenous oncology drugs for which
reimbursement is being sought through the NDFP. It contains the date, agent name, dose, fee for
each agent given and patient clinical data including height, weight, body surface area, age, and
diagnosis information.

3.1.2 Cohort identification and stratification

We used the DAD/SDS, OHIP and OCR databases to identify our study cohort consisting of
women who were identified at high risk for breast cancer during the period from January 1, 2005
to December 31, 2015 in Ontario. We defined these women as having prophylactic bilateral
mastectomy or started organized breast cancer screening (defined as having yearly screening
mammography and breast magnetic resonance imaging (MRI) [335]) during the study period.
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To identify those who had prophylactic bilateral mastectomy, we started by searching the
DAD/SDS database for female records containing at least a matching pair of the Canadian
Classification of Health Interventions codes for mastectomy (1YM89, 1YM90, 1YM91, or
1YM92) (i.e., indicating bilateral mastectomy) during the study period. We then searched the
OHIP database for a matching pair of mastectomy billing codes (R107, R108, or R117) (i.e.,
indicating bilateral mastectomy) claimed during the same time period of the earliest DAD/SDS
record indicating the bilateral mastectomy to optimize the accuracy of the coding of mastectomy
for each of these patients. In order to limit this group to those who had prophylactic bilateral
mastectomy, we used the DAD/SDS databases to exclude women with history of surgical
interventions to the breast and the OCR database to exclude women with history of cancer at
two-month following their earliest DAD/SDS record indicating the bilateral mastectomy.
To identify those who had started organized breast cancer screening during the study period
[335], we searched the OHIP database for both mammography billing codes (X184, X185, X172,
or X178) and breast magnetic resonance imaging (MRI) billing codes (X441, X445, X446, or
X447) claimed repeatedly within 11 to 16-month apart during the study period for the same
patients and continuously over patients’ follow-up time. This was done since there are no codes
specifically designed to identify breast imaging done through the high-risk screening program. In
order to limit our identified group to those who received these imaging procedures for screening,
we used the DAD/SDS to exclude women with life-time history of surgical interventions to the
breast, the OHIP database to exclude women with history of other breast MRIs at their earliest
breast MRI during the study period, and the OCR database to exclude women with history of
cancer at two-month following their earliest breast MRI during the study period.
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To ensure our cohort identification criteria was satisfied, we limited the study cohort to Ontario
residents and those with a minimum of two-year survival following either their earliest screening
breast MRI or earliest DAD/SDS admission date for prophylactic mastectomy during the study
period. We then stratified our study cohort of high-risk women by their type of breast cancer risk
management strategy undertaken. To do that, we used the DAD/SDS database to search for the
Canadian Classification of Health Intervention (CCI) specific-breast reconstruction codes (e.g.,
1YM90LAPMK for immediate one-stage ADM-assisted implant breast reconstruction,
1YM90LATPK for immediate two-stage ADM-assisted TE-implant breast reconstruction,
1YM90LATP for immediate two-stage traditional TE-implant breast reconstruction) and stratify
our study cohort to the following eight subgroups representing the eight strategies in our decision
model [Table 1]:
(A1) High-risk women who had undergone any type of prophylactic bilateral mastectomy
with immediate one-stage ADM-assisted implant breast reconstruction, representing strategy (1)
in the decision model.
(A2) High-risk women who had undergone any type of prophylactic bilateral mastectomy
with immediate two-stage ADM-assisted TE-implant breast reconstruction, representing strategy
(2) in the decision model.
(A3) High-risk women who had undergone any type of prophylactic bilateral mastectomy
with immediate two-stage traditional TE-implant breast reconstruction, representing strategy (3)
in the decision model
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(A4) High-risk women who had undergone any type of prophylactic bilateral mastectomy
with any type of immediate autologous breast reconstruction (with or without TE or breast
implant), representing strategy (4) in the decision model
(A5) High-risk women who had undergone any type of prophylactic bilateral mastectomy
with immediate one-stage non-ADM (no-flap) breast reconstruction, representing strategy (5) in
the decision model
(A6) High-risk women who had undergone any type of prophylactic bilateral mastectomy
with any type of delayed breast reconstruction, representing strategy (6) in the decision model
(A7) High-risk women who had undergone any type of prophylactic bilateral mastectomy
without breast reconstruction over their follow-up time, representing strategy (7) in the decision
model
(A8) High-risk women who received organized breast cancer screening to manage their
high risk for breast cancer and did not receive any prophylactic surgery over their follow-up
time, representing strategy (8) in the decision model

3.1.3 Linkage with Ontario administrative databases

We linked our study cohort back with Ontario administrative databases to collect follow-up
information between three-year before and up to ten-year after receiving prophylactic bilateral
mastectomy or starting organized breast cancer screening. We used this follow-up information to
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measure co-morbidity and match the subgroups of cohort of high-risk women on age and
comorbidity, estimate transition probabilities for the Markov models, and estimate the direct
healthcare cost per unit time for each health state of the Markov models. Details on these steps
are provided in the following subsections:

3.1.3.1 Comorbidity index and propensity score matching:

We linked our study cohort with both the DAD/SDS and OHIP databases to determine comorbidity through diagnoses or procedures that were recorded for each woman included in the
cohort during all patient hospital stays and physician claims between three years before and six
months after receiving prophylactic mastectomy or starting organized breast screening.

We used co-morbid diagnoses coded using the method developed by Charlson and colleagues,
The Charlson Comorbidity Index is a method of categorizing comorbidities of patients based on
the International Classification of Diseases (ICD) diagnosis codes ,it consists of Diabetes
mellitus, Liver disease, Malignancy, AIDS, Chronic Kidney Disease, Congestive Heart Failure,
Myocardial infarction, Chronic Obstructive Pulmonary Disease, Peripheral vascular disease,
Cerebrovascular Accident , Dementia, Hemiplegia, Connective tissue disease and Peptic ulcer
disease. Each comorbidity category has an associated weight (from 1 to 6), based on the adjusted
risk of mortality or resource use, and the sum of all the weights results in a single comorbidity
score for a patient. A score of zero indicates that no comorbidities were found. The higher the
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score, the more likely the predicted outcome will result in mortality or higher resource use [634636].

We then used the propensity score matching method to build comparable subgroups of high-risk
women undertaken different types of breast cancer risk management in terms of co-morbidity
and age (i.e. at time of prophylactic mastectomy or starting organized breast cancer screening)
(637,638).We considered women undertaken prophylactic bilateral mastectomy with immediate
two-stage traditional TE-implant breast reconstruction (subgroup A3) as our reference subgroup.
We used logistic regression to create a propensity score (i.e., likelihood) [637,638], for having
prophylactic bilateral mastectomy with immediate two-stage traditional TE-implant breast
reconstruction, using the Charlson co-morbidity score and age regardless of their individual
statistical significance. We used the propensity score to match each woman in the reference
subgroup (A3) with up to 4 women in each of the other subgroups (A1), (A2), (A4), (A5), (A6),
(A7), and (A8). We considered observations that were within a maximum of +/– 0.01 of
women’s propensity score in the reference group for matching and chose the closest match
without replacement (i.e., caliper matching without replacement) [637,638]. When no matches
were found, that woman was be dropped. We assessed whether the propensity score model was
adequately specified by comparing the Charlson co-morbidity score and age between the
matched subgroups of our cohort of high-risk women to test whether balance was achieved
(Table 2).
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3.1.3.2 Transition probabilities for the Markov models:
We linked the propensity score–matched subgroups that undergone prophylactic bilateral
mastectomy with the OHIP database to determine short and long-term complications associated
with prophylactic mastectomy and different breast reconstruction techniques over up to ten-year
follow-up. We defined short-term complications as having skin necrosis, infection and
hematoma, or autologous necrosis (if applicable) during the first six months following the
surgical interventions. We defined long term complications as having capsular contracture (if
applicable), implant removal (if applicable), or revision surgery due to other complications any
time during life-time following surgical interventions. To do so, we searched the OHIP database
for specific billing codes associated with short-term complications (Z080 and R004 for skin
necrosis; Z101, Z102, Z140, and Z740 for infection and hematoma; Z226 for autologous
necrosis) and long-term complications (Z142 for implant removal; Z182 and Z135 for capsular
contracture; R114 for revision surgery due to other complications) that were claimed for each
woman included in each of the matched subgroups during the first six months and up to ten-year,
respectively, following prophylactic bilateral mastectomy [Table 2]. We used this information to
estimate monthly transition probabilities to the complication health states in the Markov model
that corresponds with the prophylactic bilateral mastectomy-based risk management strategy that
each matched subgroup represents for the decision model [Table 3].
We also linked the propensity score–matched subgroups with the OCR database to determine
diagnoses of breast cancer and with the RPDB database to determine mortality after receiving
prophylactic bilateral mastectomy or starting organized breast cancer screening (Table 2). We
conducted up to ten-year survival analyses using Kaplan-Meier estimates separately among
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women who received any prophylactic bilateral mastectomy regardless of their breast
reconstruction technique and those who started organized breast cancer screening. We used this
information to estimate all monthly transition probabilities to breast cancer and death states in
each Markov model following prophylactic bilateral mastectomy-based risk management
strategies and in the Markov model following the screening-based risk management strategy,
respectively, in the decision model [Table 3].
To extrapolate transition probabilities to life time we assumed the observed average monthly
transition probabilities during the observed 10-year follow up in the studied population to be
constant over the extrapolated time period. We used baseline age-specific utilities based on
representative values for the general Ontario female population in order to account for
background morbidity of the average age of our propensity score-matched cohort (≈50 years old)
during their lifetime in the decision model [639] [Table 3].
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3.1.4 Direct healthcare cost for the Markov models
The direct costs of healthcare services comprised of inpatient and one day procedure stays, visits
to the emergency room and ambulatory clinics, physicians and other health care providers’
services and intravenous oncology drugs. The cost of these services and drugs are all publicly
funded in Ontario and recorded in the DAD/SDS, NACRS, OHIP and NDFP databases,
respectively. The hospital costing data came from ICES in what is called Case Costing Data,
which is an average cost of a procedure at an Ontario hospital for any person having that
procedure . We linked the propensity score–matched subgroups with these databases to
determine individual case-costs of healthcare services from all records of these databases for
each woman included in each of the matched subgroups after receiving prophylactic mastectomy
or starting organized screening and up to 10-year of follow-up [640].
For services that implement case-mix methodology and where the unit cost is per weighted case
(inpatient and one day procedure stays and visits to the emergency room and ambulatory clinics),
a case-cost was a product of the resource weight for the specific episode (which reflects intensity
of service utilization and acuity of a particular woman) and the appropriate unit costs (a
multiplier known as the Cost Per Weighted Case) [640]. For services with a service-specific cost,
such as physician services, tests, diagnostic procedures, and intravenous oncology drugs, a casecost was simply a unit cost (cost per visit, per hour, per service, per dose of given drug) [640].
We estimated the cost of various service categories using a phase-of-care approach [641-644].
Cost of care for patients having initial surgical or screening intervention to manage high risk of
breast cancer or having delayed reconstruction following prophylactic bilateral mastectomy were
divided into four clinically relevant phases of care: (1) Initial intervention; (2) Continuing care;
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(3) Short-term follow-up; (4) Long-term follow-up. The “initial intervention” phase consisted of
the first 6-month following the intervention, the “continuing care” phase consisted of the 6
months following the “initial intervention” phase, the “short-term follow-up” phase consisted of
the 4 years following the “continuing care” phase, and the “long-term follow-up” phase consisted
of the 5 years following the “short-term follow-up” phase. Similarly, cost of cancer care for
patients diagnosed with breast cancer was divided into four clinically relevant phases of care: (1)
Diagnostic workup and initial cancer care; (2) Continuing cancer care; (3) Short-term follow-up;
(4) Long-term follow-up. The “diagnostic workup and initial cancer care” phase consisted of the
first 6-month following the diagnosis with breast cancer, the “continuing cancer care” phase
consisted of the 6 months following the “diagnostic workup and initial cancer care” phase, the
“short-term follow-up” phase consisted of the 4 years following the “continuing cancer care”
phase, and the “long-term follow-up” phase consisted of the 5 years following the “short-term
follow-up” phase. Within each phase of care and for each cost category, we calculated the cost
per day for each patient and the average cost per day separately for each matched subgroup. We
then multiplied these average cost-per-day estimates by 30 days to calculate the average monthly
cost of each phase of care by matched subgroups and cost categories [Table 4].
We used the average monthly costs of healthcare services collected for each matched subgroup
to estimate the cost per unit time in each state of the Markov model that corresponds with the
high-risk management strategy that each matched subgroup represents for the decision model
(see cohort identification and stratification) [Table 4]. For example, the average monthly costs of
healthcare services collected for the matched subgroup (A3) was used to estimate the cost per
unit time in each state of Markov model “A” following strategy (3) in the decision mode
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3.1.5 Utilities

Quality of life data cannot be obtained from Ontario health administrative databases and

thus we used data from published literature [646-649]. QALY was generated by
multiplying the utility (0-1) by LY , for example woman lives for 28 years with
Prophylactic bilateral mastectomy with one-stage ADM-assisted implant immediate breast
reconstruction means she lives with a utility level of 0.703, this woman will have 19.706
QALYs ( 28 Years of Life x 0.703 Utility Value = 19.706 QALYs).We used baseline agespecific utilities based on representative values for the general Ontario female population
in order to account for background morbidity of the average age of women included in our
cohort during their lifetime in the decision model [639]. We derived utility decrements
associated with prophylactic bilateral mastectomy and different breast reconstruction
techniques, short and long complications and breast cancer from a variety of secondary
sources. We calculated utilities by subtracting the utility decrements from the respective
baseline utility values [Table 5].
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3.1.6 Statistical Analysis
Patient characteristics (age, modified Charlson index to reflect comorbidity, year of
intervention, type of reconstruction, complications, breast cancer and survival, and length
of follow-up) were described using mean (standard deviation) or count (percentage) as
appropriate. Furthermore, we examined differences in patient characteristics among
patients using Chi-square and t-tests to assess univariate differences. All statistical
analyses were performed using SAS software version 9.3 (SAS Institute Inc., Cary, NC,
USA).

102

Chapter 4
Results
4.1 Cohort
This study identified 19,755 Ontarian women who were classified at high risk of breast cancer
during the period from January 1, 2005 to December 31, 2015 and met our study inclusion
criteria. Of those, 1,962 had prophylactic bilateral mastectomy (10%) and 17,793 (90 %) started
intense breast cancer screening and surveillance (Table 1). Among those women with
prophylactic bilateral mastectomy, 69 women (3.5%) had immediate one-stage ADM-assisted
implant breast reconstruction, 28 women (1.4%) had immediate two-stage ADM-assisted TEimplant breast reconstruction, 432 women (22%) had immediate two-stage traditional TEimplant breast reconstruction, 163 women (8.3%) had any type of immediate autologous breast
reconstruction (with or without TE or breast implant ), 219 women (11%) had immediate onestage non-ADM (no-flap) breast reconstruction, 226 women (11.5 %) had any type of delayed
breast reconstruction , and 825 women (42% ) had bilateral mastectomies without breast
reconstruction. Women who were found to have cancers at the time of their mastectomies were
excluded from this study.
Prior to matching, women who had prophylactic bilateral mastectomy were significantly younger
and had lower estimated comorbidity scores when compared to their counterparts who were
women undergoing intense breast cancer screening and surveillance (Table 1).
Using 1 to up to 4 matching on the estimated propensity score, this study matched prophylactic
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bilateral mastectomy with immediate two-stage traditional TE-implant breast reconstruction
group of 432 women with a prophylactic bilateral mastectomy with immediate one-stage ADMassisted implant breast reconstruction group of 68 women, with a prophylactic bilateral
mastectomy with immediate two-stage ADM-assisted TE-implant breast reconstruction group of
28 women, with a prophylactic bilateral mastectomy with any type of immediate autologous
breast reconstruction of 160 women, with a prophylactic bilateral mastectomy with immediate
one-stage no-ADM breast reconstruction of 211 women, with a prophylactic bilateral
mastectomy with any type of delayed breast reconstruction group of 224 women, with a
prophylactic bilateral mastectomy without breast reconstruction group of 618 women, and with
an organized breast cancer screening group of 1,696. No women with prophylactic bilateral
mastectomy with immediate two-stage traditional TE-implant breast reconstruction were
dropped due to poor match quality. Table 2 shows the baseline patient characteristics of the
matched prophylactic bilateral mastectomy with immediate two-stage traditional TE-implant
breast reconstruction group as compared to other groups. As a result of matching, differences
between the groups in age and co-morbidity score were eliminated (Table 2).

4.1.1 Breast cancer and survival outcomes
Matched women who had prophylactic bilateral mastectomy were less likely to develop breast
cancer (p < .0001; Table 2) and had lower mortality (p = < 0.0001; Table 2) compared to their
counterparts of matched women who received an intense breast cancer screening and
surveillance.
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4.2 Base-case scenario

4.2.1 Lifetime cumulative effectiveness and cost of surgical risk reduction strategies versus
intense screening and surveillance.
Compared to the intense screening and surveillance strategy, the surgical risk reduction strategies
led to increase of 0.785 QALYs and increase cost of $15,848 per person, which resulted in an
ICER of $20,188 per QALY gained.
Compared to the intense screening and surveillance strategy, BPM without breast reconstruction
led to an increase of 0.508 QALYs per person and decrease in cost of $ 8,220 per person, which
was cost saving. In contrast, BPM with one-stage ADM-assisted immediate breast reconstruction
and BPM with one-stage non-ADM immediate breast reconstruction led to an increase of 1.157
QALYs and 0.859 QALYs per person respectively, resulting in an increase of $11,128 and
$13,282 per person respectively. While BPM with two-stage TE/implant traditional immediate
breast reconstruction, BPM with autologous immediate breast reconstruction, BPM with twostage ADM immediate breast reconstruction and BPM with delayed breast reconstruction each
led to an increase of 0.815 QALYs, 0.951 QALYs, 0.516 QALYs, and 0.691 QALYs per person
and an increased cost of $21,088, $23,784, $32,526, and $17,351 per person, respectively. This
resulted in ICERs of $25,868, $24,988, $63,010 and $25,087 per QALY gained respectively
(Table 5, Figure 4).
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4.2.2 Lifetime cumulative effectiveness and cost of BPM with immediate two-stage traditional
TE-implant breast reconstruction strategy versus other reconstructive strategies.
Compared to BPM with immediate two-stage traditional TE-implant breast reconstruction,
BPM with one-stage ADM-assisted implant immediate breast reconstruction and BPM with onestage non-ADM immediate breast reconstruction led to an increase of 0.342 QALYs and 0.044
QALYs per person respectively and decrease in cost of $9,960 and $7,807 per person
respectively, resulting in a cost saving approach. BPM with two-stage ADM reconstruction led
to decrease of 0.299 QALY per person and increase cost of $11,438 CAD, BPM with any type of
autologous immediate breast reconstruction led to an increase of 0.136 QALY per person and an
increased cost of $2,695 CAD per person, resulting in ICER of $19,732 per QALY gained. while
BPM with delayed reconstruction led to a decrease of 0.123 QALY per person and reduction in
cost of $3,737 CAD per person. Figure 4 illustrates the differences in costs and effects between
the eight model strategies using a cost-effectiveness plane where BPM with one stage ADM
reconstruction strategy is visually shown to dominate other strategies.

4.3 QALY gain and budget impact analysis at the population level

In Ontario, the average number of women received BPM annually was 173 women, 7 women
received BPM with one-stage ADM-assisted breast reconstruction and 166 women received
other than types of breast reconstructions per year (Table 2).
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Incorporating BPM into standard practice for women at high risk of developing breast cancer in
Ontario would result in total annual net gains of 13.5 QALYs with total budget of $ 1.8 million.
Since BPM is considered the current standard of care for these women, incorporating BPM with
immediate one-stage ADM-assisted implant breast reconstruction in place of all of the other
strategies would result in total annual net gain of 20 QALYs and total annual saving of $1.7
million.
Incorporating BPM with two-stage ADM-assisted TE/ Implant breast reconstruction, two-stage
traditional TE-implant breast reconstruction, BPM with immediate autologous breast
reconstruction, or BPM with immediate one-stage non-ADM breast reconstruction into standard
practice would result in total annual net gains of 8.9 QALYs, 14 QALYs, 16 QALYs or 14.9
QALYs with the total budget of $2, $2, $2 or $1.8 million respectively. Incorporating BPM
without reconstruction or with delayed breast reconstruction into standard practice would result
in total annual net gains of 8.7 QALYs or12 QALYs with the total budget of $ 1.4 or $ 1.9
million respectively.
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Table 1 Patient characteristics of 17,793 Ontarian women identified at high risk of breast cancer during the period from
January 1, 2005 to December 31, 2015 in Ontario by type of breast cancer risk management strategy undertaken.
Prophylactic
bilateral
mastectomy
with immediate
one-stage ADMassisted implant
breast
reconstruction
(n=69)

Prophylactic
bilateral
mastectomy
with immediate
two-stage
ADM-assisted
TE-implant
breast
reconstruction
(n=28)

Prophylactic
bilateral
mastectomy with
immediate twostage traditional
TE-implant
breast
reconstruction
(n=432)

Prophylactic
bilateral
mastectomy with
any type of
immediate
autologous breast
reconstruction
(with or without
TE or breast
implant) (n=163)

Prophylactic
bilateral
mastectomy
with
immediate
one-stage nonADM breast
reconstruction
(n=219)

Prophylactic
bilateral
mastectomy
with any type
of delayed
breast
reconstruction
(n=226)

Prophylactic
bilateral
mastectomy
without breast
reconstruction
(n= 825)

5 (7.24%)

<5

94 (21.75%)

24 (14.72%)

35 (15.98%)

72 (31.85%)

225 (27.27%)

2008 – 2010

12 (17.39%)

<5

121 (28%)

53 (32.51%)

69 (31.5%)

76 (33.62%)

263 (31.87%)

2011 – 2013

17 (24.6%)

11 (39.28%)

144 (33.33%)

63 (38.65)

78 (35.61%)

60 (26.54%)

200 (24.24%)

2014 – 2015

35 (50.72%)

13 (46.42%)

76 (17.59%)

23 (14.11%)

37 (16.89%)

18 (7.96%)

137 (16.6%)

6 (8.69%)

<5

31 (7.17%)

9 (5.52%)

17 (7.76%)

<5

5 (0.6%)

30 – 39

14 (20.28%)

7 (25%)

110 (25.46%)

26 (15.95%)

55 (25.11%)

15 (6.63%)

42 (5.09%)

40 – 49

25 (36.23%)

12 (42.85%)

159 (36.80%)

67 (41.1%)

79 (36.07%)

96 (42.47%)

187 (22.66%)

50 – 59

17 (24.63%)

5 (17.85%)

102 (23.61%)

49 (30.06%)

54 (24.65%)

76 (33.62%)

295 (35.75%)

60 – 69

7 (10.14%)

<5

30 (6.9%)

12 (7.36%)

14 (6.39%)

36 (15.92%)

296 (35.87%)

0

1 (3.5%)

14 (3.24%)

10 (6.13%)

8 (3.65%)

24 (10.61%)

79 (9.57%)

2,504
(14.07%)

<0.0001

0

0

2 (0.46%)

2 (1.22%)

0

2 (0.88%)

18 (2.18%)

243 (1.36%)

<0.0001

Characteristic

Year when
identified at high
risk – no. of
women (%)
2005 – 2007

Age at initial
diagnosis (years)
20 – 29

Breast cancer
during follow-up –
no. of women (%)
Deaths during

Organized
breast
cancer
screening
(n=17,793)

823 (4.62%)
2,304
(12.94%)
5,949
(33.43%)
8,717
(48.99%)

377 (2.11%)
3782
(21.25%)
6014
(33.79%)
5003
(28.11%)
2617
(14.7%)

P
value1

<0.0001

<0.0001
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follow-up – no. of
women (%)
Charlson comorbidity score2
mean (SD,
range)
Score > 0 – no.
of women (%)
0
1
2
3
≥4

0.0579
(0.1204; 0 – 1)

0.0357

0.0694
(0.28;
0 – 3)

0.0736
(0.2845;
0 – 2)

0.0594
(0.25;
0 – 2)

0.0796
(0.49;
0 – 7)

0.1697
(0.5193; 0– 6)

3 (4.34%)

1 (3.57%)

28 (6.48%)

11 (6.74%)

12 (5.48%)

12 (5.309%)

107 (12.96%)

66
2
1
0
0

27
1
0
0
0

404
27
0
1
0

152
10
1
0
0

207
11
1
0
0

217
8
3
0
1

718
84
19
1
3

0.1693
(0.5259;0 –
14)
2,405
(13.51%)
15,388
2,062
230
40
73

Subgroups were compared against each other using Fisher’s exact or chi-square, as appropriate. All statistical tests were two sided and results were considered significant at the
5% critical level. Statistical analysis was performed using SAS, version 9.3 (Cary, NC).
2
Co-morbid diagnoses were considered present if they were found during one year before and 6 months after identification at high risk of breast cancer.
Abbreviations: ADM= Acellular dermal matrix; TE= Tissue expander.
1

<0.0001
<0.0001
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Table 2 Patient characteristics of 3,428 matched1 women identified at high risk of breast cancer by type of breast cancer risk
management strategy undertaken.

Characteristic

Prophylactic
bilateral
mastectomy
with
immediate
one-stage
ADMassisted
implant
breast
reconstructio
n (n=68)

Prophylactic
bilateral
mastectomy
with immediate
two-stage
ADM-assisted
TE-implant
breast
reconstruction
(n=28)

Prophylactic bilateral
mastectomy with
immediate two-stage
traditional TE-implant
breast reconstruction
(n=423)
(reference group for
propensity score
matching)

Prophylactic
bilateral
mastectomy with
any type of
immediate
autologous breast
reconstruction (with
or without TE or
breast implant)
(n=160)

Prophylactic
bilateral
mastectomy
with
immediate
one-stage nonADM breast
reconstruction
(n=211)

Prophylactic
bilateral
mastectomy with
any type of
delayed breast
reconstruction
(n=224)

88 (21.8%)

24 (15%)

32 (15.16%)

72 (32.14%)

119 (28.13%)

53 (33.12%)

68 (32.22%)

76 (33.92%)

142 (33.56%)

61 (38.12)

76 (36.01%)

74 (17.49%)

22 (13.75%)

35 (16.58%)

Prophylactic
bilateral
mastectomy
without breast
reconstruction
(n= 618)

Organize
d breast
cancer
screening
(n=1,696)

P value2

Year when women identified at
high risk – no. of women (%)
2005 – 2007

5 (7.35%)

2008 – 2010

12 (17.64%)

2011 – 2013

17 (25%)

2014 – 2015

34 (50%)

<5
<5
11 (39.28%)
13 (46.42%)

163 (26.37%)
205 (33.17%)

59 (26.33%)

140 (22.65%)

17 (7.58%)

110 (17.79%)

82
(4.83%)
236
(13.91%)
541
(31.89%)
837
(49.35%)

<0.0001

Age at initial diagnosis (years)
120
(7.07%)
436
(25.7%)
620
(36.55%)
404
(23.82%)
116
(6.83%)

20 – 29

6 (8.82%)

<5

29 (6.85%)

9 (5.62%)

16 (7.58%)

<5

5 (0.8%)

30 – 39

14 (20.58%)

7 (25%)

109 (25.76%)

26 (16.25%)

54 (25.59%)

15 (6.69%)

41 (6.63%)

40 – 49

25 (36.76%)

12 (42.85%)

155 (36.64%)

64 (40%)

75 (35.54%)

96 (42.85%)

186 (30.09%)

50 – 59

17 (25%)

5 (17.85%)

101 (23.87%)

49 (30.06%)

52 (24.64%)

76 (33.92%)

275 (44.49%)

60 – 69

6 (8.82%)

<5

29 (6.85%)

12 (7.5%)

14 (6.63%)

34 (15.17%)

111 (17.96%)

0

1 (3.5%)

13 (3.24%)

9 (6.13%)

7 (3.65%)

24 (10.61%)

51 (9.57%)

289
(17.04%)

<0.0001

0

0

2 (0.47%)

1 (0.62%)

0

2 (0.88%)

8 (1.29%)

24
(1.41%)

<0.0001

Women diagnosed with breast
cancer during the entire followup time – no. of women (%)
Deaths during the entire followup time – no. of women (%)
Complications associated with
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prophylactic mastectomy and
different breast reconstruction
techniques
Short-term complications
during the first 6 months of
follow-up time – no. of
women (%)
Skin necrosis
Infection and hematoma
Autologous necrosis
Long-term complications
during the entire follow-up
time – no. of women (%)
Implant removal
Capsular contracture
Revision surgery due to
other complications
Follow-up time – mean in
months (SD, range)

<0.0001
2 (2.94%)
2 (2.94%)
NA

1 (3.57%)
4 (14.28%)
NA

7 (1.65%)
35 (8.27%)
NA

7 (4.37%)
14 (8.75%)
3 (1.87%)

8 (3.79%)
18 (8.5%)
1 (0.47%)

31 (14.83%)
20 (8.9%)
1 (0.44%)

5 (0.8%)
56 (9.06%)
NA

NA
NA
NA
<0.0001

11 (16.17%)
13 (19.11%)

9 (32.14%)
10 (35.71%)

85 (20%)
241 (56.97%)

24 (15%)
51 (31.87%)

39 (18.48%)
64 (30.33%)

36 (16.07%)
87 (38.83%)

NA
NA

NA
NA

11 (16.17%)

12 (42.85%)

155 (36.64%)

58 (36.25%)

71 (33.64%)

84 (37.5%)

NA

NA

16.55
(13.44, 0.06 –
47.13)

16.22
(13.71, 0.26 –
44.1)

54.45
(37.42, 0.06 – 136.53)

53.19
(33.63, 0.8 – 3908)

1421.87
(1007.86, 29 –
130.26)

76.44
(34.4, 5.8 –
136.56)

65.66
(38.14, 0.9 –
135.86)

35.85
(28.75,
0.33 –
134.7)

0.0588
(0.1204; 0 –
1)

0.0357

0.0686
(0.27;
0 – 3)

0.075
(0.287;
0 – 2)

0.061
(0.26;
0 – 2)

0.053
(0.174;
0 – 1)

0.084
(0.3; 0 – 3)

3 (4.41%)

1 (3.57%)

27 (6.38%)

11 (6.87%)

12 (5.68%)

7 (4.46%)

48 (7.76%)

65
2
1
0
0

27
1
0
0
0

396
26
0
1
0

149
10
1
0
0

199
11
1
0
0

217
8
2
0
0

570
45
2
1
0

<0.0001

Charlson co-morbidity score3
mean (SD, range)
Score > 0 – no. of women
(%)
0
1
2
3
≥4
1

0.068
(0.279;0 –
3)
108
(6.36%)
1,588
104
0
4
0

Patients were matched on the estimated propensity score.
were compared against each other using Fisher’s exact or chi-square, as appropriate. All statistical tests were two sided and results were considered significant at the 5% critical level.
Statistical analysis was performed using SAS, version 9.3 (Cary, NC).
3 Co-morbid diagnoses were considered present if they were found during one year before and 6 months after identification at high risk of breast cancer.
Abbreviations: ADM= Acellular dermal matrix; TE= Tissue expander.
2 Subgroups

.07
.08
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Table 3 Base case monthly probabilities and sources.

Variables

Base Case
value

Distribution
Duration in the decision model

Data Source
used in PSA

Risk of breast cancer
Following any type of bilateral
prophylactic mastectomy
While on organized breast cancer
screening

0.000478%

0.001877%

Lifetime in the breast cancer-free
Markov states
Lifetime in the breast cancer-free
Markov states

Beta

OCR

Beta

OCR

Age-specific risk of death
50 – 59 years

0.000215%

1st – 9th year in the model

Beta

60– 69 years

0.00048%

10th – 19th year in the model

Beta

70 – 79 years

0.001451%

20th – 29th year in the model

Beta
Statistics

80– 89 years

0.004521%

30

– 39 year in the model

Beta

90– 99 years

0.015772%

40th – 49th year in the model

Beta

≥ 100 years

0.039442%

Risk of death associated with breast
cancer
Risk of complications by type of
surgical-based breast cancer risk
management strategy
Prophylactic bilateral mastectomy
with immediate one-stage ADM-

0.001988%

th

th

During and following 50thyear in the
model
Lifetime in the breast cancer Markov
states

Canada

Beta

Beta

RPDB
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Assisted implant breast
reconstruction

Skin necrosis

0.004963%

Infection and hematoma

0.004963%

Implant removal

0.003231%

Capsular contracture

0.00353%

Revision surgery due to other
complications

0.002937%

During the first 6 months in the breast
cancer-free Markov states
During the first 6 months in the breast
cancer-free Markov states
Lifetime in the breast cancer-free
Markov states
Lifetime in the breast cancer-free
Markov states
Lifetime in the breast cancer-free
Markov states

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Prophylactic bilateral mastectomy with
immediate two-stage ADM-assisted TEimplant breast reconstruction

Skin necrosis

0.006043

Infection and hematoma

0.025365

Implant removal

0.008739

Capsular contracture

0.008739

Revision surgery due to other
complications
Prophylactic bilateral mastectomy with
immediate two-stage traditional TE-

0.011056

During the first 6 months in the breast
cancer-free Markov states
During the first 6 months in the breast
cancer-free Markov states
Lifetime in the breast cancer-free
Markov states
Lifetime in the breast cancer-free
Markov states
Lifetime in the breast cancer-free
Markov states
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implant breast reconstruction

Skin necrosis

0.002771

Infection and hematoma

0.014256

Implant removal

0.005397

Capsular contracture

0.008017

Revision surgery due to other
complications

0.004349

During the first 6 months in the breast
cancer-free Markov states
During the first 6 months in the breast
cancer-free Markov states
Lifetime in the breast cancer-free
Markov states
Lifetime in the breast cancer-free
Markov states
Lifetime in the breast cancer-free
Markov states

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Prophylactic bilateral mastectomy with
any type of immediate autologous breast
reconstruction (with or without TE or
breast implant)

Skin necrosis

0.007428

Infection and hematoma

0.015145

Autologous necrosis

0.00315

Implant removal

0.004965

Capsular contracture

0.007238

Revision surgery due to other
complications

0.008485

During the first 6 months in the breast
cancer-free Markov states
During the first 6 months in the breast
cancer-free Markov states
During the first 6 months in the breast
cancer-free Markov states
Lifetime in the breast cancer-free
Markov states
Lifetime in the breast cancer-free
Markov states
Lifetime in the breast cancer-free
Markov states
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Prophylactic bilateral mastectomy with
immediate one-stage non-ADM breast
reconstruction

Skin necrosis

0.006421

Infection and hematoma

0.014751

Autologous necrosis

0.000791

Implant removal

0.006103

Capsular contracture

0.00599

Revision surgery due to other
complications

0.006796

During the first 6 months in the breast
cancer-free Markov states
During the first 6 months in the breast
cancer-free Markov states
During the first 6 months in the breast
cancer-free Markov states
Lifetime in the breast cancer-free
Markov states
Lifetime in the breast cancer-free
Markov states
Lifetime in the breast cancer-free
Markov states

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Prophylactic bilateral mastectomy with
any type of delayed breast
reconstruction
Before breast reconstruction

During the first 6 months in the breast
Skin necrosis

0.001351

reconstruction-free Markov states and
the breast cancer-free Markov state
During the first 6 months in the breast

Infection and hematoma

0.015467

reconstruction-free Markov states and
the breast cancer-free Markov state

Following breast reconstruction
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Delayed immediate two-stage
traditional TE-implant breast
reconstruction

During the first 6 months in the breast
Skin necrosis

0.001625

cancer-free Markov states following

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

breast reconstruction
Infection and hematoma

0.00658

Implant removal

0.013687

Capsular contracture

0.015667

Revision surgery due to
other complications

0.00707

During the first 6 months in the breast
cancer-free Markov states following
breast reconstruction
Lifetime in the breast cancer-free
Markov states following breast
reconstruction
Lifetime in the breast cancer-free
Markov states following breast
reconstruction
Lifetime in the breast cancer-free
Markov states following breast
reconstruction

Delayed immediate autologous
breast reconstruction (with or
without TE or breast implant)

Skin necrosis

0.009816

Infection and hematoma

0.013883

Autologous necrosis

0.001925

Implant removal

0.002841

Capsular contracture

0.003814

Revision surgery due to
other complications

0.011521

During the first 6 months in the breast
cancer-free Markov states following
breast reconstruction
During the first 6 months in the breast
cancer-free Markov states following
breast reconstruction
During the first 6 months in the breast
cancer-free Markov states following
breast reconstruction
Lifetime in the breast cancer-free
Markov states following breast
reconstruction
Lifetime in the breast cancer-free
Markov states following breast
reconstruction
Lifetime in the breast cancer-free
Markov states following breast
reconstruction

Delayed immediate one-stage
non-ADM breast reconstruction

Skin necrosis

0.006421

Infection and hematoma

0.014751

Autologous necrosis

0.000791

During the first 6 months in the breast
cancer-free Markov states following
breast reconstruction
During the first 6 months in the breast
cancer-free Markov states following
breast reconstruction
During the first 6 months in the breast
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Implant removal

0.00602

Capsular contracture

0.007546

Revision surgery due to
other complications

0.00602

cancer-free Markov states following
breast reconstruction
Lifetime in the breast cancer-free
Markov states following breast
reconstruction
Lifetime in the breast cancer-free
Markov states following breast
reconstruction
Lifetime in the breast cancer-free
Markov states following breast
reconstruction

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Beta

OHIP

Prophylactic bilateral mastectomy
without breast reconstruction

Skin necrosis

0.001351

Infection and hematoma

0.01568

During the first 6 months in the breast
cancer-free Markov states
During the first 6 months in the breast
cancer-free Markov states

Types of delayed breast reconstruction
following prophylactic bilateral
mastectomy
Delayed immediate two-stage traditional
TE-implant breast reconstruction

0.01415%

Delayed immediate autologous breast
reconstruction (with or without TE or
breast implant)

0.01295%

Delayed immediate one-stage non-ADM
breast reconstruction

0.00218%

Lifetime in the breast cancer-free
Markov states before any breast
reconstruction
Lifetime in the breast cancer-free
Markov states before any breast
reconstruction
Lifetime in the breast cancer-free
Markov states before any breast
reconstruction

Abbreviations: PSA = probabilistic sensitivity analysis; CCO= Cancer Care Ontario; RPDB= Registered Persons Database; OHIP=
Ontario Health Insurance Plan; ADM= Acellular dermal matrix; TE= Tissue expander.
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Table 4 Base case monthly cost estimates of healthcare services and sources by type of breast
cancer risk management strategy and phase of care.
Base
1

Cost estimates , $

Case

Distribution
Duration
used in PSA

value

Data
Source

Prophylactic bilateral mastectomy with
immediate one-stage ADM-assisted
implant breast reconstruction (n= 68)
During the first 6 months following the initial
Initial intervention phase

4,426.8

surgical intervention in the model while in

DAD/SDS,
Log-logistic

any breast cancer-free Markov states

and OHIP

From the 7th month and up to one year
Continuing care phase

257.4

following the initial surgical intervention in
the model while in any breast cancer-free

DAD/SDS,
Log-logistic

From the 2nd to the 5th year following the

Long-term follow-up phase

211.5

160

initial surgical intervention in the model

NACRS,
and OHIP

Markov states

Short-term follow-up phase

NACRS,

DAD/SDS,
Log-logistic

NACRS,

while in any breast cancer-free Markov states

and OHIP

Lifetime beyond the 5th year following the

DAD/SDS,

initial surgical intervention in the model

Log-logistic

NACRS,

while in any breast cancer-free Markov states

and OHIP

During the first 6 months following the initial

DAD/SDS,

Prophylactic bilateral mastectomy with
immediate two-stage ADM-assisted TEimplant breast reconstruction(n= 28)

Initial intervention phase

3852.6

surgical intervention in the model while in

Log-logistic

any breast cancer-free Markov states
Continuing care phase

335.1

From the 7th month and up to one year

NACRS,
and OHIP

Log-logistic

DAD/SDS,
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following the initial surgical intervention in

NACRS,

the model while in any breast cancer-free

and OHIP

Markov states
From the 2nd to the 5th year following the
Short-term follow-up phase

Long-term follow-up phase

344.4

321.1

initial surgical intervention in the model

DAD/SDS,
Log-logistic

NACRS,

while in any breast cancer-free Markov states

and OHIP

Lifetime beyond the 5th year following the

DAD/SDS,

initial surgical intervention in the model

Log-logistic

NACRS,

while in any breast cancer-free Markov states

and OHIP

During the first 6 months following the initial

DAD/SDS,

Prophylactic bilateral mastectomy with
immediate two-stage traditional TEimplant breast reconstruction (n= 423)

Initial intervention phase

3033.9

surgical intervention in the model while in

Log-logistic

any breast cancer-free Markov states

and OHIP

From the 7th month and up to one year
Continuing care phase

701.1

following the initial surgical intervention in
the model while in any breast cancer-free

DAD/SDS,
Log-logistic

From the 2nd to the 5th year following the

Long-term follow-up phase

231.6

243.2

initial surgical intervention in the model

any type of immediate autologous
breast reconstruction (with or without
TE or breast implant) (n= 160)

DAD/SDS,
Log-logistic

NACRS,

while in any breast cancer-free Markov states

and OHIP

Lifetime beyond the 5th year following the

DAD/SDS,

initial surgical intervention in the model
while in any breast cancer-free Markov states

Prophylactic bilateral mastectomy with

NACRS,
and OHIP

Markov states

Short-term follow-up phase

NACRS,

Log-logistic

NACRS,
and OHIP
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During the first 6 months following the initial
Initial intervention phase

3411.9

surgical intervention in the model while in

DAD/SDS,
Log-logistic

any breast cancer-free Markov states

and OHIP

From the 7th month and up to one year
Continuing care phase

492

following the initial surgical intervention in
the model while in any breast cancer-free

DAD/SDS,
Log-logistic

From the 2nd to the 5th year following the

Long-term follow-up phase

236.4

223.7

initial surgical intervention in the model

NACRS,
and OHIP

Markov states

Short-term follow-up phase

NACRS,

DAD/SDS,
Log-logistic

NACRS,

while in any breast cancer-free Markov states

and OHIP

Lifetime beyond the 5th year following the

DAD/SDS,

initial surgical intervention in the model

Log-logistic

NACRS,

while in any breast cancer-free Markov states

and OHIP

During the first 6 months following the initial

DAD/SDS,

Prophylactic bilateral mastectomy with
immediate one-stage non-ADM breast
reconstruction (n= 211)

Initial intervention phase

2445.9

surgical intervention in the model while in

Log-logistic

any breast cancer-free Markov states

and OHIP

From the 7th month and up to one year
Continuing care phase

344.4

following the initial surgical intervention in
the model while in any breast cancer-free

DAD/SDS,
Log-logistic

From the 2nd to the 5th year following the

Long-term follow-up phase

225.6

218.2

initial surgical intervention in the model

NACRS,
and OHIP

Markov states

Short-term follow-up phase

NACRS,

DAD/SDS,
Log-logistic

NACRS,

while in any breast cancer-free Markov states

and OHIP

Lifetime beyond the 5th year following the

DAD/SDS,

initial surgical intervention in the model
while in any breast cancer-free Markov states

Log-logistic

NACRS,
and OHIP
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Prophylactic bilateral mastectomy with
any type of delayed breast
reconstruction (n= 224)
Following prophylactic bilateral
mastectomy and before breast
reconstruction (n= 224)
During the first 6 months following the initial
Initial intervention phase

1680.6

surgical intervention in the model while in
any breast cancer-free and breast

DAD/SDS,
Log-logistic

and OHIP

reconstruction-free Markov states
From the 7th month and up to one year
Continuing care phase

287.7

following the initial surgical intervention in
the model while in any breast cancer-free and

DAD/SDS,
Log-logistic

From the 2nd to the 5th year following the
Short-term follow-up phase

180.9

while in any breast cancer-free and breast

DAD/SDS,
Log-logistic

Lifetime beyond the 5th year following the
Long-term follow-up phase

162.3

while in any breast cancer-free and breast

NACRS,
and OHIP

reconstruction-free Markov states

initial surgical intervention in the model

NACRS,
and OHIP

breast reconstruction-free Markov states

initial surgical intervention in the model

NACRS,

DAD/SDS,
Log-logistic

NACRS,
and OHIP

reconstruction-free Markov states
Following breast reconstruction
Delayed immediate two-stage
traditional TE-implant breast
reconstruction (n=103)
Initial intervention phase

1659.9

Continuing care phase

726.6

Short-term follow-up phase

220.2

During the first 6 months following breast
reconstruction in the model while in breast
cancer-free Markov states
From the 7th month to one year following
breast reconstruction in the model while in
breast cancer-free Markov states
From the 2nd to the 5th year following breast
reconstruction in the model while in breast

Log-logistic

Log-logistic
Log-logistic

DAD/SDS,
NACRS,
and OHIP
DAD/SDS,
NACRS,
and OHIP
DAD/SDS,
NACRS,
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Long-term follow-up phase

233.6

cancer-free Markov states
Lifetime beyond the 5th year following breast
reconstruction in the model while in breast
cancer-free Markov states

Log-logistic

and OHIP
DAD/SDS,
NACRS,
and OHIP

Delayed immediate autologous
breast reconstruction (with or
without TE or breast implant)
(n=87)
Initial intervention phase

2461.5

Continuing care phase

464.7

Short-term follow-up phase

231

Long-term follow-up phase

223

During the first 6 months following breast
reconstruction in the model while in breast
cancer-free Markov states
From the 7th month to one year following
breast reconstruction in the model while in
breast cancer-free Markov states
From the 2nd to the 5th year following breast
reconstruction in the model while in breast
cancer-free Markov states
Lifetime beyond the 5th year following breast
reconstruction in the model while in breast
cancer-free Markov states

Log-logistic

Log-logistic

Log-logistic

Log-logistic

DAD/SDS,
NACRS,
and OHIP
DAD/SDS,
NACRS,
and OHIP
DAD/SDS,
NACRS,
and OHIP
DAD/SDS,
NACRS,
and OHIP

Delayed immediate one-stage
non-ADM breast reconstruction
(n=34)
Initial intervention phase

974.1

Continuing care phase

218.4

Short-term follow-up phase

165.6

Long-term follow-up phase

204

During the first 6 months following breast
reconstruction in the model while in breast
cancer-free Markov states
From the 7th month to one year following
breast reconstruction in the model while in
breast cancer-free Markov states
From the 2nd to the 5th year following breast
reconstruction in the model while in breast
cancer-free Markov states
Lifetime beyond the 5th year following breast
reconstruction in the model while in breast
cancer-free Markov states

Log-logistic

Log-logistic

Log-logistic

Log-logistic

DAD/SDS,
NACRS,
and OHIP
DAD/SDS,
NACRS,
and OHIP
DAD/SDS,
NACRS,
and OHIP
DAD/SDS,
NACRS,
and OHIP

Prophylactic bilateral mastectomy
without breast reconstruction (n=618)
Initial intervention phase

1387.8

Continuing care phase

266.7

Short-term follow-up phase

174.9

Long-term follow-up phase

167.6

Organized breast cancer screening
(n=1,696)

During the first 6 months following the initial
surgical intervention in the model while in
any breast cancer-free Markov states
From the 7th month and up to one year
following the initial surgical intervention in
the model while in any breast cancer-free
Markov states
From the 2nd to the 5th year following the
initial surgical intervention in the model
while in any breast cancer-free Markov states
Lifetime beyond the 5th year following the
initial surgical intervention in the model
while in any breast cancer-free Markov states

Log-logistic

DAD/SDS,
NACRS,
and OHIP

Log-logistic

DAD/SDS,
NACRS,
and OHIP

Log-logistic

Log-logistic

DAD/SDS,
NACRS,
and OHIP
DAD/SDS,
NACRS,
and OHIP
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Initial intervention phase

224.1

Continuing care phase

173.7

Short-term follow-up phase

157.5

Long-term follow-up phase

170.4

During the first 6 months following initial
screening in the model while in the breast
cancer-free Markov state
From the 7th month and up to one year
following initial screening in the model while
in the breast cancer-free Markov state
From the 2nd to the 5th year following initial
screening in the model while in the breast
cancer-free Markov state
Lifetime beyond the 5th year following initial
screening in the model while in the breast
cancer-free Markov state

Log-logistic

Log-logistic

Log-logistic

Log-logistic

DAD/SDS,
NACRS,
and OHIP
DAD/SDS,
NACRS,
and OHIP
DAD/SDS,
NACRS,
and OHIP
DAD/SDS,
NACRS,
and OHIP

Breast cancer (n=394)

1

Diagnostic workup and initial cancer
care

4398.6

During the first 6 months in the breast cancer
Markov states

Log-logistic

Continuing cancer care

1760.7

From the 7th month and up to one year in the
breast cancer Markov states

Log-logistic

Short-term follow-up

963.9

From the 2nd to the 5th year in the breast
cancer Markov states

Log-logistic

Long-term follow-up

1,104

Lifetime beyond the 5th year in the breast
cancer Markov states

Log-logistic

DAD/SDS,
NACRS,
OHIP and
NDFP
DAD/SDS,
NACRS,
OHIP and
NDFP
DAD/SDS,
NACRS,
OHIP and
NDFP
DAD/SDS,
NACRS,
OHIP and
NDFP

All costs were inflated to 2018CAD using the bank of Canada inflation calculator [694].
Abbreviations: PSA= probabilistic sensitivity analysis; ADM= Acellular dermal matrix; TE= Tissue expander; DAD/SDS= CIHI
Discharge Abstract Database and Same Day Surgery; OHI= Ontario Health Insurance Plan; NACRS= CIHI National Ambulatory Care
Reporting System; NDFP= New Drug Funding Program.
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Table 5 Baseline life-time outcomes of the decision model.

Strategy

Extensive breast cancer screening
Prophylactic bilateral mastectomy without breast
reconstruction
Prophylactic bilateral mastectomy with two-stage traditional
TE-implant immediate breast reconstruction

Overall
QALYs

Overall
cost

Extensive breast cancer screening alone
vs.
surgical interventions
Inc.
QALY

Inc. cost

ICER per
QALY
gained

Traditional two-stage TE-implant
immediate breast reconstruction
vs.
other breast reconstruction
techniques
ICER per
Inc.
Inc. cost
QALY
QALY
gained

18.549

$90,231

Ref.

Ref.

Ref.

N/A

N/A

N/A

19.057

$82,011

+0.508

−$8,220

Cost-saving

N/A

N/A

N/A

19.364

$111,319

+0.815

+$21,088

$25,868
(dominated)

Ref.

Ref.

Ref.

Prophylactic bilateral mastectomy with one-stage ADMassisted implant immediate breast reconstruction

19.706

$101,359

+1.157

+$11,128

$9,615

+0.342

−$9,960

Prophylactic bilateral mastectomy with two-stage ADMassisted TE-implant immediate breast reconstruction

19.065

$122,757

+0.516

+$32,526

$63,010
(dominated)

−0.299

$11,438

19.501

$114,014

+0.951

+$23,784

$24,988
(dominated)

+0.136

$2,695

+0.044

−$7,807

−0.123

−$3,737

Prophylactic bilateral mastectomy with any type of autologous
immediate breast reconstruction (with or without TE or breast
implant)
Prophylactic bilateral mastectomy with one-stage non-ADM
immediate breast reconstruction

Prophylactic bilateral mastectomy with delayed breast
reconstruction

19.408

$103,512

+0.859

+$13,282

$15,457
(dominated)

19.241

$107,582

+0.691

+$17,351

$25,087
(dominated)

Abbreviations: ADM= Acellular dermal matrix; TE= Tissue expander; ICER= Incremental cost-effectiveness ratio; QALY= quality adjusted life year.

More
effective and
cost-saving
(dominating)
Less
effective and
more costly
(dominated)
$19,732
(dominated)
More
effective and
cost-saving
(dominated)
Less
effective and
cost-saving
(dominated)
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Figure 4 Differences in costs and effects between model strategies using a costeffectiveness plane.
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Cost (thousands of dollars)

120
115
110
105
100
95
90
85
80
18.5

18.6

18.7

18.8

18.9

19

19.1

19.2

19.3

19.4

19.5

19.6

19.7

19.8

Effectiveness (QALY)

Extensive breast cancer screening
Prophylactic bilateral mastectomy without breast reconstruction
Prophylactic bilateral mastectomy with two-stage traditional TE-implant immediate breast reconstruction
Prophylactic bilateral mastectomy with one-stage ADM-assisted implant immediate breast reconstruction
Prophylactic bilateral mastectomy with two-stage ADM-assisted TE-implant immediate breast reconstruction
Prophylactic bilateral mastectomy with any type of autologous immediate breast reconstruction (with or without TE or breast implant)
Prophylactic bilateral mastectomy with one-stage non-ADM immediate breast reconstruction
Prophylactic bilateral mastectomy with delayed breast reconstruction
Abbreviations: ADM= Acellular dermal matrix; TE= Tissue expander; ICER= Incremental cost-effectiveness ratio; QALY= quality adjusted life year.
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Chapter 5
Discussion and conclusion

5.1 Discussion

A wide array of treatment strategies are available to manage patients at an elevated risk
of breast cancer. These strategies include chemoprevention and prophylactic surgery.
Three selective estrogen receptor (ER) modulators (i.e., tamoxifen, raloxifene, and
exemestane) have been extensively studied and approved as chemo preventive agents
[650-652]. These medications have been developed as preventive agents and as
alternatives to surgery to reduce the breast cancer risk in high-risk women. Tamoxifen
has an excellent safety profile, prevents breast cancer in mice and rats, and decreases the
risk of development of contralateral breast cancer [653-655]. A 5-year course of
tamoxifen treatment reduces the relative risk of breast cancer by 30%–50% [650]. The
Study of Tamoxifen and Raloxifene (STAR) clinical trial was initiated in postmenopausal
women who had a high breast cancer risk. In the STAR trial, 19,747 eligible
postmenopausal women were randomly assigned to a 5-year treatment with tamoxifen
(20 mg/day) or raloxifene (60 mg/day). The median follow-up time was 81 months. The
results indicated that tamoxifen was a better chemo preventive agent, compared with
raloxifene. There were no differences between tamoxifen and raloxifene in 5-year
survival rates, but the values for the incidence of uterine cancer, and blood clot and
cataract formation were significantly lower in the raloxifene group [651]. Results of
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studies of most of chemo preventive agents (i.e. tamoxifen, raloxifene) indicate that they
can prevent hormone receptor positive breast cancers [651,652]. The lack of any survival
benefit in the prevention trials suggests that these agents may prevent hormone receptor
positive breast cancers that would have been cured using current treatments, without
having any effect on prevention of aggressive, life-threatening breast cancers [652].
One option for the prevention of breast cancer in the high-risk group is prophylactic
mastectomy (PM). Retrospective and prospective studies have investigated the utility of
this approach. These studies show an 85%–100% breast cancer risk reduction with an up
to 14-year median follow-up time. These results include use of Bilateral Prophylactic
Mastectomy (BPM) in high-risk women and use of Contralateral PM (CPM) in women
previously diagnosed as having breast cancer [656 -659]. Since 1995, the use of PM have
substantially increased. This change probably is a result of elevated public awareness and
knowledge about hereditary breast cancer and greater availability and variety of
procedures for breast reconstruction [660]. Exposure to public health campaigns and to
the experiences of high-profile celebrities have also likely contributed to the increased
awareness among women [661]. Compared with other mastectomy techniques, total BPM
is the most clinically effective; this approach results in an up 90% reduction in the risk of
breast cancer development [662,663].
The aesthetic outcome of reconstruction has improved using skin-sparing mastectomy
(SSM) techniques [664]. During SSM, the glandular tissues and nipple-areolar complex
(NAC) are removed using en-bloc resection. Satisfactory aesthetic outcomes and minimal
postmastectomy deformities and scarring result when the breast contour is optimized
using the native breast skin envelope. Reconstruction after mastectomy results in
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statistically significant improvements in physical measures and quality of life (QOL),
compared with mastectomy alone [664].
There has been a trend towards the use of implant-based breast reconstruction techniques
[665-669]. The major choice of patients who undergo a breast reconstruction procedure is
prosthesis-based reconstruction [669]. However, this approach imposes various
challenges such as skin envelope damage and visible contour irregularities due to tension
caused by implant malposition [669]. The increased use of Acellular Dermal Matrix
(ADM) after mastectomy indicates an important change in breast cancer management
[669-671]. Use of ADM improves perfusion, and it prevents implant-associated damage
of the skin envelope and skin closure [670]. ADM also helps in the restructuring of the
inframammary fold, enhances lateral mammary fold definition, improves the contour of
the lower pole, allows for good positioning of the implant, prevents capsular contracture,
and reduces the filling duration required for tissue expansion [671]. Nearly one-half of
prosthetic breast reconstructions are performed using ADMs [672]. The main
disadvantage of ADMs is the high cost associated with its use. In January 2010, a 6-cm x
16-cm thick ADM sheet was US $3,463 [Jansen; economic analysis] [673]. In spite of
this higher cost, ADM has been described as a cost-effective technology for use during
two-stage, TE-implant immediate breast reconstruction (IBR) because the procedure is
more likely to be successful [674]. ADM direct-to-implant reconstruction has a lower
cost than two-stage non-ADM reconstruction [673]. In addition to ADMs, de-cellularised
tissue derived from other tissue sources, such as the pericardium and peritoneum, have
also been developed which have similar properties. With the increasing number of
products available on the market, the obvious question becomes whether one product has
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advantages over the others. Few studies have been published comparing performance and
complications among ADM [516,517] Given the high cost of ADM, and their different
rates of infection, inflammatory reactions, and seroma formation, such a comparison is
justified. The widespread acceptance of the technique together with concerns regarding
the high cost of ADMs has led to the development of alternative synthetic mesh types for
use in breast reconstruction, such as Ti-LOOP Bra, SeriSilk, TIGR® Matrix Surgical
Mesh and Vicryl mesh [675-681].
Introduction of new medical technology (e.g., devices, drugs, medical procedures, and
policies) often results in significant benefits. However, in the context of limited resource
availability, the adoption decision is a challenge that affects every health-care system.
Decision makers and society work to maximize the total conferred aggregate health
benefit when given specific levels of available resources [682]. In the often-used cost
effective analysis (CEA) framework, the “value-for-money” of a newly-developed
medical technology can assessed and an adoption decision can be taken. International
decision-making bodies (e.g., the National Institutes for Health and Clinical Excellence in
the United Kingdom [683], and the Pharmaceutical Benefits Advisory Committee in
Australia [684], include CEA in their formal processes used for review of new medical
technology and inform health technology adoption decisions [685]. In Canada, the
Common Drug Review at the national- and provincial-level committees (e.g., the Ontario
Committee to Evaluate Drugs or Cancer Care Ontario) consider CEA results when
reimbursement for use of a new pharmaceutical is considered [686]. The primary
objective of CEA is to compare the incremental costs and benefits associated with
introducing a novel surgical technique or medical technology into an existing standard of
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care. Costs are displayed as currency units; benefits are displayed in units related to life
expectancy (i.e., “life years gained”). The frequent use of “life years gained” as the
cardinal outcome variable in CEA is considerably restrictive. An effective outcome
measure for CEA combines the quality and quantity of the outcomes [687]. Therefore,
Quality Adjusted Life Years (QALY) has become the most widely used variable in CEA.
During the analysis, these life year values are obtained after adjustment by a value from 0
to 1 to reflect differences in QOL variables for different health conditions. CEA results
are usually presented as the incremental cost-effectiveness ratio (ICER). The ICER
associated with incorporation of a new medical technology is

Cost New - Cost Current
ICER =
Health New - Health Current

Because CEA involves marginal cost and benefits, the choice of which current standard
of care or technology to compare (i.e., the appropriate definition for “Current”) can affect
the calculation and the results of a CEA. Therefore, CEA is very sensitive to the choice of
strategies being compared. The new medical technology is considered “cost-effective”
based on a value of judgment (what cost is considered a good price for an additional
outcome) [688]. Heuristics used to assist with making this value judgment include
plotting the incremental cost and effectiveness in a cost-effectiveness plane [30],
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comparisons with other technologies using a league table [689], and comparisons with
pre-specified thresholds (e.g., £30,000/QALY gained in UK [690] or $100,000/QALY
gained in Canada) [682,691]. In the first of the two most used approaches for
parameterization during CEA of a new medical intervention, the data is estimated directly
from a single clinical trial (i.e., use of resources is collected at the same time that the
clinical trial is performed). The experimentally-obtained economic data are usually
analyzed using the same methods as for the analysis of the clinical data. In the second
approach, data from different sources are combined during use of decision-analytic
models (e.g., Markov models, decision trees and Monte Carlo simulation models)
[692,693]. The data for modeling-based CEA could be a mix of observational data (e.g.,
resource-use data extracted from reviews of patient charts or from a claims database),
experimental (e.g., randomized clinical trial efficacy data), routine statistics (e.g., unit
cost or price of resources data), local surveys (e.g., the effects of therapies on QOL
variables), or expert opinions (e.g., data that describe the physical quantities of resources
consumed by the strategies being compared). Even randomized clinical trial-based CEAs
often use data not obtained from a clinical trial (e.g., price or unit cost of a health-care
resource). One argument is that a CEA should use experimental data to achieve the
greatest internal validity and to comply with biostatistical and epidemiological rules,
because the differences between the compared medical interventions are unlikely to be
affected by bias [693]. However, the internal and external validity of experimental data,
and the CEA results, can be negatively affected by several factors.
Typically, only a small proportion of the targeted general population is included in a
clinical trial. The experience of the participants enrolled in these trials may not represent
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the population-wide experience [694,695]. A measured effect may not be a consequence
of exposure to the investigated treatment or technology [696,697]. Relative to the
possible durations of effect of the alternatives, clinical trials usually have limited followup durations. Use of a “lifetime” horizon is included in many CEA guidelines [698 -701].
This set of factors necessitates extrapolation of clinical trial data when used in CEAs
using models (e.g., Markov chain simulation) to assess the long-term effects of the
alternative treatment options on cost and effectiveness [698]. Also, randomization may
not always be possible, such as in studies that aim to evaluate the effects of drug
treatment adherence on real world setting clinical outcomes. Model-based CEA offers the
potential for generalization and for application of the results to other settings. However,
clinical (experimental and observational) and economic data reported in the literature,
and commonly used in these analyses, may not be entirely relevant to the population in
the studied geographic region and setting in which alternatives are likely to be used in the
real world [699]. Data used for CEA should be extracted from settings that accommodate
socioeconomic variability. These data are likely to reflect the relevant patient
population’s typical clinical and economic experience in the studied geographic region,
during long follow-up periods [700].
Administrative health databases and disease registries are valuable clinical and economic
data sources for modeling-based CEAs [701]. These databases include records of events
that have occurred under everyday conditions. The main advantage of using these
databases is that interventions or technologies studied in CEAs can be described under
actual “real world” conditions that are relevant to the studied geographic region [700].
Using Administrative health databases may slightly underestimate the true high-risk
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population prevalence because this type of study using administrative data requires
women to have sought medical care and have their high risk diagnosed, recorded in
electronic medical records and coded in the billing data. The alternative is to use
literature from clinical trials or to use observational studies data. These often populationbased (i.e., minimizing selection bias) databases have high disease ascertainment (i.e.,
disease prevalence and incidence) rates. They include large-enough populations that have
been studied over time periods long-enough to evaluate effectiveness and costs among
different age- or race-specific population subgroups [702,703].

A decision-analytic model was developed to evaluate the cost-effectiveness of BPM with
and without different reconstruction techniques to aid in the breast cancer risk reduction
decisions for women at high risk of developing breast cancer. The rate of breast cancer is
significantly lower (90% relative risk reduction) in patients who undergo risk reducing
mastactomy and is accompanied by a survival advantage when compared to the intensive
screening and surveillance group [394,395, 656]. However, the significant association
between BPM and reduced breast cancer mortality suggests an underlying selection bias
for treating potentially healthier women with BPM or aggressive breast cancer biology in
surveillance women. As a result, the previously reported associations between BPM and
reductions in breast cancer and mortality may partly be attributed to unmeasured factors
(i.e., confounders). A randomized prospective trial would be required to minimize the
effect of selection bias and determine whether BPM has a real benefit on breast cancer
event and mortality. Selecting one type of reconstruction than another is another example
of selection bias due to surgeon expertise and women preference. In the base case
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analysis, a weighted average of overall costs derived for each strategy from the decision
tree is shown in Table 5. When all factors including complications are tallied, BPM
without reconstruction is the least expensive risk reducing strategy, followed by BPM
with one-stage ADM-assisted implant immediate breast reconstruction and then BPM
with one-stage non-ADM immediate breast reconstruction. However, BPM with two
stage ADM assisted breast reconstruction was the most expensive with the highest
complication rate compared to other strategies. We estimated that BPM with one-stage
ADM-assisted implant immediate breast reconstruction and BPM with one-stage nonADM immediate breast reconstruction have ICERs of $9,615 CAD and $15,457 per
QALY gained, respectively. The ICERs of the BPM with immediate one-stage ADM
reconstruction strategy was significantly below ICER estimates for the other
reconstruction strategies which represents a strategy that has been widely adopted into
clinical practice in Canadian jurisdictions. The clinical utility of the different surgical
strategies (compared head-to-head) used in our analysis for high-risk women was based
on retrospective analyses of the Ontario administrative database obtained from the
Canadian Institute for Health Information (CIHI). The ideal study design for evaluating
the clinical utility of such surgical intervention and identifying the most cost-effective
approach would be a prospective randomized trial in which investigators compare any
new procedure with the usual procedure or current practice. Unfortunately, that type of
prospective costing data does not exist in the Canadian healthcare system. Additionally,
surgical interventions such as modes of breast reconstruction are deeply personal and
based on patient body habitus, health comorbidities and cosmetic expectations, and a
randomized trial is unethical and impossible to complete. Therefore, our study provides
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us with the best possible data to answer this important question of how best to balance
resource use with the effectiveness and QALY from each intervention.

In Canada, decisions to permit the use of expensive ADM for reconstruction are being
made at the provincial level but the actual per case funding in Ontario for breast
reconstruction does not factor or reimburse hospitals for the use of ADM in
reconstruction cases regardless of whether it saves a second surgery or not. The processes
and criteria used by the provincial ministries of health to evaluate and approve BPM with
immediate one-stage ADM reconstruction are still evolving and yet to be defined.
National or provincial agencies (e.g., the Canadian Agency for Drugs and Technologies
in Health) independently evaluate new technology or product submissions but ADMs are
yet to be included. Our results suggest that all of the risk reducing surgical strategies are
clinically and economically attractive in high risk women, but that the BPM with onestage ADM reconstruction may significantly improve the cost-effectiveness and
simultaneously provide the most appealing and quickest immediate reconstruction
recovery option for these women [Figure 4]. Ultimately, prospective field evaluations
(i.e., registry studies) of the BPM with one-stage ADM reconstruction in real world
practice for clinically appropriate women may to be the only way to verify the clinical
utility of this strategy and identify its cost-effectiveness, however these have not been
initiated in any Canadian jurisdictions.
To our knowledge, our study represents the first comprehensive and independent costeffectiveness analysis comparing the use of available screening to risk reduction using
any of the available surgical reconstruction techniques. ADM has received regulatory
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approvals through both the United States Food and Drug Administration (FDA) and
Health Canada for decentralized testing and its clinical utility is being evaluated in a large
Canadian multi-centered randomized clinical trial, the ‘Multi-Center Canadian Acellular
dermal matrix Trial (MCCAT) evaluating one-stage implant immediate reconstruction
using ADM as compared to the two-stage tissue expander/implant reconstruction but
results are not yet available. This study does not include the comparisons to screening
(non-surgical) options also available to high risk women, nor would it compare to
autologous reconstruction options as in our study. Outcome measures of this ongoing trial
do however include aesthetic outcomes, short- and long-term complications, and overall
patient satisfaction [510]. ADM use can result in an overall cost savings to the health care
system by requiring fewer second stage revision surgical procedures. The costeffectiveness between different reconstruction techniques remains incompletely
understood, however our study showed a clear cost-effective benefit of BPM with
immediate one stage ADM-assisted reconstruction with a higher rate of effectiveness
compared with women who underwent other risk reducing techniques.

None of the current funding discussions take into consideration the cost to the patient of
any of the approaches. For example, when screening with annual MRI and mammogram,
the high call-back rate for repeated false positive biopsies accompanied by the significant
anxiety and time off work, not to mention the cost to the patient and family if treatment
for cancer is required (typically patients require long term disability claims during
chemotherapy) are all enormous financial and emotional burdens to patients and their
families. Additionally, the cost associated with avoiding a new cancer in a young patient
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is not typically considered when weighing the cost of these prophylactic procedures,
including the cost associated with a significant proportion of these patients who will
become metastatic before ultimately succumbing to the disease. If one stage ADM
implant-based reconstruction is adopted as the most cost-effective reconstruction
strategy, therefore allowing women the optimal one-stage option with excellent cosmetic
outcome, it is likely that more high-risk women will agree to risk reducing surgery and
therefore avoid the development of cancer as a result. With the other most common
reconstruction options (two-stage tissue expander reconstruction or autologous
reconstruction), the cost of prolonged surgical recovery from these breast reconstructions
over several months (including several days in hospital for autologous reconstruction and
months off work), or the need for weekly hospital visits for tissue expansion followed by
a second surgery to replace the expander for the definitive final implant with the two
stage tissue expander reconstruction option, can all be prohibitive for single women,
young mothers and single income earners. For many of these, a one-stage breast
reconstruction allows them the benefit of risk reducing BPM while retaining their
psychosexual sense of femininity in a single surgical intervention, which may in fact
increase the patient acceptance and compliance with surgical risk reduction as a result.
If we were to use an alternative measure for effectiveness, such as survival, risk reducing
surgical techniques would continue to provide a more cost-effective option over intensive
imaging surveillance which detects but does not prevent cancer. Patients in the intensive
screening program would hopefully have their cancer diagnosed at an earlier stage,
although they would likely still require the addition of chemotherapy and the costs and
morbidity associated with that, and would be accompanied by the high cost of treating
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younger women with breast cancer, many of which who end up developing metastatic
disease with the very expensive cost of palliative therapies. Women who elected to
undergo BPM with immediate one-stage ADM-assisted reconstruction tended to be
younger, however there remains a misconception about the benefits of BPM with onestage ADM-assisted breast reconstruction, because the ADM itself is expensive. We have
shown that, despite the clinical benefit with risk reducing techniques, BPM with
immediate one-stage ADM-assisted reconstruction is a more cost-effective option in the
management of high-risk women, because it is less costly and provides more
effectiveness than a two-stage surgical approach. This cost analysis may assist hospital
administrators, physicians and patients alike when deciding whether or not to undergo
BPM with immediate breast reconstruction, and it is hoped that hospitals can review this
data with the understanding of the impact of permitting ADM use in one-stage
reconstruction on the institution’s global budget when both complications and repeat
surgeries are considered. These costing arguments do not even factor in the improved
quality of life and patient satisfaction associated with one-stage reconstruction and
offering patients the very best reconstruction options for them individually (weighing
their preferences, comorbidities, body shape and psychosocial goals) should be a top
priority for all institutions providing care to Canadian women.

5.2 Strengths and Limitations

The main strength of our study is that the cost measure was derived directly from an
Ontario population-wide administration database. This provides a more realistic cost
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assessment than the costs derived from other sources. However, our analysis has its
limitations. First, the clinical utilities were based on retrospective analyses, thus the
outcomes may not necessarily reflect the experience of the high-risk population in
Canada or the experience of all women due to potential differences in patient type among
the different surgical treatment options (different patient body types may require very
different reconstruction decisions). To address this, reports from potential future
prospective cohort analyses in real-world Canadian clinical practice can be used to update
our model and validate our findings. Second, we assumed relative benefit from surgery to
be the same across high risk groups, which was felt to be a reasonable assumption given
that there has been no data to date to suggest that some surgical reconstruction strategies
preferentially benefit some high-risk women more than others. Third, our study results to
different types of ADM (i.e. Human dermis, Porcine dermis, Porcine dermis, Bovine
dermis, Bovine pericardium or Porcine peritoneum) with different cost and outcome may
add limitation to our study. Fourth, we assumed woman who receive bilateral
prophylactic mastectomy or annual bilateral mammogram and MRI are high risk for
breast cancer and that due to lack of specific codes for high risk in CCI and OHIP and
OBSP. Fifth, limited follow-up time among some of our cohort by differences in time of
intervention (some had 10 years and some had 3 years follow-up). Sixth, the hospital
costing data is really an average so in some hospitals it will underestimate the true cost
and in other hospitals will overestimate the cost so although that is a potential limitation
(that it isn’t the true cost of those exact people in the study) it gives us a rough idea.
Finally, generalization of our study results to other health care systems may also be
limited by differences in hospital management at varying centers (some allowing the use
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of ADM and others none, some providing autologous reconstruction and others not), as
well as differences in preferences for reconstruction options among the patients
themselves, as well as provincial differences in approaches to pricing and reimbursement
for the different types of breast reconstruction options.

5.3 Recommendations for future research
There are a number of gaps in our knowledge around bilateral prophylactic mastectomy
in research that follow from our findings, and would benefit from further research,
including realistic evaluation to extend and further test the theory we have developed
here:
1. An In-depth exploration of how one-stage ADM reconstruction could become the
most cost-effective strategy and how the different types of ADM materials
influence would be very helpful. Further research might compare, for example,
economic impact of different ADM materials.
2. More methodological work is needed on how to robustly capture the impact and
outcomes of implant versus non-implant strategies in research, including further
economic analysis.
3. Research to develop approaches and carry out a full cost–benefit analysis of
different reconstructions strategies in high risk women in research would be
beneficial. Although methodologically challenging, it would be very useful to
conduct some longer-term studies which would seek to quantify the impact of
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prophylactic mastectomy on such key indicators as participant recruitment and
retention in clinical trials, in order to more accurately follow the clinical outcomes
of such patients.

5.4 Conclusions

The choice of breast reconstruction needs to be decided based on the patient body
habitus, general condition and patient goals with regards to the cosmetic outcome and the
extent of surgery they wish to undergo. BPM with and without reconstruction is likely
both clinically and economically attractive, however BPM without immediate breast
reconstruction is associated with a lower patient-reported quality of life and has a
significant impact on patient sense of self and on their psychosexual well-being. BPM
with immediate one-stage ADM-assisted implant breast reconstruction is the most costeffective strategy and appears to offer the highest value for money. A discussion
regarding BPM with immediate one-stage ADM-assisted reconstruction should be
individualized to each woman, as this study highlights that the more cost-effective
approach depends on each woman’s preference for a particular health state. Every effort
should be made by healthcare institutions providing breast care to Canadian women to
approve funding for ADM implant-based reconstruction, and all risk reducing strategies
should be discussed and the optimal risk reducing strategy offered to all women at high
risk of developing breast cancer.
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